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Abstract 
During bone growth, remodeling, and fracture repair, skeletal lineage cell responses require the 
coordinated activation of multiple transcriptional programs. As defective genetic regulation of bone 
formation leads to both developmental and metabolic skeletal diseases, identifying and characterizing 
novel transcriptional regulators of skeletal growth, remodeling and repair is important to the future 
development of targeted therapeutics. The functions of the paralogous transcriptional co-activators Yes-
associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in bone are 
controversial, with evidence for each either promoting or inhibiting osteogenesis in vitro. Here, we used in 
vivo mouse models of combinatorial YAP/TAZ deletion from skeletal lineage cells to investigate their 
physiologic roles in bone growth, remodeling, and fracture repair. First, YAP and TAZ in Osterix-expressing 
cells combinatorially promoted bone development and growth by regulating osteoblast function, 
paracrine regulation of osteoclastic remodeling, and bone matrix quality. Furthermore, combinatorial YAP 
and/or TAZ deletion from Osterix-expressing cells mimicked the clinical skeletal fragility disease, 
osteogenesis imperfecta, with spontaneous fractures and dysregulated collagen composition leading to 
reduced bone mechanical properties. Second, YAP and TAZ deletion later in the skeletal lineage, from 
DMP1-expressing cells, promoted bone matrix accrual, organization, and mechanical properties by 
regulating osteocyte-mediated coordination of osteoblast/osteoclast activity and osteocytic perilacunar/
canalicular remodeling. Finally, YAP and TAZ in Osterix-expressing cells combinatorially promoted the 
expansion and differentiation of periosteal osteoblast precursors to accelerate bone fracture healing. 
Taken together, these data establish the paralogous transcriptional co-activators, YAP and TAZ, as 
important regulators of bone formation and function during skeletal growth, remodeling, and fracture 
repair. Further elucidation of the signaling pathways that control YAP/TAZ-dependent transcriptional 
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During bone growth, remodeling, and fracture repair, skeletal lineage cell responses require 
the coordinated activation of multiple transcriptional programs. As defective genetic 
regulation of bone formation leads to both developmental and metabolic skeletal diseases, 
identifying and characterizing novel transcriptional regulators of skeletal growth, 
remodeling and repair is important to the future development of targeted therapeutics. The 
functions of the paralogous transcriptional co-activators Yes-associated protein (YAP) and 
transcriptional co-activator with PDZ-binding motif (TAZ) in bone are controversial, with 
evidence for each either promoting or inhibiting osteogenesis in vitro. Here, we used in 
vivo mouse models of combinatorial YAP/TAZ deletion from skeletal lineage cells to 
investigate their physiologic roles in bone growth, remodeling, and fracture repair. First, 
YAP and TAZ in Osterix-expressing cells combinatorially promoted bone development 
and growth by regulating osteoblast function, paracrine regulation of osteoclastic 
remodeling, and bone matrix quality. Furthermore, combinatorial YAP and/or TAZ 
deletion from Osterix-expressing cells mimicked the clinical skeletal fragility disease, 
osteogenesis imperfecta, with spontaneous fractures and dysregulated collagen 
composition leading to reduced bone mechanical properties. Second, YAP and TAZ 
 vi 
deletion later in the skeletal lineage, from DMP1-expressing cells, promoted bone matrix 
accrual, organization, and mechanical properties by regulating osteocyte-mediated 
coordination of osteoblast/osteoclast activity and osteocytic perilacunar/canalicular 
remodeling. Finally, YAP and TAZ in Osterix-expressing cells combinatorially promoted 
the expansion and differentiation of periosteal osteoblast precursors to accelerate bone 
fracture healing. Taken together, these data establish the paralogous transcriptional co-
activators, YAP and TAZ, as important regulators of bone formation and function during 
skeletal growth, remodeling, and fracture repair. Further elucidation of the signaling 
pathways that control YAP/TAZ-dependent transcriptional regulation during bone function 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
As a composite structure, bone is critical to bearing biomechanical stresses and 
strains to support everyday human activity. The form and function of bone tissue depends 
not only on its hierarchical structure, but also the composition and organization of the bone 
matrix. During development and post-natal growth, the skeleton forms both through direct 
intramembranous bone formation and through endochondral ossification, in which bone 
formation occurs through a cartilage intermediary. During bone homeostasis and 
remodeling, bone tissue is continuously formed and resorbed via coordinated cellular 
function. During bone fracture repair, both bone formation and remodeling occur in a 
coordinated fashion, reactivating many of the same cellular and molecular mechanisms 
found during skeletal development. Although growth, remodeling, and repair are distinct 
bone functions, each require activation of multiple transcriptional programs and signaling 
pathways. Aberrant genetic regulation of the cellular responses during bone function can 
lead to both developmental and metabolic skeletal fragility diseases, highlighting the 
importance of identifying transcriptional regulators as targets for future potential therapies. 
This work explores the roles of the paralogous transcriptional co-activators, YAP and TAZ, 
in regulating osteogenic-lineage cell function during bone growth, remodeling, and fracture 
repair. Overall, this work helps to define the implications of YAP/TAZ-mediated control 
of bone function and provides a foundation for the development of new therapeutic 
strategies to treat skeletal fragility and improve bone fracture healing. 
 2 
1.1 Bone and skeletal fragility 
The human skeleton provides rigidity to aid locomotion, protects internal organs, 
and provides a source for calcium and phosphate1–3. Bone tissue is a composite structure, 
primarily made of a collagen matrix hardened by mineralization consisting of calcium 
phosphate in the form hydroxyapatite2. To maintain structural integrity, bone mineral and 
matrix undergo dynamic remodeling, consisting of coordinated bone formation and 
resorption,  during skeletal development, growth, homeostasis, and fracture repair2,4,5. As 
tightly regulated processes, defective regulation of coordinated bone formation can lead to 
skeletal frailty diseases, such as osteoporosis, osteogenesis imperfecta, and Paget’s disease 
of bone6.  
Skeletal fragility diseases result in reduced bone quantity and quality, which 
together increase fracture risk and complicate fracture healing treatments7,8. Therapeutic 
strategies targeting both the underlying bone pathology and subsequent fractures are 
challenging9,10. Fragility fractures often relapse with fixation failure, non-union, or delayed 
healing as a result of the existing defective bone combined with an impaired cellular 
response to injury11–13. Skeletal fragility pathologies include both developmental bone 
diseases, such as osteogenesis imperfecta14–17 and metabolic bone diseases, such as 
osteoporosis18,19. Efforts to identify key cellular and genetic regulatory components of bone 
function provide critical insights for the development of potential targeted therapeutics for 
skeletal fragility diseases20,21. Thus, understanding the cellular and molecular mechanisms 
regulating bone formation during skeletal growth, remodeling and fracture healing is both 
clinically relevant and therapeutically valuable. 
 3 
1.2 Bone: Cellular responses 
1.2.1 Development and growth 
During bone development and growth, the majority of skeletal elements ossify 
through intramembranous bone formation and/or endochondral ossification22. 
Intramembranous bone formation requires mesenchymal condensations, consisting of 
mesenchymal stem cells, to directly differentiate into bone forming cells, known as 
osteoblasts23,24. Osteoblasts are cuboidal cells located along the bone surface that primarily 
secrete new bone matrix23,24. In the process of endochondral ossification, mesenchymal 
condensations first differentiate into a cartilage template, consisting of chondrocytes, 
which is then replaced with osteoblastic deposition of bone matrix25. While 
intramembranous and endochondral ossification are distinct bone formation processes, 
both involve skeletal lineage cell commitment and osteogenic differentiation, resulting in 
osteoblast-mediated bone formation occurring throughout skeletal development and 
subsequent post-natal bone growth. 
1.2.2 Remodeling and homeostasis 
Terminally differentiated osteoblasts become embedded in the bone matrix and 
transition into the most abundant bone cell, known as osteocytes23,24,26,27. Osteocytes reside 
within lacunae in the mineralized bone matrix and extend dendritic processes through an 
interconnected network of micro-channels called canaliculi that permeate the bone 
matrix24,28,29. Through this lacunar/canalicular network, osteocytes and osteocyte-derived 
molecules orchestrate bone remodeling in part through controlling osteoblast-mediated 
bone formation and osteoclast-mediated bone resorption26,27,30,31. Osteoclasts are 
terminally differentiated multinucleated cells, originating from the hematopoietic cell 
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lineage instead of the mesenchymal lineage origination of osteoblasts and osteocytes3,23. 
Osteoclasts communicate with both osteoblasts and osteocytes to resorb the bone matrix 
through excretion of H+ ion to acidify and dissolve the hydroxyapatite mineral3,23. 
Osteoclasts then secrete matrix proteases and enzymes such as tartrate-resistant acid 
phosphatase (TRAP), cathepsin K (CTSK) and matrix metalloproteinases to degrade the 
remaining bone matrix3,23. However, many of the matrix metalloproteinases and enzymes 
employed by osteoclasts are also expressed in osteocytes32–34. As a result, osteocytes 
directly resorb and deposit bone matrix in their immediate surroundings via 
perilacunar/canalicular remodeling35,36 in addition to controlling osteoblast/osteoclast-
coupled bone remodeling26,30,31. Thus, bone homeostasis requires the dynamic and 
continuous regulation of osteoblast/osteoclast-mediated and osteocyte-mediated 
perilacunar/canalicular bone remodeling to maintain skeletal integrity and functionality 
after initial bone development and post-natal growth.   
1.2.3 Fracture repair and healing 
Bone fracture healing recapitulates the cellular functions important to skeletal 
development, growth and remodeling37,38. Fracture repair requires extensive 
intramembranous and endochondral bone formation to stabilize the initial injury along with 
coordinated osteoclast-mediated bone resorption to remodel the fracture callus back into a 
functional bone39–41. The initial stages (within 24 hours) of fracture healing include 
hematoma formation followed by an infiltration of inflammatory cells, including 
macrophages, which are critical for the subsequent phases of bone healing39–42. Next, 
progenitor cells located on the periosteal bone surface rapidly expand and differentiate in 
response to fracture39,40,43,44. Periosteal progenitor cells cover the surfaces of bone in a 
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highly vascularized membrane bilayer between bone and muscle45,46 and derive from a 
common embryonic mesenchymal lineage as bone marrow stromal cells (MSCs)47–49. 
However, periosteal progenitor cells contain an enhanced post-natal regenerative capacity 
with an osteochondral differentiation potential44,47–49, suggesting contributions of the 
periosteum to both cartilaginous callus formation and direct bone formation during the 
early stages of fracture healing. Following callus generation, mineralization and 
ossification, the coupled action of osteoblasts and osteoclasts progressively remodels the 
fracture callus back to mature, functional bone50. Thus, bone fracture healing reactivates 
and employs similar populations of bone cells as development, growth, and remodeling, 
but does so in a unique post-natal environment39. 
1.2.4 Conclusion 
Although skeletal growth, remodeling, and fracture repair are distinct bone 
functions, all of these processes require skeletal-cell lineage commitment, differentiation 
into osteoblasts, and eventual functional formation of bone matrix and mineral51. The 
skeletal cell response results from the expression and repression of specific genes to acquire 
an osteoblastic phenotype24. The genetic profile of progenitor cells differentiating into 
osteoblasts, and subsequently osteocytes, is tightly regulated by a variety of transcription 
factors52–55. Transcription factors are proteins that control the rate of transcription of 
genetic information from DNA to RNA56, allowing for genetic transitions driving different 
cellular phenotypes and functionality. 
 6 
1.3 Transcriptional regulation of bone function 
1.3.1 Cre-loxP skeletal phenotyping 
Conditionally inactivating or activating genes that encode for transcription factors 
using genetically engineered mouse models has greatly enhanced our understanding of 
transcriptional regulation of bone formation57,58. Multiple transcription factors are known 
to regulate bone formation at various skeletal cell lineage stages as a result of using bone-
specific Cre-loxP mouse models51,58. The Cre-loxP system uses the Cre recombinase 
enzyme (Cre) to excise target DNA sequences from the genome that are flanked with 
genetically engineered loxP sites, termed Cre-mediated gene recombination59,60. For tissue-
specific targeting, Cre expression is downstream of a specific promoter, resulting in Cre-
mediated gene recombination in the subset of cell populations expressing that 
promoter58,59. Further, Cre-mediated gene recombination is irreversible with upstream 
promoters causing gene recombination in progenitor cell populations and their 
progeny58,59. Thus, many different Cre-expressing mouse models exist to target conditional 
gene recombination throughout the different stages of the osteogenic cell lineage57,58. 
Targeting different stages of the osteogenic cell lineage using the various skeletal-
lineage Cre-expressing mouse models has elucidated cell type-specific, genetic regulation 
of bone function. The Runx2-Cre61, 3.6kb-Col1a1-Cre62, and Osterix-Cre63 mouse models 
target early osteoprogenitors and subsequently the entire osteoblast lineage, with 
differences in promoter expression based on the stage of progenitor cell commitment to the 
osteoblast lineage. The 2.3kb-Col1a1-Cre62,64,65 and  Osteocalcin-Cre66  mouse models 
primarily target osteoblasts, with differences in promoter expression based on osteoblast 
maturity. The 10kb-DMP1-Cre67,68, 8kb-DMP1-Cre69, and SOST-Cre70 mouse models 
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primarily target late osteoblast and osteocytes with observed Cre-mediated gene 
recombination in each cell type depending on the sensitivity of the floxed alleles69–71. 
However, various limitations of skeletal lineage Cre-loxP transgenic models exist, 
including potential non-skeletal cell targeting, transient Cre expression during 
development, and Cre transgene-dependent phenotypes57,58,72–74, highlighting important 
considerations for experimental controls and model-specific data interpretation. 
Nonetheless, skeletal lineage Cre-loxP mouse models remain critical to enhancing our 
understanding and subsequent identification of key transcription factors and their signaling 
pathways important to bone health and disease.  
1.3.2 Runx2 
Runx2 is the most upstream transcription factor critical to osteoblast lineage 
commitment and differentiation75. Global deletion of Runx2 in mice caused maturational 
arrest of osteoblasts, resulting in perinatal death characterized by no bone formation or 
mineralization76,77. Global, heterozygous deletion of Runx2 in mice caused skeletal 
abnormalities similar to cleidocranial dysplasia77 while in humans, heterozygous loss of 
function mutations in Runx2 caused clinical cleidocranial dysplasia78. In addition to a 
developmental bone phenotype, global heterozygous Runx2 deletion in mice enlarged 
cartilaginous callus formation, but delayed later stages of endochondral bone fracture 
repair79, demonstrating a dominant role in chondrocyte maturation. Consistent with these 
observations, conditional deletion of Runx2 in chondrocytes using Col2a1-Cre 
phenocopied global Runx2 gene inactivation with perinatal lethality and no ossification80. 
However, the functions of Runx2 in committed osteoblasts are disputed81. Conditional 
deletion of exon 4 within the Runx2 gene in committed osteoblasts using 2.3kb-Col1a1-
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Cre caused no overt skeletal phenotype80, yet osteoblast-conditional deletion of exon 8 
resulted in a progressive reduction in post-natal bone formation and osteoblast 
functionality82,83. Several reports of conditional Runx2 overexpression using the 2.3kb-
Col1a1 promoter observed osteopenia with a reduction in mature osteoblasts and 
osteocytes84–86, suggesting Runx2 differentially regulates osteoblastogenesis depending on 
the stage of skeletal cell lineage commitment. Runx2 overexpression in committed 
osteoblasts also enhanced osteoclast-mediated bone resorption by inducing expression of 
receptor activator of nuclear factor kappa beta (Rankl)86,87, highlighting how post-natal 
osteoblastogenesis affects the tightly regulated balance of bone remodeling. Taken 
together, the observed skeletal phenotypes from global and skeletal-lineage conditional 
genetic manipulations of Runx2 underscore many critical contributions of Runx2 to bone 
formation during skeletal development, growth, remodeling, and fracture repair.   
1.3.3 WNT/β-catenin 
WNT signaling and its primary transcriptional effector molecule, β-catenin, are 
similarly critical to osteoblastogenesis with differential functions depending on the stage 
of skeletal lineage commitment88. As global β-catenin inactivation in mice caused 
embryonic lethality due to gastrulation defects89, conditional Cre-loxP-based approaches 
have extensively dissected the function of β-catenin in skeletal lineage cells during bone 
function. Conditional deletion of β-catenin in mesenchymal limb bud cells using Prx1-Cre 
resulted in ectopic chondrocyte formation instead of osteoblast differentiation, suggesting 
β-catenin promotes osteogenic commitment and differentiation of mesenchymal 
precursors90,91. However, constitutively active β-catenin in committed osteoblasts using 
2.3kb-Col1a1-Cre caused osteopetrosis due to defective osteoclast differentiation while 
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conditional deletion of β-catenin using 2.3kb-Col1a1-Cre caused low bone mass due to 
increased bone resorption92. Conditional deletion of β-catenin in mature osteoblasts and 
early osteocytes using Osteocalcin-Cre and 14kb-DMP1-cre, respectively, caused similar 
low bone mass phenotypes with premature death due to skeletal fragility in both 
models93,94. Recent work in osteocytes demonstrated a dominant active form of β-catenin 
under control of 8kb-DMP1-Cre mediated the anabolic bone formation response71, 
corroborating numerous studies demonstrating the importance of β-catenin to osteocyte 
viability, function, and mechanotransduction95. Similar to development and remodeling, 
the function of β-catenin during fracture repair depends on the stage of healing96. During 
early stages of fracture healing, β-catenin regulates mesenchymal progenitor osteogenic 
differentiation97, while in later stages, active β-catenin signaling in osteoblasts promotes 
coordinated osteoblast-osteoclast mediated callus remodeling98. In summary, the resulting 
phenotypes from conditional genetic manipulation of β-catenin throughout the different 
stages of the skeletal lineage highlight various critical functions for β-catenin in regulating 
bone formation during skeletal development, growth, remodeling, and fracture repair.    
1.3.4 TGF-β/Smad 
TGF-β signaling and its primary signal transducer molecules, Smads, are also 
critical to osteoblastogenesis throughout skeletal development, growth, and 
homeostasis99,100. Activated TGF-β binds a tetrameric receptor complex consisting of two 
TGF-β type I (TβRI) and two type II kinase receptors (TβRII), resulting in the subsequent 
phosphorylation of receptor activated Smads, Smad2 and 3101. Smad2 and 3 then interact 
with Smad4 in order to translocate to the nucleus, where the Smad complex recruits various 
co-factors to regulate subsequent gene expression101. Thus, identifying roles for each 
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component of TGF-β/Smad signaling during osteoblastogenesis is complex with many 
insights coming from skeletal lineage conditional genetic manipulations.  Conditional 
deletion of both TβRI and TβRII in mesenchymal limb bud cells using Prx1-Cre resulted 
in short long bones and defective joint development characterized by decreased 
chondrocyte proliferation and increased chondrocyte hypertrophy102–104. In contrast, 
conditional TβRII deletion in mature osteoblasts using Osteocalcin-Cre resulted in a high 
bone mass phenotype105 while conditional TβRII deletion in early osteocytes using 10kb-
DMP1-Cre demonstrated increased trabecular bone mass, despite defective osteocyte 
perilacunar canalicular remodeling106. Furthermore, global Smad3 inactivation caused 
osteopenia with decreased bone formation and increased osteoblast apoptosis107. 
Conditional ablation of Smad4 from embryonic development onward in osteoprogenitor 
cells using Osterix-Cre impaired collagen matrix synthesis, causing an osteogenesis 
imperfecta-like phenotype108, while post-natal ablation of Smad4 in osteoprogenitors 
increased osteoblast proliferation, yet impaired osteogenic differentiation109. Similarly, 
conditional Smad4 disruption in osteoblasts using Osteocalcin-Cre inhibited bone 
formation and osteoblast differentiation during post-natal bone homeostasis110. Together, 
these observations suggest TGF-β/Smad signaling likewise plays multiple important roles 
during osteoblastogenesis to regulate bone formation during development, growth, 
remodeling, and homeostasis. 
1.3.5 Conclusion 
Although additional transcription factors and their respective signaling pathways 
regulate bone function, Runx2, WNT/ β-catenin and TGF-β/Smad signaling are known to 
have signaling crosstalk amongst each other111, adding another layer of contextual 
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complexity to the regulation of bone formation. Thus, a multilayered interplay between 
these various signaling pathways and their essential transcriptional regulators is required 
to coordinate skeletal lineage cell responses during bone function. 
1.4 YAP and TAZ 
1.4.1 Crosstalk 
Despite our growing knowledge of transcription factor regulation of skeletal 
function, the current understanding is insufficient to fully explain the vast heterogeneity 
found in bone disease and fracture healing. The paralogous transcriptional co-activators, 
YAP (Yes-associated protein) and TAZ (Transcriptional co-activators with a PDZ-binding 
motif) are known to interact with the above-mentioned, signaling pathways and their co-
effectors, which are critical to bone function. Both YAP and TAZ were shown to 
independently bind to and mediate Runx2-dependent osteogenic transcriptional 
activity112,113. In addition, WNT/ β-catenin114–116 and TGF-β-Smad2/3117,118 signaling 
pathways converge on YAP/TAZ via interactions with the β-catenin destruction complex 
and Smad-dependent nucleocytoplasmic shuttling. Furthermore, YAP and TAZ are known 
as potent regulators of organ growth and tissue regeneration in non-skeletal tissues119,120. 
These distinct tissue functions require a diverse YAP/TAZ-dependent transcriptional 
regulatory capacity within different cellular contexts. YAP and TAZ contain transcription 
activation domains, but lack DNA-binding domains121. Thus, YAP/TAZ-dependent 
transcriptional regulation is inherently diverse in part through forced interactions with co-
effectors containing DNA-binding domains (e.g. Runx2, β-Catenin, Smad2/3, etc.) to 
regulate gene expression and subsequent cellular function112–118,122, positioning YAP/TAZ 
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as a critical signaling node to potentially regulate bone growth, remodeling, and fracture 
repair. 
1.4.2 Regulation 
YAP and TAZ are primarily known as the main downstream effectors of the Hippo 
signaling pathway in vertebrates, yet become activated by numerous upstream signals 
including G protein-coupled receptors, adherens junctions, and cytoskeletal tension123–125 
(Figure 1-1). The most potent and well-studied downstream co-effector interactions of 
YAP and TAZ are with the transcriptional enhancer activator-domain (TEAD) family 
proteins126, as TEAD proteins lack transcriptional activation domains that provide 
specificity for YAP/TAZ-TEAD signaling (Figure 1-1). Canonical Hippo pathway 
signaling is composed of two sets of kinases, named MST and LATS, which control 
YAP/TAZ activation127–129. MST activates LATS and LATS in turn phosphorylates YAP 
and TAZ at specific serine residues located within each protein, which targets YAP and 
TAZ for 14-3-3 protein sequestration in the cytoplasm, inhibiting YAP/TAZ-dependent 
gene regulation127–129. If YAP and TAZ are not phosphorylated by LATS kinase, they 
translocate to the nucleus and bind with various co-effectors (e.g. TEAD, Runx2, β-
Catenin, Smad2/3) to regulate gene expression112–118,121. Non-canonical Hippo-signaling 
refers to when YAP and TAZ are regulated independently of MST/LATS kinase cascade, 
which include a diverse set of upstream signal inputs and post-transcriptional modifications 
that further modulate YAP/TAZ activity129–131.  
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Figure 1-1: YAP/TAZ activation and co-factor interaction.  
YAP and TAZ are activated by a diverse network of signals, including cytoskeletal stretch (ɛ), extracellular 
matrix stiffness (E), shear stress (τ), cell-cell junctions, and biochemical cues. Following activation, YAP 
and TAZ translocate to the nucleus to interact with transcriptional co-factors, such as TEAD. Figure made 
by J. Boerckel. Reproduced with permission. 
1.4.3 Structure 
As paralogs, the protein configurations of YAP and TAZ contain subtle structural 
differences that enable distinct interactions of YAP versus TAZ, resulting in either 
equivalent or divergent regulatory capacities132–134 (Figure 1-2). Both YAP and TAZ 
contain at least one WW domain135, consisting of two tryptophan residues with 20-23 
amino acids in between, that allow interactions with co-factors containing PPxY 
motifs131,136. Both YAP and TAZ contain a C-terminal PDZ-binding motif131,137, an 
extended C-terminus with a transcriptional activation domain (TAD)112,138,139, a TEAD-
binding region134,140, and a 14-3-3 binding region141,142 (Figure 1-2). Structural differences 
between YAP and TAZ include the N-terminus end of YAP consisting of a proline-rich 
region and an SH3-binding motif131,143, both of which are not found in TAZ (Figure 1-2). 
Thus, both distinct and overlapping functions of YAP versus TAZ are beginning to 
emerge131,133, depending on cell type and context. However, the current evidence for the 
contributions of YAP versus TAZ during osteogenesis in vitro and in vivo is complicated. 
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Figure 1-2: Regulatory structure of YAP and TAZ. 
Illustration of the key regulatory domains found in the protein structure if YAP and TAZ, including the 
TEAD binding domain, the WW domain(s), the transcriptional activation domain (TAD), and the PDZ-
binding motif. Figure made by J. Boerckel. Reproduced with permission. 
1.5 YAP and TAZ in osteogenic lineage cells  
1.5.1 In vitro evidence 
Although identified as critical regulators of mesenchymal progenitor cell 
differentiation, the evidence for positive vs. negative roles for YAP and/or TAZ during 
osteogenic differentiation in vitro is complicated. Studies have demonstrated both pro- and 
anti-osteogenic functions for both YAP and TAZ, depending on the context. Differences 
in experimental and cellular context may partially explain the conflicting evidence, but 
further study is necessary. Here, the existing evidence for both YAP and/or TAZ in both 
promoting and inhibiting in vitro osteogenic differentiation in model and primary skeletal 
cells is discussed.  
A majority of the evidence for YAP and/or TAZ in inhibiting in vitro osteogenic 
differentiation is focused on YAP. YAP was first reported to suppress osteoblastic 
differentiation through sequestration and transcriptional repression of RUNX2 in 
ROS17/2.8 rat osteosarcoma cells112. Sen and colleagues found that, in mouse bone marrow 
stromal cells (BM-MSCS), nuclear YAP inhibited RUNX2-mediated initiation of 
osteogenic differentiation while YAP nuclear export enhanced osteogenic 
differentiation144. More recently, activator protein 2a (AP2a) was shown to recruit YAP 
and release the inhibition of RUNX2 by forming a YAP-AP2a protein complex, resulting 
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in elevated osteogenic differentiation145. Similarly, Basu-Roy and colleagues observed that 
SOX2 antagonized YAP expression to reduce osteogenic differentiation and maintain 
stemness in mOS-482 mouse osteosarcoma cells while YAP overexpression in primary 
mouse osteoblasts inhibited alkaline phosphatase activity and osteogenic differentiation146. 
Seo and colleagues identified YAP as a target of SOX2 that antagonized activation of 
WNT/b-catenin target genes to inhibit osteogenic differentiation in both a model stem cell 
line (C3H10T1/2) and primary bone marrow stromal cells147. With respect to TAZ, Park 
and colleagues implicated both YAP and/or TAZ as mediators of alternative WNT 
signaling via antagonizing WNT/b-catenin signaling, and found that either YAP or TAZ 
overexpression inhibited WNT/b-catenin signaling and osteogenesis148.  
In contrast, YAP has also been found to promote osteogenic differentiation in vitro. 
YAP overexpression enhanced, while YAP depletion inhibited, osteogenic differentiation 
in MC3T3-E1 cells149. In BM-MSCs, over-expressing a constitutively active YAP mutant 
(YAP5SA) promoted osteogenic differentiation even under conditions more favorable for 
adipogenesis150. Further, enhanced YAP activation by cytoskeletal contractility in 
differentiating BM-MSCs promoted osteogenic capacity in both the context of 
topographical cues151 and mechanical stimulation152. Both pharmacological treatment and 
RNAi-depletion of YAP inhibited topography-induced osteogenic differentiation in BM-
MSCs153. In addition to topographical cues, reductions in extracellular pH inhibited 
osteogenic differentiation by suppressing YAP in BM-MSCs154. Finally, olfactomedin-like 
protein (OLFML1) negatively regulated mineralization in primary calvarial osteoblasts by 
inhibiting YAP nuclear translocation, consistent with a role for YAP promoting osteogenic 
differentiation in vitro155. 
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In contrast to YAP, evidence for TAZ is largely consistent and indicates a role for 
TAZ in promoting in vitro osteogenic differentiation. TAZ was first identified as a RUNX2 
co-activator and inhibitor of adipogenic nuclear receptor, PPARg, in C2C12 cells156,157. 
More recent evidence in both C2C12 and C3H10T1/2 cells further found TAZ promoted 
osteogenic differentiation through both RUNX2-158,159 and b-catenin-160 dependent 
transcription. Similar work by Byun and colleagues observed that TAZ activation 
downstream of FGF2 and ERK mediated RUNX2-related osteogenic gene expression161. 
Similar to YAP, both topographical cues and mechanical stimulation affected TAZ-
dependent in vitro osteogenic differentiation in BM-MSCs. For example, both nano-
topographical surfaces162,163 and extracellular matrix stiffness164 promoted osteogenic 
differentiation through nuclear TAZ activation. Furthermore, simulated microgravity 
depolymerized F-actin and reduced TAZ nuclear translocation, which hindered osteogenic 
differentiation in BM-MSCs165. Conversely, fluid shear stress stimulated TAZ nuclear 
localization and increased osteogenic differentiation166. Lastly, pharmacological activation 
of TAZ enhanced osteogenic differentiation in adipose-derived stem cells167 while BM-
MSCS from mice with heterozygous global deletion of TAZ exhibited defective in vitro 
osteogenic differentiation168.  
In addition to their individual roles, a few studies have modulated both YAP and 
TAZ during in vitro osteogenic differentiation. For example, Park and colleagues 
demonstrated RNAi-depletion of YAP/TAZ in BM-MSCs reduced alkaline phosphatase 
activity and mineral deposition148. Similarly, dual RNAi-depletion of YAP/TAZ in BM-
MSCs inhibited alkaline phosphatase activity under conditions favorable for 
osteogenesis150. Finally, heterozygous deletion of both YAP and TAZ in BM-MSCs 
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inhibited osteogenic differentiation with reduced mineral deposition and downstream 
osteogenic gene expression169.   
Synthesizing these studies suggest TAZ primarily promotes osteogenic 
differentiation in vitro, while YAP can either promote and inhibit osteogenic differentiation 
in vitro, depending on the cellular and experimental context. Despite the emerging 
important roles of YAP and TAZ during osteogenic differentiation in vitro, continued 
careful and thorough interpretation of experiments modulating either YAP and/or TAZ is 
warranted. For example, the limitations of overexpression approaches that non-
physiologically express otherwise tightly regulated transcriptional co-effectors should be 
taken into consideration. Further, dissecting the individual roles of YAP versus TAZ during 
osteogenic differentiation is necessary as current evidence suggests the potential for both 
divergent and convergent functions of YAP versus TAZ. While important for dissecting 
molecular mechanisms, in vitro studies must be supported and validated by in vivo 
approaches that enable the study of YAP/TAZ function in a physiologic context. 
1.5.2 In vivo evidence 
In light of the conflicting in vitro evidence for the roles of YAP and TAZ during 
osteogenic differentiation, genetic manipulations using bone-specific Cre-loxP mouse 
models have partially elucidated the in vivo roles of YAP and TAZ in osteoblast lineage 
cells. Here, the current evidence for the roles of YAP and/or TAZ in vivo throughout the 
osteoblast lineage is discussed.  
Evidence for the roles of YAP and TAZ in osteoprogenitor cells using Osterix-Cre 
is seemingly contradictory. Constitutive, homozygous deletion of both YAP and TAZ 
using Osterix-Cre caused perinatal lethality due to asphyxiation secondary to rib cage 
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malformation, signifying a critical role for YAP and TAZ together in osteoprogenitors for 
overall survival170,171. Mice with a single allele of YAP or a single allele of TAZ in Osterix-
expressing cells survived the perinatal lethal phenotype, suggesting mutual, but partial 
compensation of YAP and TAZ in this context. Mice expressing only a single allele of 
either gene exhibited severe skeletal defects including spontaneous neonatal femoral 
fractures, defects in collagen content and organization, and altered osteoblast/osteoclast-
mediated bone remodeling, implicating both YAP and TAZ promote post-natal bone 
function170. However, post-natal deletion of both YAP and TAZ (tetOFF-Osterix-Cre-
mediated deletion at 3 weeks of age, and assayed at 12 weeks of age) increased osteoblast 
numbers and mineralizing surface percentage, yet represents a distinct experimental 
context from constitutive deletion of YAP and/or TAZ from embryonic skeletal 
development onward171. Orthogonally, Li and colleagues demonstrated that genetic 
deletion of MST1/2, an upstream regulator of YAP/TAZ, using Osterix-Cre inhibited bone 
accrual, formation and remodeling while stabilizing the key glucose transporter, Glut1172. 
Although the effect of MST1/2 deletion on glucose metabolism was independent of 
YAP/TAZ expression, these data further implicate the importance of understanding how 
upstream regulators in the Hippo pathway coordinate bone function in addition to YAP and 
TAZ.  
 In contrast to their roles in osteoprogenitor cells, the evidence for the roles of YAP 
and TAZ in osteoblasts is largely convergent. To date, neither the 3.6kb- nor the 2.3kb-
Cola1-Cre173,174 model has been used to conditionally delete YAP and/or TAZ. However, 
Col-1(2.3kb)-conditional over-expression of TAZ promoted bone formation, suggesting a 
similar role for TAZ in osteoblasts compared to osteoprogenitors175. Although not specific 
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to skeletal lineage cells, in vivo lentiviral delivery of TAZ alleviated osteoporotic 
symptoms in ovariectomized rats, further implicating that TAZ promotes bone formation 
in vivo176. Consistently, YAP deletion from osteoblasts using Osteocalcin-Cre significantly 
reduced bone formation, impairing osteoblast proliferation induced by YAP co-activation 
of β-catenin signaling177, supporting a role for YAP in promoting osteogenesis in vivo. In 
contrast, dual deletion of the upstream YAP/TAZ regulator MST1/2 from Osteocalcin-
expressing cells inhibited bone accrual and formation, consistent with a negative role for 
YAP in bone formation172. Nonetheless, deletion of both downstream YAP/TAZ-TEAD 
target genes, CTGF and CYR61, from osteoblasts using Osteocalcin-Cre resulted in a 
reduced bone mass phenotype178,179, consistent with the evidence of osteoblast-specific 
genetic manipulations of YAP and TAZ.  
Although the roles of YAP and TAZ in osteoclasts using cell-specific loss of 
function models has not been directly investigated, their functional roles in regulating 
osteoblast/osteoclast signaling in conditional osteoblast-lineage knockout models are 
consistent. Dual deletion of MST1/2 using Osteocalcin-Cre inhibited osteoclast formation, 
suggesting YAP/TAZ negatively regulate osteoclasts172. Consistent with this role, both 
deletion of YAP and/or TAZ using Osterix-Cre and deletion of CYR61 with Osteocalcin-
Cre cells increased osteoclast activity170,178. However, deletion of YAP in osteoblasts using 
Osteocalcin-Cre did not significantly impact osteoclastic remodeling, potentially due to the 
compensatory effects of TAZ and/or the Cre model used177. As the roles for YAP and TAZ 
in regulating both osteoblastogenesis and osteoclastogenesis are beginning to emerge, a 
complete mechanistic understanding of their role in osteoblast/osteoclast-mediated bone 
remodeling during skeletal development remains incomplete. 
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 Similar to their role in osteoblasts, the evidence for the roles of YAP and TAZ in 
late stage osteoblasts and osteocytes is consistent. Despite the cell population targeting 
differences between the 10kb- and 8kb-DMP1-Cre model, consistent evidence exists for 
the role of YAP/TAZ in both models. Dual, homozygous YAP/TAZ deletion using both 
10kb-DMP1-Cre and 8kb-DMP1-Cre reduced bone formation in vivo with decreased 
osteoblast numbers and increased osteoclast activity171,180. Furthermore, dual deletion of 
YAP/TAZ using 8kb-DMP1-Cre impaired perilacunar/canalicular remodeling, resulting in 
skeletal fragility180. Thus, YAP/TAZ in late stage osteoblasts and osteocytes promote bone 
function in vivo. 
 The evidence for YAP/TAZ-mediated regulation of bone formation at various 
stages of the osteoblast lineage in vivo are beginning to emerge. In contrast to the in vitro 
evidence, these studies suggest both YAP and TAZ promote bone formation throughout 
different stages of the osteoblast lineage. However, evidence exists demonstrating negative 
YAP and/or TAZ-dependent regulation earlier in the mesenchymal lineage, using Prx1-
Cre171 and Col2a1-Cre181, suggesting potential cell lineage stage-specific differences in 
how YAP and TAZ regulate bone function. Overall, the existing evidence for the roles of 
YAP and TAZ in skeletal lineage cells in vivo demonstrates how critical these paralogous 
transcriptional co-activators are to bone function, similar to their previously identified roles 
in non-skeletal tissue regeneration and organ growth182,183. 
1.6 Significance of Studies 
1.6.1 Clinical significance: Skeletal fragility 
YAP and TAZ are known to drive aberrant cellular function in many diseases 
including atherosclerosis184, cancer185, fibrosis186,187, cardiac hypertrophy188, and muscular 
 21 
dystrophy189,190, but the role of YAP and TAZ in bone disease is unknown. Due to the 
altered mechanical environment in disease pathogenesis, the mechanotransductive effects 
of YAP and TAZ are implicated in driving abnormal cellular function191. Further synthesis 
of the upstream signals and the downstream targets of YAP/TAZ signaling in bone is 
therapeutically important to understand skeletal fragility disease pathology and potential 
therapeutic interventions. Accordingly, the emerging roles of YAP and TAZ in skeletal 
lineage cells implicate YAP and TAZ in both developmental and metabolic skeletal 
fragility diseases.  
1.6.2 Bone development diseases 
Dysfunctional YAP and/or TAZ signaling in mice mimicked characteristics of 
human cases of developmental bone diseases in humans such as skeletal dysplasia192 and 
osteogenesis imperfecta (OI)16,17,170,193. As a heterogeneous group of inheritable diseases, 
the severity of OI ranges from mildly increased fracture risk to perinatal lethality16. OI is 
characterized by increased bone fragility and deformity as well as collagen matrix 
disorganization17. Osterix-Cre-mediated YAP and/or TAZ deletion in mice also mimicked 
several established mouse models of OI194–196 with spontaneous fractures, disorganized 
collagen, and altered osteoblast/osteoclast-mediated remodeling. More recently, a novel 
transgenic mouse model of OI type I with mutations in the COL1A1 gene demonstrated 
downregulation of YAP expression in bone, potentially implicating a feedback loop 
between upstream matrix activation and downstream transcriptional regulation197. 
Although the emerging evidence of YAP/TAZ in skeletal lineage cells resembles OI 
pathogenesis, loss of function mutations directly in either YAP or TAZ are unlikely to play 
a casual role in human OI. Nonetheless, a variety of signaling axes such as TGFb117,118 and 
 22 
WNT-b-catenin115,116 are already implicated in developmental bone diseases and converge 
on YAP/TAZ signaling, potentially placing YAP/TAZ upstream of development skeletal 
diseases.  
1.6.3 Bone metabolic diseases 
In addition to developmental bone diseases, the emerging role of skeletal cell YAP 
and/or TAZ in regulating bone remodeling implicate a potential link to metabolic skeletal 
diseases, specifically related to the coordination of osteoblast/osteoclast and osteocyte-
intrinsic remodeling. Metabolic skeletal disorders and diseases primarily result from 
abnormal bone remodeling, which include Paget’s disease and osteoporosis198. In the 
context of both diseases, aberrant cellular function in osteoblasts, osteoclasts, and 
osteocytes causes altered bone remodeling, resulting in low bone mass, structural 
deterioration and/or deformities198. DMP1-Cre-mediated YAP/TAZ deletion in mice 
resulted in low bone mass with increased osteoclastic remodeling, similar to these 
diseases171,180. While targeting osteoblast/osteoclast-mediated bone remodeling is under 
clinical investigation, therapies targeting bone quality to treat metabolic bone remodeling 
disease are currently emerging. Treating bone quality to improve bone strength relates 
improving the integrity of the osteocyte lacunar/canalicular network. Both increased age199 
and reduced TGFb signaling106 caused defects in osteocyte lacunar/canalicular network 
associated with skeletal fragility. Correspondingly, YAP/TAZ deletion from osteocytes 
using 8kb-DMP1-Cre reduced both bone quantity and quality via defects in 
perilacunar/canalicular remodeling, resulting in skeletal fragility180. Evidence for 
YAP/TAZ signaling in both regulating osteoprogenitor cell function during skeletal 
development and coordinating osteocyte-mediated bone remodeling suggests a more 
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mechanistic understanding of how YAP/TAZ activity regulates bone function could 
contribute new insights into the heterogeneity and/or etiology of both metabolic and 
developmental skeletal diseases. 
1.7 Specific Aims 
This study uses a comprehensive approach to identify the contributions of YAP and 
TAZ to bone growth, remodeling, and fracture repair. Using three novel, transgenic 
conditional knockout mouse model approaches, the combinatorial roles of YAP versus 
TAZ as well as the dual roles of YAP and TAZ together are identified at multiple stages of 
the osteogenic lineage in the context of bone function. Characterizing the roles of YAP and 
TAZ during each bone function (i.e. growth, remodeling, and fracture repair) were 
evaluated using skeletal phenotyping techniques at multiple length-scales complemented 
with a combination of in vitro assays using various osteogenic-lineage cells.    
 Specific Aim 1 evaluated the combinatorial roles of skeletal cell YAP and/or TAZ 
during bone growth. In this aim, we targeted combinatorial YAP and/or TAZ deletion in 
osteoprogenitor cells and their progeny with Osterix-Cre using an allele dose-dependent 
breeding strategy. The resulting phenotype of YAP and/or TAZ deletion from Osterix-
expressing cells was evaluated at three stages of post-natal growth, corresponding to early 
post-natal growth and ending with early skeletal maturity. Here, we used a multifaceted 
approach to measure bone growth and function on the whole bone (microCT and 
mechanical testing), tissue (histological and multiphoton imaging), cellular 
(immunohistochemistry and primary cell isolations), and molecular (RT-qPCR) levels.  
 Specific Aim 2 identified the dual roles of osteocyte YAP and/or TAZ during bone 
growth and remodeling. In this aim, we targeted combinatorial YAP and/or TAZ deletion 
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in osteocytes with 8kb-DMP1-Cre using an allele dose dependent breeding strategy, but 
subsequently only compared dual homozygous YAP/TAZ knockouts to WT control mice. 
The resulting phenotype of YAP and/or TAZ deletion from 8kb-DMP1-expressing cells 
was evaluated at two stages of post-natal growth, corresponding to early post-natal growth 
and early skeletal maturity. Here, we again used a multifaceted approach to measure bone 
remodeling and function on the whole bone (microCT and mechanical testing), tissue 
(histological, multiphoton imaging, and confocal imaging), cellular 
(immunohistochemistry and in vitro cell model), and molecular (RT-qPCR) levels. 
 Specific Aim 3 investigated the combinatorial roles of skeletal cell YAP and/or TAZ 
during bone fracture repair. In this aim, we again targeted combinatorial YAP and/or TAZ 
deletion in osteoprogenitor cells and their progeny with Osterix-Cre using two deletion 
models. In the first model, we constitutively deleted YAP and/or TAZ from Osterix-
expressing cells from embryonic development onward, similar to Aim 1, and evaluated 
adult bone fracture repair. In the second model, we induced dual YAP/TAZ deletion from 
Osterix-expressing cells following skeletal maturity, but prior to fracture and evaluated 
adult bone fracture repair. Here, we used a similar multifaceted approach to measure bone 
fracture repair on the whole bone (microCT and mechanical testing), tissue (histological 
and multiphoton imaging), cellular (immunohistochemistry and primary cell isolations), 
and molecular (RT-qPCR) levels. 
1.8 Approach 
1.8.1 Overall Strategy 
This study characterizes the contributions of the paralogous transcriptional co-
activators, YAP and TAZ, to bone growth, remodeling, and fracture repair at two distinct 
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stages of the osteogenic cell lineage. Here, we used in vivo conditional knockout mouse 
models with a combinatorial deletion strategy both in early osteoprogenitors and their 
progeny (using Osterix-Cre) and in late stage osteocytes (using 8kb-DMP1-Cre). The 
relative contributions of YAP and/or TAZ to bone growth, remodeling and fracture repair 
were evaluated at multiple, post-natal time points, with an emphasis on characterizing how 
YAP and/or TAZ deletion affected bone function at multiple length scales. Each mouse 
model and distinct bone function (i.e. growth, remodeling, and fracture repair) were 
evaluated using a similar set of methodologies. Whole-bone architectural and mechanical 
properties were evaluated using both X-ray-based microCT imaging and three-point 
bending or torsional testing. Bone tissue-level characteristics were assessed using both 
standard histological and whole-mount stains, but also immunohistochemical and 
immunofluorescent techniques combined with multiphoton and confocal microscopy 
imaging. To assess cellular behavior in response to YAP/TAZ manipulation, both primary 
cell isolations and osteogenic-lineage cell models were evaluated in vitro with a 
combination of functional and gene expression analyses. Our overall hypothesis is that 
skeletal cell YAP and TAZ promote osteogenesis during bone growth, development, and 
remodeling while their combinatorial and dual deletion will result in decreased 
osteogenesis with severity depending on the targeted cell type (i.e. Osterix- vs. DMP1-
expressing cells) and allele dosage (e.g. single copy of TAZ vs. single copy of both YAP 
and TAZ).  
1.8.2 Study Design and Animal Model 
This study characterizes two transgenic conditional knockout mouse models at 
various stages of post-natal development in the context bone growth, remodeling and 
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fracture repair. Both models were generated using Cre-loxP technology and target distinct 
osteogenic cell lineage populations. In Aim 1, we use the Osterix-Cre model63 to target 
combinatorial deletion of YAP and/or TAZ in osteoprogenitors and their progeny from 
embryonic development onward (Figure 1-3A). In Aim 2, we used the 8kb-DMP1-Cre 
model69 to target combinatorial deletion of YAP and/or TAZ in osteocytes, but 
subsequently compared YAPfl/fl;TAZfl/fl and YAPfl/fl;TAZfl/fl;8kb-DMP1-Cre mice  (Figure 
1-3B,C). In Aim 3, we again use the Osterix-Cre model63 to target combinatorial deletion 
of YAP and/or TAZ in osteoprogenitors and their progeny, using either a constitutive 
deletion model (from embryonic deletion onward) or an adult onset-inducible deletion 
model (following skeletal maturity) (Figure 1-3D,E). In all aims, we used a breeding 
strategy targeting YAP/TAZ deletion that yielded an allele dose dependent decrease in 
YAP/TAZ allele number within littermates (Figure 1-3). Sample sizes were determined a 
priori by power analysis based on effect sizes and population standard deviations taken 
from published phenotypic data on YAPfl/fl;TAZfl/fl mice in other tissues188, assuming a 
power of 80% and α=0.05. 
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Figure 1-3: Breeding strategy resulting in combinatorial allele dosage-dependent YAP/TAZ deletion. 
A) For Aim 1, YAPfl/fl;TAZfl/fl were bred to YAPfl/+;TAZfl/+;Osx-Cre, resulting in an allele dosage-dependent 
deletion of YAP and/or TAZ from osteoprogenitor cells and their progeny. The five experimental genotypes 
shown were compared. B) For Aim 2, YAPfl/fl;TAZfl/fl were bred to YAPfl/+;TAZfl/+;8kb-DMP1-Cre, resulting 
in an allele dosage-dependent deletion of YAP and/or TAZ from osteocytes. The five experimental genotypes 
shown were compared initially, but subsequent analyses were performed on genotypes shown in (C). D) For 
Aim 3, the same allele-dosage dependent deletion of YAP and/or TAZ from osteoprogenitor cells and their 
progeny was used for constitutive deletion from embryonic development onward. The four experimental 
genotypes shown were compared in this model. E) For the inducible deletion model, dual homozygous 
YAP/TAZ knockout mice (YAPcKOi;TAZcKOi) were compared to both WT littermate control mice 
(YAPWT;TAZWT) and separately bred Osterix-Cre (Osx-Cre) control mice. 
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In Aim 1 we combinatorially deleted YAP and/or TAZ from embryonic 
development onward in osteoprogenitors and their progeny using Osterix-Cre and 
evaluated bone growth at various stages of post-natal development. At P0 and P10, we 
evaluated bone growth using a combination of microCT, whole-mount skeletal 
preparations, and histological approaches. At P28, we evaluated bone formation rate using 
flourochrome-labeling of actively mineralizing bone surfaces. At P56, we evaluated bone 
architecture, mechanical, and matrix composition properties using microCT, three-point 
bend testing, histology, and second-harmonic generated imaging.  
In Aim 2 we combinatorially deleted YAP and/or TAZ in osteocytes using 8kb-
DMP1-Cre and evaluated bone remodeling at various stages of post-natal development. At 
P0, we evaluated skeletal formation using whole-mount skeletal preparations. At P28, we 
evaluated bone formation using flourochrome-labeling of actively mineralizing bone 
surfaces and osteocyte lacunar-canalicular network formation. At P84, we evaluated bone 
architecture, mechanical, and matrix composition properties with similar methods as Aim 
1, but further analyzed osteocyte expression using immunohistochemistry. 
In Aim 3, we combinatorially deleted YAP and/or TAZ from embryonic 
development onward in osteoprogenitors and their progeny using Osterix-Cre and also 
induced dual YAP/TAZ deletion after skeletal maturity using the tetracycline-sensitive 
element of the Osterix-Cre model. In both deletion models, adult bone fracture repair was 
evaluated in skeletally mature mice 18-21 weeks of age. In the constitutive deletion model, 
fracture healing was evaluated 14 days post fracture (dpf) and 42 dpf with a combination 
of microCT and torsional testing. In the inducible deletion model, fracture healing was 
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evaluated 4, 7 and 14 dpf with a combination of microCT, immunohistochemistry, 
immunofluorescence and second-harmonic generated imaging.  
1.9 Chapter Overview 
Chapter 2 will describe how YAP and/or TAZ in osteoprogenitor cells and their 
progeny contribute to matrix formation and organization during bone growth. Chapter 3 
will describe how YAP and TAZ in osteocytes coordinate both osteocyte-intrinsic and 
osteocyte-extrinsic functions during bone remodeling. Chapter 4 will describe how YAP 
and/or TAZ in osteoprogenitor cells and their progeny contribute to the development, 
activation and differentiation capabilities of periosteal osteoprogenitors during bone 
fracture repair. Chapter 5 will summarize the conclusions of the previous chapters and 









CHAPTER 2: SKELETAL CELL YAP AND TAZ COMBINATORIALLY 
PROMOTE BONE DEVELOPMENT 
2.1 Abstract 
The functions of the paralogous transcriptional co-activators Yes-associated protein 
(YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in bone are 
controversial. Each has been observed to either promote or inhibit osteogenesis in vitro, 
with reports of both equivalent and divergent functions. Their combinatorial roles in bone 
physiology are unknown. Here we report that combinatorial YAP/TAZ deletion from 
skeletal lineage cells, using Osterix-Cre, caused an osteogenesis imperfecta-like phenotype 
with severity dependent on allele dosage and greater phenotypic expressivity with 
homozygous TAZ vs. YAP ablation. YAP/TAZ deletion decreased bone accrual and 
reduced intrinsic bone material properties through impaired collagen content and 
organization. These structural and material defects produced spontaneous fractures, 
particularly in mice with homozygous TAZ deletion, and caused neonatal lethality in dual 
homozygous knockouts. At the cellular level in vivo, YAP/TAZ ablation reduced 
osteoblast activity and increased osteoclast activity, in an allele dosage-dependent manner, 
impairing bone accrual and remodeling. Transcriptionally, YAP/TAZ deletion and small 
molecule inhibition of YAP/TAZ interaction with the transcriptional co-effector TEAD 
reduced osteogenic and collagen-related gene expression both in vivo and in vitro. 
Together, these data demonstrate that YAP and TAZ combinatorially promote bone 
development through regulation of osteoblast activity, matrix quality, and osteoclastic 
remodeling.  
*This chapter is modified from publication in FASEB J (DOI: 10.1096/fj.201700872R). Authors: Kegelman 
CD, Mason DE, Dawahare JH, Horan DJ, Vigil GD, Howard SS, Robling AG, Bellido TM, Boerckel JD. 
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2.2 Introduction 
Bone is a living hierarchical composite whose form and function depend not only 
on tissue structure, but also matrix composition and organization. Each of these 
components is controlled during development by skeletal cell lineage progression and by 
dynamic regulation of bone deposition and remodeling. Various genetic, hormonal, or 
environmental abnormalities can impair these processes, leading to debilitating diseases 
including osteoporosis and osteogenesis imperfecta. However, the molecular mechanisms 
that govern cell fate and matrix production in bone remain poorly understood, limiting 
therapeutic intervention. Several transcriptional programs have been described as essential 
regulators of bone development, but current understanding is insufficient to fully explain 
the heterogeneity found in congenital and acquired bone diseases52,200,201. In this study, we 
sought to define the functions of the paralogous transcriptional co-activators YAP and TAZ 
in bone development.  
Yes-associated protein (YAP) and Transcriptional co-activator with PDZ-binding 
motif (TAZ; also known as WWTR1) display either equivalent or divergent functions, 
depending on cell type and context131. While YAP and TAZ possess transcription 
activation domains, they lack DNA-binding domains and require interaction with co-
factors for transcriptional activity121. Their most potent and well-studied interactions are 
with the transcriptional enhancer activator-domain (TEAD) family proteins, which 
themselves lack activation domains, providing specificity for YAP/TAZ-TEAD 
signaling126. However, other co-effectors are also known, including Runx2122, β-catenin114–
116, and Smad2/3117,118, each of which contributes to bone development and osteoprogenitor 
lineage progression76–78,202,203. Thus, independent pathways that regulate coincident 
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activation of these various binding partners could provide additional layers of contextual 
specificity in bone. Further, as paralogs, the YAP and TAZ proteins also possess structural 
differences (reviewed in Ref.132) that enable distinct protein interactions to confer unique 
physiological functions of YAP versus TAZ. Notably, global YAP deletion in mice is 
embryonic lethal (E8.5) due to impaired yolk sac vasculogenesis204, while the global TAZ 
knockout lives to maturity with modest skeletal defects and polycystic kidney disease205, 
demonstrating conclusive gene-specific functions. However, in other contexts, they exhibit 
clear functional homology, with either protein capable of compensation for the other188,206.  
Roles for YAP and TAZ in osteogenesis were first described in 2004 and 2005, 
respectively112,113. YAP was reported to suppress osteoblastic differentiation through 
sequestration and transcriptional repression of Runx2112, while TAZ was identified as a 
Runx2 co-activator and an inhibitor of the adipogenic nuclear receptor, PPARγ113,157. A 
subsequent study found that overexpression of a constitutively-active YAP mutant in 
marrow stromal cells (MSCs) promoted osteogenic differentiation even under conditions 
more favorable for adipogenesis150. In contrast, another report found that YAP 
overexpression inhibited osteogenesis in MSCs by suppressing activation of WNT target 
genes147. The role of TAZ in osteogenic differentiation in vitro is similarly complicated, 
with reports demonstrating both inhibition148 and induction160 of osteogenic differentiation 
by modulating the canonical WNT pathway. In vivo, osteoblast-specific overexpression of 
TAZ promoted bone formation with higher expression levels of Runx2 expression175, while 
YAP overexpression in chondrocytes impaired cartilage template formation during 
endochondral bone development181. Together, these observations suggest the importance 
of YAP and TAZ in bone, but the conflicting evidence remains unresolved and their 
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combinatorial roles in bone physiology remain unknown. To address these questions, we 
implemented a combinatorial deletion approach in vivo to evaluate the influence of allele 
dosage-dependent YAP/TAZ deletion on bone development. 
2.3 Methods 
2.3.1 Animals 
Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed 
C57BL/6J background were kindly provided by Dr. Eric Olson (University of Texas 
Southwestern Medical Center). Tetracycline responsive (tetOFF) B6.Cg-Tg(Sp/7-
tTA,tetO-EGFP/Cre)1AMc/J (Osterix-Cre) mice from The Jackson Laboratory (Bar 
Harbor, MA, USA) were raised, bred, and evaluated without tetracycline administration to 
induce constitutive gene recombination in osteoprogenitor cells and their progeny from 
embryonic development onward63.  
Mice with homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl) 
were mated with double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;Osx-
Cre) to produce eight possible genotypes in each litter, but only Cre-positive and 
YAPfl/fl;TAZfl/fl  animals were compared (Table 2-1). Both male and female mice were 
evaluated, with YAPfl/fl;TAZfl/fl mice serving as littermate control mice (WT). The different 
analyses were performed in both male and female young mice at postnatal day 0 (P0), 
postnatal day 10 (P10), postnatal day 28 (P28), and postnatal day 56 (P56). All mice were 
fed regular chow ad libitum and housed in cages containing 2-5 animals each. Mice were 
maintained at constant 25°C on a 12-hour light/dark cycle. Mice were tail or ear clipped 
after weaning or prior to euthanasia and genotyped by an external service (Transnetyx, Inc., 
Cordoba, TN, USA). All protocols were approved by the Institutional Animal Care and 
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Use Committees at the University of Notre Dame and the University of Pennsylvania and 
in adherence to federal guidelines for animal care. 








2.3.2 Skeletal preparations 
Skeletal preparations were stained with Alcian blue (A3157; Sigma-Aldrich, St. 
Louis, MO, USA) and Alizarin red (A5533; Sigma-Aldrich, St. Louis, MO, USA) as 
described previously207.  
2.3.3 Microcomputed tomography 
Micro-computed tomography (microCT) was performed according to published 
guidelines208. Harvested femora from P56 mice were stored at -20°C until evaluation. 
Frozen specimens were thawed and imaged using a vivaCT 80 scanner (Scanco Medical, 
Zurich, Switzerland) to determine trabecular and cortical femoral bone architecture prior 
to mechanical testing. The mid-diaphysis and distal femur were imaged with an X-ray 
intensity of 114 µA, energy of 70 kVp, integration time of 300 ms, and resolution of 10 
µm. Mid-diaphyseal and distal femoral 2D tomograms were manually contoured, stacked 
and binarized by applying a Gaussian filter (sigma =1, support =1) at a threshold value of 
550 mg HA/cm3. Eight mice were analyzed per group except for the YAPcKO;TAZcKO 






Yapfl/fl;Tazfl/fl;Osx-CretetOff  YAPcKO;TAZcKO 
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2.3.4 Mechanical testing 
Following microCT scanning, femurs from P56 mice were tested in three point 
bending to failure. Femurs were loaded with the condyles facing down onto the bending 
fixtures with a lower span length of 4.4 mm, which attenuated the effect of femur length 
on the measured mechanical properties. The upper fixture was aligned with the mid-
diaphysis. The femora were loaded to failure at a rate of 0.5 mm/s using the ElectroForce 
3220 Series testing system (TA Instruments, New Castle, DE, USA). Stiffness, maximum 
load to failure, work to maximum load and work to failure were quantified using a custom 
MATLAB script170. Eight mice were analyzed per group except for the YAPcKO;TAZcKO 
genotype. Investigators were blinded to animal genotype during data quantification.  
2.3.5 Histology, immunohistochemistry, and immunofluorescence 
Femurs and tibias from P10, P28, and P56 mice were fixed with 10% neutral 
buffered formalin for 48 hours and decalcified following standard procedures. Paraffin 
sections (5 µm thickness) for were processed for either immunohistochemistry or 
histology. Primary antibodies were compared to IgG control sections. Anti-Osterix (abcam, 
Eugene, OR, USA: Cat# ab22552, 1:250), anti-YAP (Cell Signaling, Danvers, MA, USA: 
Cat# 14074, 1:400), anti-TAZ (Cell Signaling, Danvers, MA, USA: Cat# 4883, 1:400) 
were applied overnight. Colorimetric detection using the DAB Peroxidase HRP-linked 
Substrate Kit (Vector Labs, Burlingame, CA, USA) allowed for immunohistochemical 
detection of YAP, TAZ, or Osterix-positive cells. Hematoxylin and eosin stains (H&E), 
Safranin O/Fast Green (Saf-O), Tartrate-resistant acid phosphatase (TRAP), and 
Picrosirius Red stains were used.  
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Methyl-methacrylate-embedded bones from P28 mice injected with Calcein (Sigma 
#:  C0875-25G) and Alizarin Complexone (Sigma #:A3882-25G ) were processed for 
dynamic bone histomorphometry. Using a diamond-embedded wire saw (Histo-saw; 
Delaware Diamond Knives, Wilmington, DE, USA), transverse sections (40 µm) were cut 
from the midshaft and ground to a final thickness of 20 µm. The slice sections were 
mounted on slides, and three sections per limb were analyzed using OsteomeasureTM 
(OsteoMetrics, Decatur, GA, USA).  
2.3.6 Imaging and histomorphometric analysis 
Histological and immunohistochemical sections were imaged either on a 90i 
Upright/Widefield Research Microscope (Nikon Instruments, Melville, NY, USA) at the 
4x, 10x, 20x, and 40x objectives or an Axio Observer Z1 (Zeiss) at the 20x and 40x 
objectives. Osteoblast number per bone surface and osteocyte number per bone area were 
quantified using OsteomeasureTM (OsteoMetrics, Decatur, GA, USA) and ImageJ (NIH, 
Bethesda, MD, USA) on H&E stained sections in the cortical bone compartment using 3-
6 separate fields of view per mouse. Osteoclast surface per bone surface was quantified on 
TRAP stained sections in the cancellous bone compartment using 3 separate fields of view 
per mouse. Hypertrophic chondrocyte zone percent thickness (HZ thickness %) was 
calculated using ImageJ (NIH, Bethesda, MD, USA) by measuring three separate lines 
across the area of positive Saf-O staining in the center metaphyseal region, normalized to 
the respective length of the total growth plate within each line, and averaged together for 
each mouse. 
The samples tested in three-point bending were stained with Picrosirius Red and 
imaged under polarized light using an Eclipse ME600 Microscope (Nikon Instruments, 
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Melville, NY, USA) at the 20x objective while second harmonic image microscopy (SHG) 
images were taken on a multiphoton-enabled Fluoview Research Microscope (Olympus, 
Center Valley, PA, USA) at a fundamental wavelength of 875nm with the 25x objective 
on sections oriented in the same direction for all groups. All SHG images were quantified 
using ImageJ and reported as mean pixel intensity within the cortical region relative to WT 
bone. Mean pixel intensities across four separate regions of interest within each image of 
the cortex were averaged as technical replicates for a given sample.  
Dynamic bone histomorphometry sections of P28 femurs were imaged on an Axio 
Observer Z1 (Zeiss) at the 20x, 40x, and 63x objectives. Dynamic bone histomorphometry 
parameters were quantified using OsteomeasureTM (OsteoMetrics). The following primary 
data were collected: total bone surface length (BS); single label perimeter (sL.Pm); double 
label perimeter (dL.Pm); and double label width (dL.Ith). From primary data, we derived 
mineralizing surface (MS/BS = [1/2sL.Pm+dL.Pm]/B.Pm ×100; %); mineral apposition 
rate (MAR = dL.Ith/5 days; µm/day) and bone formation rate (BFR/BS = MAR × MS/BS; 
µm3/µm2 per day). Eight mice were analyzed per group except for the YAPcKO;TAZcKO 
genotype. Investigators were blinded to animal genotype during image acquisition and 
quantification of all histology and immunofluorescent images. 
2.3.7 Marrow stromal cell isolation and culture 
Mouse bone marrow stromal cells (MSCs) were isolated from either WT or Osterix 
conditional YAP/TAZ deficient mice and cultured at 37°C and 5% O2 in media 
supplemented with FGF-2, as described previously209. Briefly, mice were anesthetized by 
isoflurane inhalation (2%) and euthanized via cervical dislocation. Long bone samples 
were dissected and then marrow cavities were flushed out into a tissue culture plastic flask 
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for 3-5 days. MSCs were cultured at 5% O2 in Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% FBS, 10 ng/ml bFGF (Austral Biologicals, San Ramon, CA, cat # GF-
030-5), 1% penicillin-streptomycin, and 1 µg/ml doxycycline.  
During passaging, culture media was removed and the cells were quickly rinsed 
once with 4mL of TrypLE Express Enzyme (Thermo-Fisher Scientific, Philadelphia, PA, 
USA, cat# 12605036) by rolling the trypsin over the plate to allow the senescent cells from 
the cultures to initially detach209. These senescent cells were then discarded prior to 
standard passaging of the MSCs. MSCs were then seeded, at 21% O2, into 6-well plates (9 
x 103 cells/cm2) containing 30 mL osteogenic induction media, which included 2 mg/ml b-
glycerophosphate, 50 µM dexamethasone, and 3.75 mg/ml ascorbic acid to the previously 
described media without doxycycline of FGF-2. Osteogenic media was changed every 
other day prior to RNA isolation.  
2.3.8 UMR-106 cell culture 
Osteoblast-like UMR-106 cells (UMRs) were cultured in DMEM containing 4 mM 
L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500 mg/L sodium 
bicarbonate and 10% FBS according to American Type Culture Collection (ATCC, 
Manassas, VA, USA: Catalog #: 30-2002) recommendations. UMRs at 50 % confluence in 
96-well plates were transfected in antibiotic-free media for four hours with four previously 
described luciferase reporter constructs: 1) Runx2-responsive 6xOSE2, 2) 657 bp 
Osteocalcin promoter210, 3) TEAD-responsive 8XGTIIC (Addgene, Cambridge, MA, 
USA) and a control renilla plasmid, kindly provided by Dr. Munir Tanas (University of 
Iowa).  
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Forty-eight hours after transfection, UMRs were treated with either DMSO, 0.5 
µM, or 1 µM verteporfin (VP) for 4 hours then in serum-free conditions for 3 hours. All 
VP experiments were carried out in the dark to prevent photoactivation. Cells were then 
lysed immediately using the Dual-Luciferase Reporter Assay System according to 
manufactures instructions (Promega, Madison, WI, USA). Luciferase activity was 
measured on a VICTOR 3 (Perkin Elmer, Waltham, MA, USA) plate reader and 
normalized to baseline renilla activity as previously described211. Separately cultured 
UMR-106 cells were seeded (4 x 103 cells/cm2) onto 6-well plates and simultaneously 
treated with either DMSO, 0.5 µM, or 1µM VP and cultured for 4 hours and then under 
serum-free conditions for 3 hours prior to RNA isolation.  
2.3.9 Verteporfin delivery in vivo 
Six littermate control (four male and two female) mice (YAPWT;TAZWT) were aged 
until 16 weeks. Three mice each (two males and one female each) were assigned to 
verteporfin (VP) or vehicle control (dimethyl sulfoxide, DMSO) groups. Briefly, DMSO-
solubilized VP was diluted in 0.9% saline and injected intraperitoneally at 100 mg/kg every 
other for day for 2 weeks. Control animals received corresponding injections of DMSO in 
0.9% saline. Livers and femurs from both VP-treated and DMSO-treated mice were 
harvested on the day of the last injection for RNA isolation. 
2.3.10 RNA isolation and qPCR 
Bone and liver samples were snap frozen in liquid nitrogen-cooled isopentane for 
1 minute prior to storage at -80°C until processing. Tissue was then homogenized via 
mortar and pestle and RNA from the sample was collected using Trizol Reagent (Life 
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Technologies Inc., Carlsbad, CA, USA) followed by centrifugation in chloroform. RNA 
from tissue samples and cell culture experiments were purified using the RNA Easy Kit 
(Qiagen, Germantown, MD, USA) and quantified by spectrophotometry using a NanoDrop 
2000 (Thermo-Fisher Scientific, Philadelphia, PA, USA). Reverse transcriptase 
polymerase chain reaction (RT-PCR) was performed on 0.1-0.5 μg/μl concentration of 
RNA using the TaqMan Reverse Transcription Kit (Thermo-Fisher Scientific, 
Philadelphia, PA, USA). Quantitative polymerase chain reaction (qPCR) assessed RNA 
amount using a CFX Connect (Bio-Rad, Hercules, CA, USA) relative to the internal control 
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are presented using the 
DDCt method. Six mice per group were used except for the YAPcKO;TAZcKO genotype. 
Specific mouse and rat primer sequences are listed (Table 2-2).   
Table 2-2: qPCR primers (Aim 1) 
A) Mouse primers used for qPCR B) Rat primers used for qPCR 
A) Mouse gene Primer Sequence (5’ to 3’) 
Gapdh F R 
TCACTGCCACCCAGAAGAC 
TGTAGGCCATGAGGTCCAC 
Yap F R 
TGGACGTGGAGTCTGTGTTG 
AAGCGGAACAACGATGGACA 
Taz F R 
GTCCATCACTTCCACCTC 
TTGACGCATCCTAATCCT 
Col1a1 F R 
GCTCCTCTTAGGGGCCACT 
CCACGTCTCACCATTGGGG 
Col1a2 F R 
GTAACTTCGTGCCTAGCAACA 
CCTTTGTCAGAATACTGAGCAGC 
Col2a1 F R 
GACTGAAGGGACACCGAG 
CCAGGGATTCCATTAGAG 
Col10 F R 
ATGCTGCCTCAAATACCCT 
TGCCTTGTTCTCCTCTTACT 




Runx2 F R 
AGCCTCTTCAGCGCAGTGAC 
CTGGTGCTCGGATCCCAA 
Osx F R 
CTGGGGAAAGGAGGCACAAAGAAG 
GGGTTAAGGGAGCAAAGTCAGAT 
Ocn F R 
TGAGCTTAACCCTGCTTGTG 
TAGGGCAGCACAGGTCCTA 
Alp F R 
GGACAGGACACACACACACA 
CAAACAGGAGAGCCACTTCA 
Bsp F R 
ACAATCCGTGCCACTCACT 
TTTCATCGAGAAAGCACAGG 
Cyr61 F R 
CTGCGCTAAACAACTCAACGA 
GCAGATCCCTTTCAGAGCGG 
Ctgf F R 
GGGCCTCTTCTGCGATTTC 
ATCCAGGCAAGTGCATTGGTA 
B) Rat gene Primer Sequence (5’ to 3’) 
Gapdh F R 
CATGGCCTTCCGTGTTCCTA 
GCGGCACGTCAGATCCA 
Col1a1 F R 
ACAGCGTAGCCTACATGG 
AAGTTCCGGTGTGACTCG 
Col1a2 F R 
ATGGTGGCAGCCAGTTTG 
GCTGTTCTTGCAGTGGTAGG 
SerpinH1 F R 
TCATGGTGACCCGCTCCTAC 
GCTTATGGGCCAAGGGCATC 
Runx2 F R 
CAGGTTCAACGATCTGAGATTTGT 
TGAAGACCGTTATGGTCAAAGTGA 
Osx F R 
CAGCCTGCAGCAAGTTTGG 
TTTTCCCAGGGCTGTTGAGT 
Alp F R 
GAGCAGGAACAGAAGTTTGC 
GTTGCAGGGTCTGGAGAGTA 
Bsp F R 
TCCTCCTCTGAAACGGTTTCC 
CGAACTATCGCCATCTCCATT 





2.3.11 Statistics and regression 
All statistics and regression analyses were performed in GraphPad Prism (San Diego, 
CA, USA) or using R (Version 2.13.1). Comparisons between two groups were made using 
the independent t-test while comparisons between 3 or more groups were made using a 
one-way ANOVA with post-hoc Bonferroni’s multiple comparisons test, if the data were 
normally distributed according to D’Agostino-Pearson omnibus normality test and 
homoscedastic according to Bartlett’s test. When parametric test assumptions were not met, 
data were log-transformed and residuals were evaluated. If necessary, the non-parametric 
Kruskal-Wallis test with post-hoc Dunn’s multiple comparisons was used. A p-value < 
0.05 (adjusted for multiple comparisons) was considered significant. On the graphs, 
repeated significance indicator letters (e.g., “a” vs “a”) signify P > 0.05. while groups with 
distinct indicators (e.g., “a” vs “b”) signify P < 0.05. Data are represented as individual 
samples with mean ± standard error of the mean (SEM). Sample sizes were selected a 
priori by power analysis based on effect sizes and population standard deviations of 
phenotypic differences taken from published data on YAPfl/fl;TAZfl/fl mice in other 
tissues,188 assuming a power of 80% and α=0.05. 
Multivariate analysis was performed following a previously described procedure, with 
some modifications212. Briefly, we used an exhaustive best subsets algorithm to determine 
the best predictors of maximum load and stiffness from a subset of morphological 
parameters measured, which included moment of inertia (I) or section modulus (I/c), tissue 
mineral density (TMD), and relative second harmonic generated (SHG) intensity based on 
the Akaike’s information criterion (AIC).213 The best subsets algorithm selects the optimal 
model using the Akaike’s information criterion (AIC), which gives preference to less 
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complex models with fewer explanatory parameters to avoid overfitting the data213. The 
overall “best” multivariate model for each predicted mechanical property was selected with 
the lowest relative AIC value, indicative of having the least variables with the greatest 
predictive power. AIC values were used to determine the “best” model for predicting new 
data instead of R2 values, which describe how well the model fits existing data. Further, 




2.4.1 YAP/TAZ expression and deletion in bone 
To determine YAP/TAZ expression profiles in bone, we immunostained YAP and 
TAZ in the growth plate and cancellous and cortical bone of 8-week-old C57Bl6/J mouse 
femora. YAP and TAZ immunolocalized in hypertrophic chondrocytes, osteoblasts, and 
osteocytes with minimal detectable expression in quiescent or proliferating chondrocytes 
(Figure 2-1A). Based on these expression patterns, we chose to evaluate the physiological 
roles of YAP and TAZ by combinatorial conditional ablation188 in cells of the skeletal 
lineage using Osterix-Cre63. We selected a breeding strategy that yielded littermates with 
variable YAP/TAZ allele dosage. To assess Cre-mediated recombination and deletion of 
YAP and TAZ, we measured mRNA expression in femoral bone preparations by qPCR 
(Figure 2-1B), and qualitatively observed reduced cellular expression in the growth plate 
of conditional knockout mice by IHC (Figure 2-1C). YAP/TAZ expression in skeletal cells 




Figure 2-1: YAP/TAZ expression and deletion in skeletal cells. 
In vivo YAP/TAZ expression and deletion efficiency were assessed by immunohistochemistry (IHC) and 
quantitative (qPCR). A) YAP/TAZ were expressed in hypertrophic chondrocytes, osteoblasts, and osteocytes 
in bone. Scale bars in the first column are 50 microns for the growth plate, and 100 microns for magnified 
images of trabecular and cortical bone. B) YAP and TAZ transcript expression in Osterix-conditional 
knockout mice in femoral bone lysates. C) Qualitative comparison of IHC for YAP and TAZ expression in 
Osterix-conditional cKO growth plates. Scale bars in the first column are 50 microns. 
2.4.2 Neonatal lethality and hypermineralization 
All Osterix-conditional knockouts and littermate controls were born at expected 
Mendelian ratios, but dual homozygous conditional deletion (YAPcKO;TAZcKO) caused 
neonatal asphyxiation secondary to ribcage malformation and fracture (Figure 2-2A-C), 
resulting in 75% mortality at postnatal day 0 (P0) and 99% by P7 (Figure 2-2B). Only one 
female YAPcKO;TAZcKO mouse lived to P56 for each endpoint analysis. YAPcKO;TAZcKO 
neonates exhibited spinal scoliosis, cranial vault deformity, and spontaneous fractures of 
the ribs, tibia, femur, radius and ulna (Figure 2-2A,C-E). Spontaneous extremity fractures 
were not present in other genotypes at P0 (Figure 2-2A). YAPcKO;TAZcKO  mice displayed 
reduced whole-skeleton bone volume (Figure 2-2F; p < 0.05, ANOVA) and significantly 
elevated bone tissue mineral density (Figure 2-2G; p < 0.01, ANOVA) compared to 
littermate control mice. Osterix-conditional YAP/TAZ deletion also significantly reduced 
birth weight and intact femoral length in an allele dosage-dependent manner (Figure 2-3). 
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Males and females exhibited similar phenotypes in both growth deficits and P0 skeletal 
morphology (Figure 2-3). 
 
Figure 2-2: Combinatorial YAP/TAZ ablation from Osterix-expressing cells caused allele dosage-
dependent perinatal skeletal deformity and lethality. 
Skeletal structures of littermate mice were evaluated at postnatal day 0 (P0). A) Whole body skeletal 
preparations of Osterix-conditional YAP/TAZ knockouts and controls stained with Alcian blue/Alizarin red 
and microCT reconstructions reveal progressive skeletal malformation with decreasing allele dosage. B) 
Survival curves for each genotype show 99% lethality of YAPcKO;TAZcKO mice by P56. C-E) Skeletal 
preparations and microCT reconstructions of rib cages, hindlimbs, and femora, respectively, illustrate 
spontaneous perinatal fractures in YAPcKO;TAZcKO mice. F) P0 whole skeleton bone volume was 
significantly altered by dual homozygous YAP/TAZ deletion. G) P0 whole skeleton tissue mineral density 
(TMD increased with YAP/TAZ allele deletion. Data are presented as individual samples with lines 




Figure 2-3: Allele dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-week-old mice 
reduced overall long bone growth independent of sex. 
Allele-dosage-dependent YAP/TAZ ablation from Osterix-expressing cells reduced body mass in (A,B) male 
and (D,E) female mice with similar trends in (C,F) survival curves for each sex by P56. Reduced femoral 
length in (G) males and (H) females. * indicates death of male YAPcKO;TAZcKO mouse at P10, “a” indicates 
difference between YAPcHET;TAZcHET and WT, “b” indicates difference between YAPcKO;TAZcHET and WT, 
“c” indicates difference between YAPcHET;TAZcKO and WT, “d” indicates difference between 
YAPcKO;TAZcKO and WT. Sample sizes, n = 8 for both sexes and genotypes at except n = 1 for 
YAPcKO;TAZcKO male and n = 2 for YAPcKO;TAZcKO females.  I) P0 bone volumes reduced similarly between 
sexes with # indicating lower bone volumes in YAPcKO;TAZcKO mice for both sexes. Sample sizes, n = 7-15 
per genotype at P0. 
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2.4.3 Spontaneous neonatal long bone fractures & defective endochondral bone 
formation 
A single copy of either gene rescued neonatal lethality, with 83 and 85% of 
YAPcHET;TAZcKO and YAPcKO;TAZcHET mice surviving to terminal analysis at P56, 
respectively. However, between P1 and P10, both YAPcHET;TAZcKO and YAPcKO;TAZcHET 
mice sustained spontaneous femoral and other bone fractures (Figure 2-4A-B), with 
significantly increased femoral fracture incidence in the YAPcHET;TAZcKO mice (p<0.01, 
χ2 test; Figure 2-4C). Fractures healed by endochondral repair in all groups, though 
YAPcHET;TAZcKO and YAPcKO;TAZcKO calluses exhibited empty lacunae in the 
hypertrophic transition zone, suggesting increased hypertrophic chondrocyte death or 
insufficient progenitor cell recruitment (Figure 2-4C c.f. Figure 2-4D). Consistently, 
staining of Osterix-positive cells was qualitatively reduced in the transition zone of the 
YAPcKO;TAZcKO growth plate, but differences in the thickness of the resting (RZ), 
proliferating (PZ), and hypertrophic (HZ) zones of the growth plate did not reach statistical 
significance at either P10 (p>0.05, Figure 2-4E-G) or P56 (p>0.05, Figure 2-5A,B).  
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Figure 2-4: YAP/TAZ ablation from Osterix-expressing cells induced spontaneous neonatal femoral 
fractures and impaired endochondral bone formation. 
A) Representative radiographs with matched (B) microCT reconstructions of femoral fracture calluses at 
P10. C) Quantification of the number of mice with femoral fractures demonstrated significantly increased 
fracture incidence in YAPcHET;TAZcKO mice. D) Safranin-O/fast green staining of mid-diaphysis bone collar 
and (E) growth plates of matched P10 femora split into resting zone (RZ), proliferating zone (PZ), and 
hypertrophic zone (HZ). Scale bar = 50 µm. F) Histomorphometric quantification of P10 hypertrophic zone 
thickness as percentage of total growth plate thickness (HZ thickness %). G) Representative micrographs of 
P10 distal femur growth plates immunostained for osterix-positive cells (brown). Scale bar = 25 µm. Data 
presented as individual samples with lines corresponding to the mean and standard error of the mean (SEM). 





Figure 2-5: Allele-dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-weeks-old mice 
does not significantly alter growth plate morphology. 
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A) Safranin-O/fast green staining of P56 femoral growth plates with inset of larger field of view. Scale bar = 
50 µm. B) Quantification of P56 hypertrophic zone thickness as a percentage of total growth plate thickness 
in the femoral metaphyseal region (HZ thickness %). Data presented as individual samples with lines 
corresponding to the mean and standard error of the mean (SEM). Sample sizes, n = 8 mice except 
YAPcKO;TAZcKO n = 1. 
2.4.4 Reduced cortical and cancellous microarchitectural properties 
YAP/TAZ deletion from osteoblast precursor cells and their progeny altered 
cancellous (Figure 2-6A,B) and cortical bone (Figure 2-6C,D) in adolescent mice (P56) 
according to allele dosage. Distal femur metaphyseal cancellous bone exhibited reduced 
trabecular bone volume fraction (BV/TV), thickness (Tb.Th), and number (Tb.N), and 
increased spacing (Tb.Sp) and structural model index (SMI, indicative of more rod-like 
trabeculae) (Figure 2-6B, Figure 2-7A-C). The cumulative distribution of trabecular 
thicknesses shifted in an allele dosage-dependent manner, toward reduced numbers of both 
small and large trabeculae (Figure 2-7B). Volumetric bone mineral density was 
significantly reduced, suggesting no differences in local tissue mineral density proportional 
to the decrease in trabecular bone volume (Figure 2-6B). Mid-diaphyseal femoral cortical 
bone (Figure 2-6C,D, Figure 2-7D,E) similarly exhibited reduced thickness (Ct.Th), area 
(B.Ar), and moment of inertia (I) in cKO mice, attributable both to reduced periosteal and 
endocortical bone accumulation, as indicated by significant reductions in endocortical 
perimeter (Ec.Pm), periosteal perimeter (Ps.Pm), and bone area (B.Ar). Cortical tissue 
mineral density (Ct.TMD) was not significantly altered. 
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Figure 2-6: YAP/TAZ ablation altered bone microarchitectural properties in a manner dependent on allele 
dosage. 
Femora from 8 weeks-old Osterix-conditional YAP/TAZ littermates were evaluated by microCT analysis. 
A) Representative microCT reconstructions of distal metaphyseal cancellous bone, arranged in decreasing 
allele dosage. B) Cancellous bone microarchitectural parameters were impaired according to YAP/TAZ allele 
dosage: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), number (Tb.N) and spacing (Tb.Sp), 
volumetric bone mineral density (vBMD), and structural model index (SMI). C) Representative microCT 
reconstructions of the mid-diaphyseal cortex, arranged in decreasing allele dosage. D) Cortical cross-
sectional properties were reduced in cKO mice: bone area (B.Ar), endocortical perimeter (Ec.Pm), periosteal 
perimeter (Ps.Pm), cortical thickness (Ct.Th), moment of inertia in the direction of bending (I), and cortical 
tissue mineral density (Ct.TMD). Data are presented as individual samples with lines corresponding to the 
mean and standard error of the mean (SEM). Sample sizes, n= 8 mice except YAPcKO;TAZcKO n = 1. Scale 




Figure 2-7: Allele-dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-week-old mice 
altered bone microarchitecture. 
Femora from 8 weeks-old Osterix-conditional YAP/TAZ littermates were evaluated by microCT analysis. 
A) Representative 3D microCT reconstructions of distal metaphyseal cancellous bone, arranged in decreasing 
allele dosage. B) Trabecular thickness histogram distributions (Tb.Th). C) Total tissue area and D) medullary 
area of cortical bone from the mid-diaphysis. Sample sizes, n= 8 except YAPcKO;TAZcKO n = 1. 
2.4.5 Reduced intrinsic bone mechanical properties and matrix collagen content and 
microstructure 
In general, extrinsic bone properties (e.g., failure load, bending stiffness) depend 
on both the intrinsic mechanical properties of the bone matrix and the bone amount and 
cross-sectional distribution. To determine whether Osterix-conditional YAP/TAZ deletion 
impaired bone matrix quality, we performed three-point bend testing to failure on each 
femur previously analyzed by microCT (Figure 2-8A,B). YAP/TAZ deletion reduced 
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stiffness, maximum force at failure, work to maximum load, and work to failure (Figure 2-
8C-F). Since the assumptions of Euler-Bernoulli beam theory are decidedly not met in 
three-point bend testing of mouse long bones214,215, we performed an analysis of covariance 
(ANCOVA) using linear regression (Figure 2-8G,H) to decouple the contributions of bone 
quantity and distribution from the mechanical behavior216. If the variability in extrinsic 
mechanical properties is best predicted by individual regression lines for each genotype, 
this would indicate differences in intrinsic matrix mechanical properties between 
genotypes; however, a best-fit by a single regression line for all groups would indicate that 
differences in extrinsic behavior are sufficiently described merely by changes in bone 
geometry216. We found that individual regression lines for each genotype best predicted 
maximum load at failure, indicating significant differences in intrinsic failure properties 
(Figure 2-8G). In contrast, a single regression line best fit the stiffness data (Figure 2-8H), 
indicating that the differences in stiffness can be attributed to changes in moment of inertia 
rather than intrinsic matrix elastic properties. 
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Figure 2-8: YAP/TAZ ablation reduced intrinsic bone failure properties. 
Femora from 8-weeks-old osterix-conditional YAP/TAZ littermates were tested in (A) three point bending 
to failure. B) Representative, average load-displacement curves collected during testing. C-F) YAP/TAZ 
deletion reduced extrinsic mechanical properties measured from the load-displacement curves including (C) 
maximum load, (D) stiffness, (E) work to maximum load and (F) work to failure. ANCOVA analysis 
accounting for bone geometry revealed significant differences in (G) intrinsic failure properties, but not (H) 
intrinsic elastic properties. Data are presented as individual samples with lines corresponding to the mean 
and standard error of the mean (SEM). Sample sizes, n = 8, except YAPcKO;TAZcKO, n = 1. 
 
As a composite material, quasi-static bone mechanical behavior is determined 
predominantly by its two primary matrix components: mineral and collagen. We noted 
above that femora from mice with Osterix-conditional YAP/TAZ deletion did not exhibit 
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differences in mineralization (Figure 2-6D). Next, to characterize the bone matrix collagen 
in these same samples, we performed polarized light microscopy of Picrosirius red-stained 
sections (Figure 2-9A) and second harmonic imaging microscopy (SHG, Figure 2-9B)217. 
Both approaches revealed that YAP/TAZ deletion significantly reduced local collagen 
content and organization (Figure 2-9C). Therefore, to determine the contributions of 
geometry, mineralization, and collagen content and microstructure to bone mechanical 
behavior, we performed a best-subsets correlation analysis to identify significant predictors 
based on Akaike’s information criterion (AIC)212,213. For both elastic (Figure 2-9D) and 
failure (Figure 2-9E) properties, bone tissue mineral density was not a significant predictor; 
however, moment of inertia and SHG intensity significantly improved model capability to 
explain variation with reduced AIC (Figure 2-10). Addition of tissue mineral density 
(TMD) to the models did not improve predictive power as measured by AIC (Figure 2-10). 
 
Figure 2-9: YAP/TAZ ablation reduced bone matrix collagen content and organization. 
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Imaging of matrix collagen was performed on femora from 8 weeks-old osterix-conditional YAP/TAZ 
littermates. Representative (A) polarized light and (B) second harmonic generation (SHG) microscopy 
images from cortical bone tissue sections of three-point bend tested femora. C) Second harmonic generated 
(SHG) intensity, relative to WT, was reduced according to allele-dosage. Best subsets regression analyses 
indicating significant contributions of both bone geometry and collagen content and microstructure, but not 
tissue mineral density, to both (D) elastic and (E) failure mechanical properties. Sample sizes, n = 8 except 





Figure 2-10: Best subsets analysis on morphological parameters from YAP/TAZ ablation in Osterix-
expressing cells from 8-week-old mice demonstrated increased predictiveness by accounting for collagen 
content and organization. 
Within the mice with Osx-driven deletion of YAP/TAZ, we compared experimental ultimate load (Fmax) with 
predicted model values with (A) only moment of inertia as a predictor, (B) moment of inertia and second 
harmonic generated signal intensity, or (C) moment of inertia, second harmonic generated signal intensity, 
and tissue mineral density. Similarly, we compared experimental to predicted stiffness using (D-F) the same 
predictors, respectively. Akaike’s information criterion (AIC) was at a minimum for both ultimate load and 
stiffness with geometry and SHG as independent parameters, suggesting optimal predictive power by 
geometry and SHG. Sample sizes n = 8, except YAPcKO;TAZcKO n = 1. 
 
Static histomorphometric analysis of Osterix-conditional YAP/TAZ-deficient P56 
femora revealed an allele dose-dependent decrease in periosteal osteoblast number per 
bone surface (Ob.N/BS), but a dose-dependent increase in osteoclast surface per bone 
surface (Oc.S/BS) in the metaphyseal secondary spongiosa (Figure 2-11A,B,D-E). Cortical 
osteocyte density (Ot.N/B.Ar) was not significantly altered (Figure 2-11A,F). Dynamic 
histomorphometric analysis of Osterix-conditional YAP/TAZ deficient P28 femora 
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revealed no significant differences in mineralizing surface percentage (MS/BS), while 
mineral apposition rate (MAR) was significantly reduced, according to allele dosage 
(Figure 2-11C,G,H). Differences in bone formation rate (BFR/BS) did not reach statistical 
significance (Figure 2-11C,I). YAP/TAZ deletion qualitatively reduced fluorescent 
labeling of epiphyseal and metaphyseal cancellous bone compartments (Figure 2-12).  
 
Figure 2-11: YAP/TAZ ablation reduced osteoblast numbers and increased osteoclast activity. 
Femora were evaluated by static and dynamic histomorphometry from Osterix-conditional YAP/TAZ 
deletion. A) Representative micrographs of P56 mid-diaphyseal cortical bone stained by H&E from the 
Osterix-conditional YAP/TAZ deletion. B) Representative micrographs of P56 metaphyseal cancellous bone 
stained by TRAP from the Osterix-conditional YAP/TAZ deletion. C) Representative micrographs of double 
fluorochrome-labeled P28 femoral cortices. Static histomorphometric quantification of (D) osteoblast per 
bone surface (Ob.N/BS) and (E) osteocyte number per bone area (Ot.N/B.Ar) quantified in the mid-diaphysis 
and (F) the osteoclast surface per bone surface (Oc.S/BS) quantified in the metaphyseal region. Dynamic 
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histomorphometric quantification of (G) mineralizing surface percentage (MS/BS), (H) mineral apposition 
rate (MAR) and (I) bone formation rate (BFR/BS). Data presented as individual samples with lines 
corresponding to the mean and standard error of the mean (SEM). Sample sizes n = 8, except YAPcKO;TAZcKO 
n = 1. Scale bars indicate 25, 50, and 100 μm in H&E, TRAP, and double labeled micrographs, respectively. 
 
 
Figure 2-12: YAP/TAZ ablation qualitatively reduced mineralized bone formation in cancellous 
compartments. 
Femora were evaluated by dynamic histomorphometry from Osterix-conditional YAP/TAZ deletion. A) 
Qualitative comparison of micrographs from double fluorochrome labeled P28 femoral cortices. Sample sizes 
n = 8, except YAPcKO;TAZcKO n = 1. Scale bar indicate 200 μm. 
2.4.6 YAP/TAZ-deletion and acute YAP/TAZ-TEAD inhibition reduced osteogenic 
and collagen-related gene expression 
To identify potential YAP/TAZ transcriptional targets, we evaluated expression of 
candidate genes known to regulate osteogenesis or whose mutations cause osteogenesis 
imperfecta in bone marrow stromal cells (BM-MSCs) isolated from WT and Osterix-
conditional YAPcKO;TAZcKO mice. For all tested genes, mRNA expression levels were 
equivalent prior to osteogenic induction, verifying Osterix-dependence of gene 
recombination (Figure 2-13). However, after seven days in osteogenic media, Osterix-
conditional Cre-mediated recombination evaluated by qPCR significantly reduced TAZ 
mRNA expression, while the reduction in YAP expression did not reach statistical 
significance (Figure 2-14A,B). However, mRNA expression of canonical YAP/TAZ target 
genes, Cyr61 and Ctgf, was significantly reduced (Figure 2-15A,B). Of the collagen-related 
genes, mRNA expression of Col1a1 and SerpinH1, but not Col1a2, collagen type II (Col2) 
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or collagen type 10 (Col10) was significantly reduced in YAP/TAZ cKO cells (Figure 2-
14C-E, Figure 2-15C,D). Of the osteogenic genes, mRNA expression of osteocalcin (Ocn), 
alkaline phosphatase (Alp), and bone sialoprotein (Bsp) were significantly reduced, but 
expression of Runx2 and Osterix were not altered (Figure 2-14F-J).  
We next sought to determine whether this gene regulation was dependent on 
YAP/TAZ-TEAD in osteoblast-like cells using a small molecule inhibitor, verteporfin 
(VP), which blocks YAP/TAZ interaction with TEAD218. We found that VP treatment of 
osteoblast-like UMR-106 cells reduced expression of the known YAP/TAZ-TEAD target 
gene, CTGF, concomitant with reduced YAP/TAZ-TEAD-sensitive synthetic promoter 
activity (8xGTIIC-lux) (Figure 2-14K). mRNA expression of OI-related genes Col1a1 and 
Col1a2 was reduced by YAP/TAZ-TEAD inhibition, while differences in SerpinH1 
expression did not reach statistical significance (Figure 2-14L). VP treatment did not alter 
Runx2 transcriptional activity (OSE2-lux) or Runx2 and Osterix expression levels, but 
reduced Ocn promoter activity (Ocn-657 bp-lux) concomitant with reduced expression of 
Bsp and Alp mRNA (Figure 2-14M,N).  
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Figure 2-13: Osterix-mediated YAP/TAZ deletion did not occur prior to osteogenic induction. 
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic 
conditions for zero days. Expression levels, normalized to GAPDH, were evaluated for (A) YAP and (B) 
TAZ along with collagen–related genes, (C) Col1a1, (D) Col1a2, and (E) SerpinH1 and key upstream 
osteogenic transcription factors, (F) Runx2 and (G) Osterix (Osx), and downstream osteogenic genes, (H) 





Figure 2-14: YAP/TAZ deletion and acute inhibition of YAP/TAZ-TEAD with verteporfin reduced 
osteogenic and collagen-related gene expression in vitro. 
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic 
conditions. Expression levels, normalized to GAPDH, were evaluated for (A) YAP and (B) TAZ along with 
collagen–related genes, (C) Col1a1, (D) Col1a2, and (E) SerpinH1 and key upstream osteogenic transcription 
factors, (F) Runx2 and (G) Osterix, and downstream osteogenic genes, (H) osteocalcin (Ocn), (I) alkaline 
phosphatase (Alp), and (J) bone sialoprotein (Bsp). Osteoblast-like UMR-106 cells were treated with the 
inhibitor Verteporfin (VP), to block interaction of YAP/TAZ with TEAD. K) Effectiveness was assessed by 
mRNA expression of the canonical YAP/TAZ-TEAD target gene CTGF and synthetic TEAD (8xGTIIC) 
reporter activity. 8xGTIIC reporter activity was normalized to renilla luciferase expression and expressed as 
fold vs. DMSO. VP treatment dose dependently reduced mRNA levels of (L) Col1a1, Col1a2, and SerpinH1 
in UMR-106 cells in comparison to DMSO. M) The activity of the Runx2 (6xOSE2) reporter activity was 
not altered following VP-treatment, but the activity of the 657 bp Ocn promoter was reduced following VP 
treatment. VP treatment dose dependently reduced mRNA levels of (N) Bsp and Alp, but not Runx2 and 





Figure 2-15: YAP/TAZ deletion reduced canonical downstream targets but not collagen type2-a1 or 
collagen 10 gene expression in vitro. 
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic 
conditions for seven days. Expression levels, normalized to GAPDH, were evaluated for (A) Cyr61, (B) Ctgf, 
(C) Col2a1 and (D) Col10. Sample sizes n = 3. 
 
         To determine whether YAP and TAZ regulate expression of these genes in vivo, we 
performed quantitative real-time PCR amplification of mRNA transcripts isolated from 
femoral cortical bone preparations. Osterix-conditional YAP/TAZ deletion significantly 
reduced Col1a1 and SerpinH1 expression in a manner dependent on allele dosage (Figure 
2-16A,B). No differences in Col1a2 (Fig 2-17A) or Col2a1 or Col10 (Figure 2-17B,C) 
expression were observed. Similarly, gene expression of osteogenic transcripts, Runx2, 
Osx, Ocn, Alp and Bsp did not exhibit any statistical differences in expression levels in 
vivo (Figure 2-17D-G). Next, we evaluated whether YAP/TAZ-TEAD regulate the 
identified collagen-related candidate genes in vivo by acute YAP/TAZ inhibition in WT 
mice by verteporfin (VP) injection. VP delivery (100mg/kg i.p. injection every other day 
for two weeks) significantly reduced expression of CTGF and SerpinH1 in liver tissue in 
vivo, but reductions in Col1a1 expression in liver and CTGF, Col1a1, and SerpinH1 in 
bone did not reach statistical significance (Figure 2-16C,D).  
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Figure 2-16: YAP/TAZ deletion and acute inhibition of YAP/TAZ-TEAD with verteporfin reduced 
collagen-related gene expression in vivo. 
Femoral cortical bone from Osterix-conditional YAP/TAZ-deficient mice were harvested to quantify mRNA 
expression. Expression levels, normalized to GAPDH, were evaluated in Osterix-conditional YAP/TAZ-
deficient cortical bone for (A) Col1a1 and (B) SerpinH1. 16-week-old wild type mice received intraperitoneal 
injections of VP (100 mg/kg) every two days for two weeks. VP treatment did not significantly reduce mRNA 









Figure 2-17: YAP/TAZ deletion did not significantly reduce collagen type1-a2, collagen type2-a1, 
collagen 10 and downstream osteogenic gene expression in vivo. 
Femoral cortical bone from Osterix-conditional YAP/TAZ-deficient mice were harvested to quantify mRNA 
expression. Expression levels, normalized to GAPDH, were evaluated in Osterix-conditional YAP/TAZ-
deficient cortical bone for (A) Col1a2, (B) Col2a1, (C) Col10, (D) Runx2, (E) Osx, (F) Alp, (G) Ocn, and 
(H) Bsp. Sample sizes n = 4-6 per group except YAPcKO;TAZcKO n = 1. 
 
2.5 Discussion 
Reports on the roles of YAP and TAZ in bone are 
contradictory112,113,147,148,150,157,160,175,219–221. To resolve these apparent conflicts in a 
physiologic context, we performed combinatorial conditional YAP/TAZ deletion in mice 
to dissect the roles of YAP and TAZ in the cells of the osteoblast lineage, from the 
precursors to terminal osteocytes, using Osterix-Cre. Our data reveal that YAP and TAZ 
have combinatorial roles in promoting osteogenesis by regulating bone formation, 
remodeling, and matrix mechanical properties. 
Bone cell-conditional YAP/TAZ deletion caused skeletal defects similar to 
osteogenesis imperfecta (OI), with severity dependent on allele dosage. OI is a highly 
heterogeneous group of inherited genetic diseases characterized by bone fragility and 
deformity, whose severity varies from mildly increased fracture risk to perinatal lethality16. 
YAP/TAZ conditional knockout mice mimicked clinical OI222 and several established OI 
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mouse models194–196 with reduced bone volume in both cancellous and cortical 
compartments. For example, the human Col1a1 minigene mouse194,195, which expresses a 
human transgene containing a clinically-observed mutation in pro-α1(I) collagen, dose-
dependently reproduces the phenotypes seen in Osterix-conditional YAP/TAZ knockouts, 
including neonatal lethality at high transgene dose and spontaneous femoral fractures and 
reduced failure, but not elastic, bone material properties at moderate dose. Similarly, the 
naturally-occurring oim mouse, caused by a frameshift mutation in pro-α2(I) collagen, also 
features reduced bone mechanical properties and increased fracture incidence with elevated 
mineral density,196,223 a product of increased mean tissue age.  
In addition, multivariate regression analyses revealed intrinsic matrix mechanical 
property deficiencies in YAP/TAZ cKO mice similar to the oim mouse, also attributable to 
defects in local collagen content and organization223,224. Similarly, conditioned medium 
from osteoprogenitor cells isolated from oim mice increased osteoclast formation in 
vitro225, consistent with our observation of increased osteoclast activity in Osterix-
conditional YAP/TAZ knockout bone. This suggests altered osteoclast recruitment and/or 
activation as a result of defective skeletal cell communication. Because global YAP 
deletion is embryonic lethal in animal models, loss-of-function mutations in YAP/TAZ are 
unlikely to be a cause in human OI; however, many pathways including TGFb-
Smad2/3117,118 and WNT-b-catenin115,116 converge on YAP/TAZ, which could place this 
signaling axis upstream of the human disease. Further research will be required to evaluate 
whether YAP/TAZ signaling is causally linked to clinical OI. The elucidation of this 
pathway in bone may contribute new insights into the heterogeneity and/or etiology of the 
disease. 
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Mice possessing a single copy of either gene in Osterix-expressing cells rescued 
the lethality found in dual homozygous knockouts, indicating mutual compensatory 
function. However, mice with homozygous deletion of TAZ (i.e., YAPcHET;TAZcKO) 
exhibited consistently increased phenotypic expressivity compared to YAPcKO;TAZcHET 
for all outcome measures, including bone formation, osteoclast activity, and bone quality. 
This suggests that either TAZ is the more potent of the two paralogs in bone, or that the 
two floxed loci exhibited differential efficiency of Cre-mediated excision. This latter 
possibility is supported by the greater reduction in TAZ expression observed in 
differentiating MSCs isolated from YAPfl/f;TAZfl/fl;Osx-Cre mice; however, in vivo, 
mRNA and protein levels of YAP and TAZ were similarly reduced. Thus, further study 
will be required to elucidate potentially distinct co-effectors or transcriptional efficiency 
for YAP vs. TAZ in bone. A recent report demonstrated a unique binding mode of TAZ to 
TEAD4 based on crystal structure, suggesting a potential difference in regulatory function 
of TAZ vs. YAP226. In addition, the Osterix-Cre transgene exhibits some non-skeletal cell 
targeting, including potential recombination in muscle73 and causes defects in craniofacial 
development72; however, we did not observe differential YAP/TAZ expression in skeletal 
muscle, and the allele dosage-dependent response establishes YAP/TAZ specificity. 
Together, these data demonstrate a critical combinatorial role for both YAP and TAZ in 
bone development and combinatorial function, evidenced by the rescue of neonatal 
lethality by a single intact allele of either gene.  
A recent study found that YAP overexpression in developing chondrocytes, under 
control of the Col2a1 promoter impaired bone development181. This appears to contradict 
our results; however, this study was not designed to isolate the role of YAP in the skeletal 
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lineage and featured YAP overexpression in the cartilaginous anlage as well as the 
osteoblast precursors. YAP has elsewhere been reported to negatively regulate 
chondrogenesis227, and changes in anlage formation may therefore alter bone development 
independent of defects in osteogenic cells. Further, the developmental phenotype appeared 
only in homozygously-overexpressed transgenics, which points to the limitations of 
overexpression approaches for tightly regulated transcriptional regulators that may exhibit 
non-physiologic transcriptional activity at high concentrations. Consistent with our 
observations that YAP and TAZ have compensatory roles, they did not observe statistically 
significant effects of Col2a1-conditional YAP deletion on skeletal development181. 
Similarly, Yang et al. overexpressed TAZ in collagen I-expressing cells and observed 
increased bone formation175. This is consistent with the present data and the phenotype of 
the global homozygous TAZ knockout, which also presents bone development defects205. 
Synthesis of these studies indicates the importance of dual and combinatorial loss-of-
function approaches to interrogate YAP/TAZ compensatory function.  
Bone cell-conditional YAP/TAZ deletion produced an allele dosage-dependent 
phenotype characterized by defects in both osteogenesis and matrix composition, 
associated with reduced osteogenic and collagen-related gene expression. These 
transcriptional patterns were consistent in vitro and in vivo. YAP/TAZ deletion reduced 
osteogenic gene induction in isolated osteoprogenitors and reduced osteoblast numbers and 
mineral apposition rates in vivo, indicating that YAP/TAZ deletion impaired osteoblast 
differentiation and activation. Further, reduced collagen content and organization in vivo 
and impaired expression of Col1a1 and the endoplasmic reticulum-associated collagen 
chaperone, SerpinH1, suggest that YAP/TAZ regulate collagen production. Together, these 
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findings support a convergent, pro-osteogenic function for both YAP and 
TAZ113,150,157,160,175. 
YAP and TAZ control gene expression through formation of transcriptional 
complexes with other transcription factors. These include TEAD1-4 as well as Runx2, 
among others 114–116117,118. Runx2 has previously been identified as a YAP/TAZ co-effector 
in osteogenesis in vitro112,113,157, but the role of TEAD in bone is unclear. To determine 
whether TEAD could be involved in YAP/TAZ regulation of osteogenesis- and collagen-
related genes, we evaluated the effects of disrupting the YAP/TAZ-TEAD interaction using 
the small molecule inhibitor, verteporfin (VP), in vitro and in vivo. Quantification of 
YAP/TAZ-TEAD transcriptional activity and canonical downstream gene expression 
showed that VP treatment significantly inhibited YAP/TAZ-TEAD activity. Analysis of 
published ChIP-seq data on the UCSC Genome Browser228 reveals that TEAD is capable 
of binding its canonical recognition sequence (3’-ACATTCCA-5’) in the promoter region 
of both Col1a1 and SerpinH1, suggesting the possibility of direct regulation. However, as 
YAP/TAZ are known to regulate gene expression through both promoter and enhancer 
binding, further research using chromatin immunoprecipitation combined with targeted 
mutagenesis will be required to isolate the binding domains and associated co-effectors. In 
contrast, VP treatment had no effect on Runx2 transcriptional reporter activity or direct 
Runx2 target genes (i.e., autoregulatory Runx2 or Osterix) either in vitro or in vivo. Despite 
this, expression of mature osteoblast markers was decreased by VP treatment, concomitant 
with Osteocalcin promoter activity, suggesting that YAP/TAZ-TEAD may be involved in 
both osteogenic and collagen-related gene regulation. In vivo, verteporfin treatment 
significantly reduced Col1a1 in the liver, but did not significantly alter gene expression in 
 68 
bone, likely due to the small sample size and the four-fold less efficient biodistribution of 
porphyrins to bone compared to liver229,230. Verteporfin may also exhibit off-target 
effects231, but both VP treatment and YAP/TAZ-conditional deletion produced consistent 
gene expression profiles.  
Taken together, these data demonstrate that YAP and TAZ have combinatorial roles 
in promoting skeletal development by regulating osteoblast activity, osteoclast-mediated 














CHAPTER 3: YAP AND TAZ MEDIATE PERILACUNAR/CANALICULAR 
REMODELING 
3.1 Abstract 
Bone fragility fractures are caused by low bone mass or impaired bone quality. 
Osteoblast/osteoclast coordination determines bone mass, but the factors that control bone 
quality are poorly understood. Osteocytes regulate osteoblast and osteoclast activity on 
bone surfaces but can also directly reorganize the bone matrix to improve bone quality 
through perilacunar/canalicular remodeling; however, the molecular mechanisms remain 
unclear. We previously found that deleting the transcriptional regulators Yes-associated 
protein (YAP) and Transcriptional co-activator with PDZ-motif (TAZ) from osteoblast-
lineage cells caused lethality in mice due to skeletal fragility. Here, we tested the 
hypothesis that YAP and TAZ regulate osteocyte-mediated bone remodeling by 
conditional ablation of both YAP and TAZ from mouse osteocytes using 8kb-DMP1-Cre. 
Osteocyte-conditional YAP/TAZ deletion reduced bone mass and dysregulated matrix 
collagen content and organization, which together decreased bone mechanical properties. 
Further, YAP/TAZ deletion impaired osteocyte perilacunar/canalicular remodeling by 
reducing canalicular network density, length, and branching, as well as perilacunar 
fluorochrome-labeled mineral deposition. Consistent with recent studies identifying TGF-
b as a key inducer of osteocyte expression of matrix-remodeling enzymes, YAP/TAZ 
deletion in vivo decreased osteocyte expression of matrix proteases MMP13, MMP14, and 
CTSK. In vitro, pharmacologic inhibition of YAP/TAZ transcriptional activity in 
osteocyte-like cells abrogated TGF-b-induced matrix protease gene expression. Together, 
these data show that YAP and TAZ control bone matrix accrual, organization, and 
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mechanical properties by regulating osteocyte-mediated bone remodeling. Elucidating the 
signaling pathways that control perilacunar/canalicular remodeling may enable future 
therapeutic targeting of bone quality to reverse skeletal fragility. 
*This chapter is modified from publication in JBMR (DOI: 10.1002/jbmr.3876). Authors: Kegelman CD, 
Coulombe JC, Jordan KM, Horan DJ, Qin L, Robling AG, Bellido TM, Boerckel JD. 
3.2 Introduction 
Skeletal fragility diseases are characterized by decreased bone strength. Bone 
strength is determined by both the quantity and quality of the bone, both of which are 
necessary to explain fracture susceptibility232–234. Decreased bone mass is a hallmark of 
osteoporosis, but defects in bone geometry, microarchitecture, porosity, or matrix material 
properties are significant contributors to bone fragility235. Both bone quantity and quality 
are influenced by bone remodeling, a tightly coordinated process by which old, damaged 
bone is resorbed and new, strong bone is deposited. Imbalanced bone remodeling, either 
by excessive bone resorption or decreased bone formation can impair bone quantity and 
quality6,236. Understanding the mechanisms that control bone remodeling is both 
scientifically and therapeutically valuable.  
The most abundant cell type in bone, osteocytes regulate bone remodeling26,27. As 
terminally differentiated osteoblasts, osteocytes reside within lacunae in the mineralized 
bone matrix, and extend dendritic processes through an interconnected network of micro-
channels called canaliculi that permeate the bone matrix28,29,237. In humans, this 
lacunar/canalicular network contains an estimated 3.7 trillion dendritic projections and 
covers more than 215 m2 of bone surface area238. Through this widespread network, 
osteocyte-derived molecules reach the bone surfaces and regulate bone remodeling by 
coordinating osteoblast/osteoclast coupled remodeling30,31. In addition, osteocytes directly 
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resorb and deposit bone in their surrounding bone matrix via perilacunar/canalicular 
remodeling32,35,36. However, the molecular mechanisms by which osteocytes control bone 
remodeling remain poorly understood.  
Osteoblast/osteoclast coordinated bone remodeling is regulated in part through the 
CCN family of matricellular growth factors, cysteine-rich angiogenic inducer-61 (CYR61, 
CCN1) and connective tissue growth factor (CTGF, CCN2)239,240. CYR61 and CTGF have 
been implicated in activation of osteoblastogenesis241–244 and inhibition of 
osteoclastogenesis245. Both CYR61 and CTGF are downstream gene targets of the 
paralogous transcriptional regulators Yes associated protein (YAP) and Transcriptional co-
activator with PDZ-binding motif (TAZ)126,246. YAP and TAZ are the key effector proteins 
of the Hippo signaling pathway and regulate important biological functions including organ 
size determination, tissue regeneration, and cancer119,120. Transcriptional complex 
formation of nuclear YAP and/or TAZ with the transcriptional enhancer activator domain 
(TEAD) family proteins is required to induce expression of CYR61 and CTGF126,247.  
In addition to paracrine regulation of osteoblast/osteoclast activity, osteocytes 
directly remodel the bone matrix through perilacunar/canalicular remodeling. Osteocyte 
perilacunar/canalicular remodeling is regulated by the TGF-b signaling pathway106. The 
TGF-b and YAP/TAZ signaling pathways are known to interact in a variety of cell types 
including cancer cells, fibroblasts, and epithelial cells117,118,248,249, and the mechanisms by 
which TGF-b regulate YAP and TAZ continue to emerge. For example, YAP/TAZ form 
complexes with the R-SMAD proteins to co-activate TGF-b/SMAD-target gene 
expression117,118. Independent of the R-SMAD proteins, YAP/TAZ interact with additional 
transcriptional co-factors, such as AP-1 and MRTF, to regulate TGF-b/SMAD-target gene 
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expression248,249. Taken together, these observations position YAP and TAZ as potential 
mediators of TGF-b-mediated bone remodeling in osteocytes. 
Here, we conditionally ablated both YAP and TAZ from DMP1-expressing cells and 
evaluated bone remodeling. In vivo, we found that osteocyte YAP and TAZ regulate 
perilacunar/canalicular remodeling as well as coordinate osteoblast/osteoclast activity. In 
vitro, YAP/TAZ inhibition abrogated TGF-b-induced expression of matrix proteases 
required for osteocyte perilacunar/canalicular remodeling and expression of the 
matricellular growth factors Cyr61 and Ctgf. Together, these data demonstrate that 
osteocyte YAP and TAZ control bone matrix accrual, organization, and mechanical 




Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed 
C57BL/6J genetic background were kindly provided by Dr. Eric Olson (University of 
Texas Southwestern Medical Center). Osteocytes were targeted using Cre-recombination 
under the control of an 8kb fragment of the dentin matrix protein-1 promoter (8kb-DMP1-
Cre)69. All mice were fed regular chow (PicoLab Rodent Diet, Cat#: 0007688, LabDiet) ad 
libitum and housed in cages containing 2-5 animals each. Mice were maintained at constant 
25°C on a 12-hour light/dark cycle.  
Mice with homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl) 
were mated with double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;DMP1-
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Cre) to produce eight possible genotypes in each litter, but only the genotypes in (Table 3-
1) were compared. Mice were tail or ear clipped after weaning or prior to euthanasia and 
genotyped by an external service (Transnetyx Inc.). Both male and female mice were 
evaluated with YAPfl/fl;TAZfl/fl mice serving as littermate controls (WT). The different 
analyses were performed in both male and female young mice at either postnatal day 28 
(P28) or postnatal day 84 (P84) as indicated. All protocols were approved by the 
Institutional Animal Care and Use Committees at the University of Notre Dame and the 
University of Pennsylvania. All animal procedures were performed in adherence to federal 
guidelines for animal care and conform to the Animal Research: Reporting of In Vivo 
Experiments (ARRIVE) guidelines. 








3.3.2 Microcomputed tomography 
Micro-computed tomography (microCT) was performed according to published 
guidelines208. Harvested femurs from P84 mice were stored at -20°C until evaluation. 
Frozen specimens were thawed and imaged using a vivaCT 80 scanner (Scanco Medical) 
to determine trabecular and cortical femoral bone architecture prior to mechanical testing. 
The mid-diaphysis and distal femur were imaged with an X-ray intensity of 114 µA, energy 
of 70 kVp, integration time of 300 ms, and resolution of 10 µm. Mid-diaphyseal and distal 
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femoral 2D tomograms were manually contoured, stacked and binarized by applying a 
Gaussian filter (sigma =1, support =1) at a threshold value of 550 mg HA/cm3. Eight mice 
were analyzed per group. Investigators were blinded to animal genotype during scan 
quantification. 
3.3.3 Mechanical testing 
Following microCT scanning, femurs from P84 mice were tested in three-point 
bending to failure. Femurs were loaded with the condyles facing down onto the bending 
fixtures with a support span length of 4.4 mm, which attenuated the effect of femur length 
on the measured mechanical properties. The upper fixture was aligned with the mid-
diaphysis. The femurs were loaded to failure at a rate of 0.5 mm/s using the ElectroForce 
3220 Series testing system (TA Instruments). Stiffness, maximum load to failure, work to 
maximum load and work to failure were quantified using a custom MATLAB script170. 
Eight mice were analyzed per group. Investigators were blinded to animal genotype during 
data quantification. 
3.3.4 Osteocyte lacunae visualization and quantification 
Nano-computed tomography (nanoCT) was used to evaluate the morphological 
characteristics of osteocyte lacunae in the proximal tibia (Xradia Versa XRM-520, Zeiss, 
Dublin, CA). Tibiae from P84 mice were harvested and removed of all non-osseous tissue. 
Samples were scanned in 70% EtOH, in custom-made sample holders that oriented the 
samples vertically on the stage. Tibiae were originally scanned with a 4x objective to 
determine regions of interest. A 650 µm3 region of bone was located on the anterior medial 
aspect of the tibia, 8 mm from the tibiofibular junction (TFJ). Nano-computed tomography 
images image were collected in the region of interest using a 20x objective with energy 
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settings of 40 V, 3.0 W, using the Air Filter and 3,201 projections. To obtain a constant 
resolution of 0.6 µm voxel for all the samples, the source and detector distance were varied 
between 5.8 and 8.5 mm from the sample, and excitation ranged from 6 - 8 seconds 
contingent on resulting intensity values. 
Dragonfly 3.6 (Object Research Systems (ORS) Inc, Montreal, QC) was used for 
segmentation of bone types and osteocyte lacunae regions. Cortical and trabecular bone 
were manually segmented. Osteocyte lacunae were identified and segmented in three 
dimensions using a global Otsu threshold, defined for each sample to most closely match 
grayscale images250. Threshold values were not statistically different between genotypes 
(31,382 ± 1,080 for YAPWT;TAZWT and 31,032 ± 1,168 for YAPcKO;TAZcKO; p = 0.83). 
Voids that were too small or too large (< 50 µm3 and > 1,500 µm3)251–253 to be an osteocyte 
lacuna were removed. Osteocyte volume, surface area, and aspect ratio were measured for 
each osteocyte. Additionally, custom python code based on previous work251,254,255 was 
implemented to analyze osteocyte lacunar shape measures, oblateness and stretch. 
Oblateness and stretch are calculated from the eigenvalues of the shape tensor for each 
individual osteocyte lacuna. Lacunar oblateness is defined as the “plateness” of a lacuna 
and ranges from [−1,1], where −1 corresponds to a perfect rod (strongly prolate), and 1 to 
a perfect plate (strongly oblate)251. 
𝐿𝐿𝐿𝐿. 𝑂𝑂𝑂𝑂	 = 2(!"#	!%
!&#!%
) − 1	  (Eq. 1) 
Similarly, lacunar stretch measures the sphericity of the osteocyte lacunae. Lacunar stretch 
is evaluated between [0,1], where 0 corresponds to a perfectly spherical, and 1 to an 
infinitely stretched object251.  
𝐿𝐿𝐿𝐿. 𝑆𝑆𝑆𝑆	 = !&#	!%
!&
         (Eq. 2) 
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3.3.5 Histology, immunohistochemistry, and immunofluorescence 
Femurs and tibias from P28 and P84 mice were fixed with 10% neutral buffered 
formalin for 48 hours at 4°C and decalcified for 4 weeks with 0.25M EDTA (pH 7.4) at 
4°C. Paraffin sections (5 µm thickness) were processed for either immunohistochemistry 
or histology. Primary antibodies were compared to both normal rabbit sera IgG control 
sections. For immunostaining, anti-CTSK (1:75, ab19027; abcam), anti-MMP13 (1:100, 
ab39012; abcam), anti-MMP14 (1:100, ab38971; abcam), anti-YAP (1:200, 14074; Cell 
Signaling), and anti-TAZ (1:200 NB110-58359; Novus Biologicals) primary antibodies 
were applied overnight. Next, sections were incubated with corresponding biotinylated 
secondary antibody, avidin-conjugated peroxidase, and diaminobenzidine substrate 
chromogen system (329ANK-60; Innovex Biosciences), which allowed for 
immunohistochemical detection of positively stained cells. Hematoxylin and eosin stains 
(H&E), Tartrate-resistant acid phosphatase (TRAP), Picrosirius Red, and silver nitrate 
stains were used to stain for osteoblasts, osteoclasts, collagen, and the osteocyte 
lacunar/canalicular network as previously shown256,257. 
Femurs from P28 mice were fixed with 10% neutral buffered formalin for 48 hours 
at 4°C, transferred to 30% sucrose in PBS overnight at 4°C, and then embedded in O.C.T. 
compound (Tissue-Tek). Thin sections (7 µm thickness) were made from undecalcified 
femurs using cryofilm IIC tape (Section Lab Co. Ltd.) as previously described258 and 
processed for immunofluorescence. Taped sections were glued to microscope slides using 
chitosan adhesive glue, rehydrated and then decalcified with 0.25M EDTA (pH 7.4) for 5 
minutes prior to immunofluorescence staining. Terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) assays were then performed using the Click-iT Plus 
 77 
TUNEL Assay kit (C10618; Invitrogen) according to the manufacturer’s instructions. 
Thick sections (20 µm thickness), were processed similarly and stained for F-actin with 
Alexa Fluor 488-conjugated phalloidin (1:50, Life Technologies) for confocal imaging.  
Femurs from P28 mice injected with Calcein (C0875-25G; Sigma-Aldrich) at P21 
and Alizarin Complexone (A3882-25G; Sigma Aldrich) at P26 were embedded in methyl-
methacrylate and processed for dynamic bone histomorphometry. Using a diamond-
embedded wire saw (Delaware Diamond Knives), transverse sections (40 µm) were cut 
from the midshaft and ground to a final thickness of 20 µm. The slice sections were 
mounted on slides, and three sections per limb were analyzed. 
3.3.6 Imaging and histomorphometric analysis 
Histological and immunohistochemical sections were imaged on either a 90i 
Upright/Widefield Research Microscope (Nikon Instruments) at the 20x and 40x objectives 
or an Axio Observer Z1 (Zeiss) at the 20x, 40x, and 63x objectives.  Quantification of 
paraffin immunohistochemistry and histology was performed using ImageJ (NIH) and 
OsteomeasureTM (OsteoMetrics). To determine the number of positively immunostained 
cells, 3 fields of view per mouse per antibody were manually scored as either positive or 
negative and reported as percentage positively stained lacunae per total number of lacunae 
using ImageJ (NIH). To determine canalicular length, primary canaliculi emanating from 
each lacuna and extending as a single, unbranched process106 were traced with ImageJ 
(NIH). The mean length was taken from at least 5 osteocytes per field within the mid-
cortex, with 3 fields per mouse and 6 mice per group106. Osteoblast number per bone 
surface, osteocyte number per bone area, and osteoclast surface per bone surface were 
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quantified using OsteomeasureTM (OsteoMetrics) on H&E and TRAP stained sections in 
the metaphyseal cancellous bone with 8 mice per group.  
The samples tested in three-point bending were stained with Picrosirius Red to 
construct a multivariate regression model that included collagen organization and content 
as a predictor of mechanical behavior. These samples were imaged both under polarized 
light using an Eclipse ME600 Microscope (Nikon Instruments) at the 20x objective and 
using second harmonic generated (SHG) microscopy. SHG images were taken on a 
multiphoton-enabled Fluoview Research Microscope (Olympus) at a fundamental 
wavelength of 875 nm with the 25x objective on sections oriented in the same direction for 
all groups. All SHG images were quantified using ImageJ (NIH) and reported as mean 
pixel intensity within the mid-cortical region relative to WT bone. Mean pixel intensities 
across four separate regions of interest within each image of the cortex were averaged as 
technical replicates for a given sample.  
Confocal images were acquired using an LSM 710 confocal (Zeiss) with the 63x 
objective on 20-micron thick sections. 15-micron thick z-stack images were acquired using 
a step size of 0.5 microns. Three separate regions of interest within the mid-cortex were 
averaged as technical replicates for a given animal sample. All confocal image stacks were 
quantified using ImageJ (NIH). Stacks were smoothed by applying a Gaussian filter (sigma 
= 0.3), then skeletonized using the Skeletonize3D function. The AnalyzeSkeleton2D/3D 
function was then used to quantify mean branch length, number of branches, and number 
of junctions259. Six YAPWT;TAZWT  and four  YAPcKO;TAZcKO mice were analyzed.  
Immunofluorescence sections of P28 femurs were imaged on an Axio Observer Z1 
(Zeiss) at the 20x, 40x, and 63x objectives. To determine the number of positively TUNEL-
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stained lacunae, 3 fields of view per mouse in the metaphyseal cancellous bone were 
manually scored as either positive or negative and reported as percent positively stained 
per total number of lacunae scored in ImageJ (NIH). Dynamic bone histomorphometry 
parameters were quantified using OsteomeasureTM (OsteoMetrics). The following primary 
data were collected: total bone surface length (BS); single label perimeter (sL.Pm); double 
label perimeter (dL.Pm); and double label width (dL.Ith). From primary data, we derived 
mineralizing surface (MS/BS = [1/2sL.Pm+dL.Pm]/B.Pm ×100; %); mineral apposition 
rate (MAR = dL.Ith/5 days; µm/day) and bone formation rate (BFR/BS = MAR × MS/BS; 
µm3/µm2 per day). Six mice were analyzed per group. Investigators were blinded to animal 
genotype during image acquisition and quantification of all histology, 
immunohistochemistry, and immunofluorescent images. 
3.3.7 Cell culture 
IDG-SW3 cells were cultured in a-MEM supplemented with 10% fetal bovine 
serum, 1% antibiotic/antimycotic (15240062; Gibco) and 1 U/mL INF-g (PMC4031; 
Invitrogen) at 33°C. OCY454 cells were cultured in a-minimum essential media (a-MEM) 
supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic (Gibco) at 33°C. 
Prior to treatment, OCY454 cells were differentiated for 12 days at 37°C while IDG-SW3 
cells were differentiated for 21 days at 37°C in a-MEM supplemented with 10% fetal 
bovine serum (100-106; Gemini Bio-Products), 1% antibiotic/antimycotic (15240062; 
Gibco), 50 µg/ml ascorbic acid (A-4544; Sigma-Aldrich), and 4 mM b-glycerophosphate 
(G-9422; Sigma-Aldrich) without INF-g. Prior to treatment on the last day of 
differentiation, both OCY454 and IDG-SW3 cells were treated with 3 µM verteporfin 
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(SML0534; Sigma-Aldrich) overnight in 1% fetal bovine serum. The next morning, the 
media was changed and supplemented with 3 µM verteporfin and 5ng/ml TGF-b1 
(HZ1011; Humanzyme) for 6 hours before mRNA isolation.  
3.3.8 RNA isolation and qPCR 
P84 femur samples were dissected and removed of all non-osseous tissue. The ends 
were cut at the growth plate and marrow flushed before being snap-frozen in liquid 
nitrogen-cooled isopentane for 1 minute prior to storage at -80°C until processing. Tissues 
were then homogenized via mortar and pestle and RNA from the sample was collected 
using Trizol Reagent (15596026; Life Technologies) followed by centrifugation in 
chloroform. RNA from femur tissue and cell culture experiments were purified using the 
RNA Easy Kit (74106; Qiagen) and quantified by spectrophotometry using a NanoDrop 
2000 (Thermo-Fisher Scientific). Reverse transcriptase polymerase chain reaction (RT-
PCR) was performed on 0.1-0.5 μg/μl concentration of RNA using the High-Capacity 
cDNA Reverse Transcription Kit (4368814; Thermo-Fisher Scientific). Quantitative 
polymerase chain reaction (qPCR) assessed RNA amount using a StepOnePlusTM Real-
Time PCR System (Thermo-Fisher Scientific) relative to the internal control of 18S 
ribosomal RNA (18S rRNA). Data are presented using the DDCt method. Six mice per 
group were used. Specific mouse primer sequences are listed (Table 3-2).   
Table 3-2: qPCR primers (Aim 2) 
Mouse primers used for qPCR 
Gene Primer Sequence (5’ to 3’) 
18S rRNA F R 
  CGAACGTCTGCCCTATCAAC 
  GGCCTCGAAAGAGTCCTGTA 
Yap F R 
  TGGACGTGGAGTCTGTGTTG 
  AAGCGGAACAACGATGGACA 
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Taz F R 
  GTCCATCACTTCCACCTC 
  TTGACGCATCCTAATCCT 
Col1a1 F R 
  GCTCCTCTTAGGGGCCACT 
  CCACGTCTCACCATTGGGG 
Alp F R 
  GGACAGGACACACACACACA 
  CAAACAGGAGAGCCACTTCA 
Ocn F R 
  TGAGCTTAACCCTGCTTGTG 
  TAGGGCAGCACAGGTCCTA 
Bsp F R 
  ACAATCCGTGCCACTCACT 
  TTTCATCGAGAAAGCACAGG 
Dmp1 F R 
  GAACAGTGAGTCATCAGAAG 
  AAAGGTATCATCTCCACTGTC 
Ctsk F R 
  GAGGGCCAACTCAAGAAGAA 
  GCCGTGGCGTTATACATACA 
Mmp13 F R 
  CGGGAATCCTGAAGAAGTCTACA 
  CTAAGCCAAAGAAAGATTGCATTTC 
Mmp14 F R 
  AGGAGACGGAGGTGATCATCATTG 
  GTCCCATGGCGTCTGAAGA 
Sost F R 
  TCCTCCTGAGAACAACCAGAC 
  TGTCAGGAAGCGGGTGTAGTG 
Phex F R 
  TCATTGATACCAGACTCTACC 
  CAATGGTTTTCTTCCTCTCG 
Serpine1 F R 
  CAGATGACCACAGCGGGGAA 
  GGCATGAGCTGTGCCCTTCT 
Opg F R 
  AGAGCAAACCTTCCAGCTGC 
  CTGCTCTGTGGTGAGGTTCG 
Rankl F R 
  CCAAGATCTCTAACATGACG 
  CACCATCGCTGAAGATAGT 
 
3.3.9 Statistics and regression 
Sample sizes were selected a priori by power analyses based on effect sizes and 
population standard deviations taken from published data on YAPfl/fl;TAZfl/fl mice in other 
tissues188, assuming a power of 80% and α=0.05. All statistics and regression analyses were 
performed in GraphPad Prism or using R (Version 3.5.1). Repeated-measures ANOVA 
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with post hoc Tukey’s HSD comparison test was performed using R (Version 3.5.1) for 
osteocyte lacunae quantification. All other comparisons between two groups were made 
using the two-tailed student’s t-test, provided the data were normally distributed according 
to D’Agostino-Pearson omnibus normality test and homoscedastic according to Bartlett’s 
test in GraphPad Prism. When parametric test assumptions were not met, data were log-
transformed, and residuals were evaluated. If necessary, the non-parametric Mann-
Whitney test was used. A p-value < 0.05 was considered significant. Post-hoc power 
analyses were performed using R (Version 3.5.1) for phenotypic results as indicated. Data 
are presented as bars and individual samples with lines corresponding to the mean and 
standard error of the mean (SEM).  
Multivariate regression analyses were performed as described previously212, using 
R (Version 3.5.1) with some modifications170. Briefly, we used an exhaustive best subsets 
algorithm to determine the best predictors of maximum load and stiffness from a subset of 
morphological parameters measured, which included moment of inertia (I) or section 
modulus (I/c), microCT-measured tissue mineral density (TMD), second harmonic 
generated (SHG) intensity, and femur length. The best subsets algorithm selects the optimal 
model using the Akaike’s information criterion (AIC), which gives preference to less 
complex models with fewer explanatory parameters to avoid overfitting the data213. The 
overall “best” multivariate model for each predicted mechanical property was selected with 
the lowest relative AIC value, indicative of having the least variables with the greatest 
predictive power. AIC values were used to determine the “best” model for predicting new 
data instead of R2 values, which describe how well the model fits existing data. Further, 
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3.4.1 DMP1-Cre conditionally ablates YAP and TAZ primarily in osteocytes 
To determine the roles of YAP and TAZ in osteocyte-mediated bone remodeling, 
we used Cre-lox to selectively delete YAP and TAZ from 8kb-DMP1-Cre expressing 
cells69,260. We used a breeding strategy that generated YAP/TAZ allele dosage-dependent 
DMP1-conditional knockouts170. All genotypes (Table 3-1) appeared at expected 
Mendelian ratios. By early skeletal maturity (P84), YAP/TAZ allele dosage-dependent 
DMP1-conditional deletion did not significantly alter body mass in either males or females 
(Figure 3-1A). YAP/TAZ deletion reduced femoral length at P84 only in double 
homozygous knockouts, for both sexes (Figure 3-2A,B; Figure 3-1B). A single copy of 
either gene was sufficient to rescue this defect. Therefore, for further analyses, we selected 
littermate YAPfl/fl;TAZfl/fl wild type (YAPWT;TAZWT) and YAPfl/fl;TAZfl/fl;8kb-DMP1-Cre 
conditional double knockout (YAPcKO;TAZcKO)  mice for comparison.  
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Figure 3-1: Combinatorial YAP/TAZ ablation with 8kb-DMP1-Cre is functionally redundant and does 
not recombine in growth plate chondrocytes. 
A) Body masses from mice with allele-dose dependent YAP/TAZ ablation from DMP1-expressing cells until 
P84. B) Femoral lengths from mice with allele-dose dependent YAP/TAZ ablation from DMP1-expressing 
cells at P84 for both males and females. C) Histomorphometric quantification of P84 growth plate thickness. 
HZ = hypertrophic zone. PZ = proliferating zone. D) Representative micrograph of P84 wild type 
(YAPWT;TAZWT) growth plate. E) Representative micrograph of P84 conditional double knockout 
(YAPcKO;TAZcKO) growth plate. F) Representative micrographs of chondrocyte immunostaining for IgG 
control, YAP, and TAZ in YAPWT;TAZWT femurs at P28. G) Representative micrographs of growth plate 
chondrocyte immunostaining for IgG control, YAP, and TAZ in YAPcKO;TAZcKO femurs at P28. Body mass 
data presented as mean with lines corresponding to the standard error of the mean (SEM). Sample sizes, N = 
6-22 per sex per group. Femoral length data presented as a box and whiskers plots with whiskers 
corresponding to maximum and minimum values. Sample sizes, N = 2-10 per sex per group. Growth plate 
thickness percentage data presented as bars with lines corresponding to the mean and standard error of the 




Figure 3-2: 8kb-DMP1-Cre selectively ablated YAP/TAZ expression from osteocytes. 
A) Representative radiographs for P84 wild type (YAPWT;TAZWT) and B) conditional double knockout 
(YAPcKO;TAZcKO) mice. C) P84 femur microCT reconstructions and D) quantification of femoral lengths. E-
J) Recombination efficiency and specificity was assessed by measurement of YAP and TAZ protein and 
mRNA expression. E) Representative micrographs of osteocyte (Ocy) immunostaining for IgG control, YAP, 
and TAZ in YAPWT;TAZWT and YAPcKO;TAZcKO femurs at P28. F) Representative micrographs of osteoblast 
(Ob) immunostaining for IgG control, YAP, and TAZ in YAPWT;TAZWT and YAPcKO;TAZcKO femurs at P28. 
G) YAP protein expression in osteocytes (Ocy) and osteoblasts (Ob) from femoral sections at P28. H) Yap 
mRNA expression, relative to 18S rRNA, from femoral bone preparations at P84. I) TAZ protein expression 
in osteocytes (Ocy) and osteoblasts (Ob) from femoral sections at P28. J) Taz mRNA expression, relative to 
18S rRNA, from femoral bone preparations at P84. Data are presented with individual samples in scatterplots 
and bars corresponding to the mean and standard error of the mean (SEM). N = 5-6 per group for qPCR and 
N = 4-6 per group for IHC. Brown arrows indicate positive osteocytes. Blue arrows indicate negative 
osteocytes. Scale bars equal 1 mm in microCT reconstructions and 30 µm in all images. 
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To analyze the specificity of 8kb-DMP1-Cre-mediated YAP/TAZ deletion, we 
evaluated YAP/TAZ expression in osteocytes, osteoblasts, and growth plate chondrocytes. 
YAP mRNA expression was significantly reduced by 67% in YAPcKO;TAZcKO femoral 
bone preparations (Figure 3-2C). YAP cellular expression was significantly reduced in 
osteocytes (58% reduction), but not osteoblasts (0% reduction; p = 0.98) (Figure 3-2G). 
Similarly, TAZ mRNA expression was significantly reduced by 72% in YAPcKO;TAZcKO 
femoral bone preparations (Figure 3-2F), and TAZ cellular expression was significantly 
reduced in osteocytes (79% reduction), but not osteoblasts (6% reduction; p = 0.12) (Figure 
3-2H). The reduction in YAPcKO;TAZcKO growth plate thickness did not reach statistical 
significance within the hypertrophic zone (16% reduction; p = 0.26), the proliferating zone 
(12% reduction; p = 0.39), or total growth plate thickness (13% reduction; p = 0.27; Figure 
3-1C). Further, YAPcKO;TAZcKO growth plate chondrocytes did not show differential 
expression of YAP or TAZ in either proliferating or hypertrophic zones (Figure 3-1D-G).  
3.4.2 DMP1-conditional YAP/TAZ deletion impaired bone accrual 
Dual homozygous YAP/TAZ deletion from DMP1-expressing cells reduced bone 
accrual and microarchitectural parameters in both the cancellous and cortical 
compartments of P84 femurs. In metaphyseal cancellous bone, conditional YAP/TAZ 
deletion significantly reduced bone volume fraction, trabecular number, and thickness and 
increased trabecular spacing and structural model index (Figure 3-3A-F). In mid-
diaphyseal femoral cortical bone, conditional YAP/TAZ deletion reduced cortical 
thickness and bone area without changing medullary area (Figure 3-3G-I; Figure 3-4). 
Differences in tissue mineral density (p = 0.24), periosteal perimeter (p = 0.15), and 
moment of inertia (p = 0.08) were not statistically significant (Figure 3-3J-L).  
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Figure 3-3:YAP/TAZ ablation from DMP1-expressing cells altered bone microarchitecture.  
A) Representative microCT reconstructions of distal metaphysis of P84 femurs. Quantification of cancellous 
bone microarchitecture: (B) bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th), (D) number 
(Tb.N), (E) spacing (Tb.Sp), and (F) structural model index (SMI). G) Representative microCT 
reconstructions of mid-diaphysis cortical microarchitecture in P84 femurs. Quantification of cortical 
microarchitectural properties: (H) cortical thickness (Ct.Th), (I) bone area (B.Ar), (J) periosteal perimeter 
(Ps.Pm), (K) moment of inertia in the direction of bending (I), and (L) cortical tissue mineral density 
(Ct.TMD). Data are presented with individual samples in scatterplots and bars corresponding to the mean 





Figure 3-4:YAP/TAZ ablation from DMP1-expressing cells altered bone microarchitecture. 
A) Representative microCT reconstructions of distal metaphyseal microarchitecture in P84 femurs. B) 
Quantification of trabecular thickness distributions in cancellous bone. C-E) Quantification of cortical 
microarchitectural properties: (C) total area, (D) medullary area (Me.Ar), and (E) endocortical perimeter 
(Ec.Pm). Data are presented as bars and individual samples with lines corresponding to the mean and standard 
error of the mean (SEM). Sample sizes, N = 8 per group. 
 
To determine if the low bone mass phenotype resulted from decreased bone 
formation and/or increased bone resorption, we evaluated osteoblast and osteoclast 
activity. Conditional YAP/TAZ deletion increased osteoclast surface per bone surface 
(Figure 3-5A,B) and decreased osteoblast number per bone surface (Figure 3-5C,D) in P84 
distal femur metaphyseal cancellous bone. YAP/TAZ deletion decreased bone formation 
rate, reducing both mineralizing surface percentage and mineral apposition rate at P28 in 
distal femur metaphyseal cancellous bone (Figure 3-5E-H). In the cortical compartment, 
YAP/TAZ deletion similarly reduced osteoblast number per endosteal bone surface (Figure 
3-6A,B) and decreased bone formation rate by reducing mineral apposition rate without 




Figure 3-5:YAP/TAZ ablation from DMP1-expressiong cells increased osteoclast activity and decreased 
osteoblast activity. 
A) Representative high magnification micrographs with insets of low magnification micrographs of P84 
cancellous metaphyseal bone (outlined in black) stained by TRAP. B) Quantification of osteoclast surface 
per bone surface (Oc.S/BS). C) Representative high magnification micrographs with insets of low 
magnification micrographs of P84 cancellous metaphyseal bone (outlined in black) stained by H+E. D) 
Quantification of osteoblast number per bone surface (Ob.N/BS). E) Representative high magnification 
micrographs with insets of low magnification micrographs of double fluorochrome labeled P28 cancellous 
metaphyseal bone (outlined in white). F-H) Quantification of (F) mineralizing surface percentage (MS/BS), 
(G) mineral apposition rate (MAR) and (H) bone formation rate (BFR/BS). I-J) Femoral bone preparations 
from P84 mice were harvested to quantify mRNA expression. Expression levels, normalized to 18S rRNA, 
were evaluated for (I) cysteine-rich angiogenic inducer 61 (Cyr61) and (J) connective tissue growth factor 
(Ctgf). Data are presented with individual samples in scatterplots and bars corresponding to the mean and 
standard error of the mean (SEM). Sample sizes N = 6-8. Scale bars indicate 15 µm in all images. 
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Figure 3-6: YAP/TAZ ablation from DMP1-expressing cells altered cortical osteoblast number and 
function. 
A) Representative micrographs of P84 cancellous metaphyseal bone stained by H+E. B) Quantification of 
osteoblast number per bone surface (Ob.N/BS). C) Representative micrographs of double fluorochrome 
labeled cortical bone in P28 femurs. D-F) Quantification of (D) mineralizing surface percentage (MS/BS), 
(E) mineral apposition rate (MAR) and (F) bone formation rate (BFR/BS). Data are presented as bars and 
individual samples with lines corresponding to the mean and standard error of the mean (SEM). Sample sizes 
N = 6-8. Scale bars indicate 50 µm in all images. 
 
Further, YAP/TAZ deletion significantly reduced mRNA expression of YAP/TAZ-
TEAD target genes, Cyr61 and Ctgf in femoral bone at P84 (Figure 3-5I,J).  However, 
YAP/TAZ deletion did not alter sclerostin (SOST), receptor activator of nuclear factor 




Figure 3-7: YAP/TAZ ablation from DMP1-expressing cells did not affect bone turnover markers. 
A-C) Femoral bone preparations from P84 mice were harvested to quantify mRNA expression. Expression 
levels, normalized to 18S rRNA, were evaluated for (A) sclerostin (Sost), (B) receptor activator of nuclear 
factor kappa-B ligand (Rankl), and (C) osteoprotegerin (Opg), Data are presented as bars and individual 
samples with lines corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 5-6 
per group. 
3.4.3 DMP1-conditional YAP/TAZ deletion impaired bone mechanical properties and 
matrix collagen composition 
To determine whether YAP/TAZ deletion impaired functional mechanical 
properties, we tested P84 femurs in three-point bending to failure (Figure 3-8A). 
Conditional YAP/TAZ deletion did not significantly reduce maximum load to failure 
(Figure 3-8B; p = 0.07) but significantly reduced bending stiffness, work to maximum load 
and work to failure (Figure 3-8C-E).  
 92 
 
Figure 3-8:YAP/TAZ ablation from DMP1-expressing cells impaired bone mechanical behavior by 
altering bone geometry and matrix collagen. 
A) P84 femurs were tested in three-point bending to failure. B-E) Quantification of (B) maximum load to 
failure, (C) bending stiffness, (D) work to max load, and (E) work to failure. F) Representative micrographs 
of polarized light microscopy and second harmonic generated (SHG) images of cortical bone from the P84 
femurs tested in three-point bending. G-H) Quantification of (G) SHG intensity normalized to wild type. H) 
Best-subset multivariate regression model predicting experimental bending stiffness (K) using moment of 
inertia and SHG intensity as predictors. Data are presented with individual samples in scatterplots and bars 
corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 8 per group. Scale bars 
equal 100 and 25 µm in the Picrosirius red and SHG, respectively. 
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Intrinsic bone material properties are determined, in part, by collagen content and 
organization170. To test whether osteocyte YAP/TAZ regulate the local collagen matrix, 
we performed polarized light and second harmonic generation (SHG) microscopy (Figure 
3-8F). YAP/TAZ deletion qualitatively reduced Picrosirius red staining and significantly 
reduced SHG intensity per bone area, indicative of both collagen content and organization 
(Figure 3-8G). Both cross sectional bone geometry (section modulus and moment of 
inertia) and collagen matrix content and organization significantly contributed to bone 
stiffness according to a multivariate best-subsets regression analysis using the Akaike’s 
information criterion (AIC), which selects the model with the lowest number of predictors 
with the greatest predictive power170,213. Neither microCT-measured tissue mineral density 
nor femur length contributed to the overall best model according to AIC for stiffness and 
maximum load to failure (Figure 3-8H, Figure 3-9). 
 
Figure 3-9: Best subsets analysis on morphological parameters from YAP/TAZ ablation in DMP1-
expressiong cells demonstrated increased goodness of fit for stiffness by accounting for collagen content 
and organization. 
 94 
Using the femurs that were scanned by microCT, tested in three-point bending, and imaged using SHG, 
experimental ultimate load (Fmax) values were compared with predicted values from the top three “best” 
multivariate models in order from left to right.  Models were ranked based on their relative Akaike’s 
information criterion (AIC) value with the lowest AIC being the “best.” The three “best” multivariate models 
for ultimate load were A) only section modulus (I/c), (B) I/c and second harmonic generated signal intensity 
(SHG), and (C) I/c and tissue mineral density (TMD) as predictors. Similarly, (K) were (D) moment of inertia 
(I) and SHG, (E) I, SHG and femur length, and (C) I and femur length as predictors. Sample sizes, N = 8 per 
group. 
 
3.4.4 DMP1-conditional YAP/TAZ deletion impaired the osteocyte canalicular 
network, but not lacunar morphology 
We initially hypothesized that the primary function of YAP/TAZ in osteocytes was 
to regulate expression of genes that control osteocyte-osteoblast and -osteoclast 
communication, such as secreted factors CYR61 and CTGF. However, the reduced bone 
mechanical properties and disorganized collagen matrix in mice lacking YAP/TAZ from 
osteocytes phenocopied matrix metalloproteinase-13 (MMP13) knockout mice, which had 
defective collagen organization as a result of impaired perilacunar/canalicular 
remodeling33. This led us to ask whether YAP/TAZ deletion from osteocytes impaired 
perilacunar/canalicular remodeling.  
Conditional YAP/TAZ deletion did not significantly alter osteocyte density but 
increased empty lacunae percentage in cancellous metaphyseal bone (Figure 3-10A-C).  
Accordingly, conditional YAP/TAZ deletion increased the number of TUNEL-positive 
lacunae, suggesting an increase in osteocyte apoptosis within the cancellous bone 
compartment (Figure 3-10D-E). Conditional YAP/TAZ deletion significantly reduced 
canalicular density and mean process length, measured in silver nitrate-stained, mid-
cortical bone sections (Figure 3-10F-H).  
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Figure 3-10: YAP/TAZ ablation from DMP1-expressing cells increased osteocyte apoptosis and reduced 
canalicular number and length. 
A) Representative micrographs of P84 cancellous metaphyseal bone stained by H+E. B-C) Quantification of 
(B) osteocyte number per bone area (Ot.N/B.Ar), and (C) percentage of empty lacunae. D) Representative 
immunofluorescence micrographs of P28 cancellous metaphyseal bone stained with TUNEL positive cells 
(red) and DAPI (blue). E) Quantification of the percentage of TUNEL positive lacunae. F) Representative 
micrographs of P84 mid-cortical bone silver stained for the osteocyte canalicular network. G-H) 
Quantification of (G) canalicular density per cell and (H) average canalicular length. Data are presented with 
individual samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). 
Sample sizes, N = 6-8 per group. Scale bars equal 15 µm all images. 
 
As the canalicular system is a three-dimensional network of branched cell processes 
that physically connect osteocytes to their neighbors238, we next quantified the 3D 
canalicular network by laser scanning confocal microscopy of the osteocyte actin 
cytoskeleton, labeled with phalloidin (Figure 3-11A). YAP/TAZ deletion significantly 
reduced branch length (Figure 3-11B,C), number of branches per cell (Figure 3-11D), and 
number of junctions per cell (Figure 3-11E).  
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Figure 3-11: YAP/TAZ ablation from DMP1-expressing cells reduced canalicular network length and 
branching, but not lacunar morphology in 3D. 
A) Representative 15-micron thick confocal reconstructions of phalloidin-stained osteocyte F-actin 
cytoskeletons in cortical bone at P28. B) Average distributions of branch length. C-E) Quantification of (C) 
average branch length, (D) number of branches, and (E) number of junctions. F) Representative lacunar 
morphologies in 3D in cancellous bone from P84 tibiae using X-ray microscopy (XRM). G) Average 
distributions of lacunar volume. H-J) Quantification of (H) average lacuna volume, (I) oblateness, and (J) 
stretch. Data are presented with individual samples in scatterplots and bars corresponding to the mean and 
standard error of the mean (SEM). Sample sizes, N = 4-6 for confocal network analysis and N = 8 for XRM. 
Each side of scale parallelograms equal 10 µm for both confocal and XRM. 
 
To determine the effect of YAP/TAZ deletion on osteocyte lacunar morphology, 
we performed high resolution (0.6 um voxel) X-Ray microscopy (XRM) imaging of both 
cortical and cancellous bone in the proximal tibia metaphysis (Figure 3-11F). YAP/TAZ 
deletion did not significantly alter lacuna volume (Figure 3-11G,H) or shape (Figure 3-
11I,J), as significant interaction factors were observed between sex, bone compartment, 
and genotype for all lacunar morphology parameters. Using post-hoc multiple 
comparisons, no differences in lacunar parameters were observed between genotypes 
within either a single sex or bone compartment.  
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3.4.5 DMP1-conditional YAP/TAZ deletion reduced osteocyte-mediated bone matrix 
remodeling 
Perilacunar/canalicular remodeling involves both the deposition and degradation of 
the bone matrix directly surrounding the osteocytes. Prior studies used 3H-proline pulses 
and tetracycline labeling to identify osteocyte lacunae as sites of active collagen deposition 
and mineralization35,261,262. Here, we measured collagen I gene expression and 
fluorochrome incorporation in osteocyte lacunae to assess peri-osteocyte matrix 
deposition. Conditional YAP/TAZ deletion reduced the percentage of Calcein-labeled 
osteocyte lacunae (Figure 3-12A,B) and reduced transcript expression of Col1a1 (Figure 
3-12C). However, YAP/TAZ deletion did not alter expression of either osteogenic genes, 
including alkaline phosphatase (Alp), osteocalcin (Ocn), and bone sialoprotein (Bsp), or 
osteocyte-marker genes, dentin matrix protein-1 (Dmp1) or phosphate-regulating neutral 
endopeptidase, X-linked (Phex) (Figure 3-13).  
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Figure 3-12:YAP/TAZ ablation from DMP1-expressing cells reduced osteocyte-mediated bone 
remodeling. 
A) Representative double fluorochrome-labeled osteocytes (white) in cortical bone from P28 femurs (Calcein 
label injected at P21). B-C) Quantification of (B) Calcein labeled lacunae and (C) relative transcript 
expression for collagen1a1 (Col1a1) in P84 femoral bone preparations. D) Representative micrographs of 
cancellous metaphyseal bone from P84 femurs immunostained for cathepsin K (CTSK). E-F) Quantification 
of (E) CTSK immunostained lacunae and (F) relative transcript expression for Ctsk in P84 femoral bone 
preparations. G) Representative micrographs of cancellous metaphyseal bone from P84 femurs 
immunostained for matrix metalloproteinase 13 (MMP13). E-F) Quantification of (E) MMP13 
immunostained lacunae and (F) relative transcript expression for Mmp13 in P84 femoral bone preparations. 
J) Representative micrographs of cancellous metaphyseal bone from P84 femurs immunostained for matrix 
metalloproteinase 14 (MMP14). K-L) Quantification of (K) MMP14 immunostained lacunae and (L) relative 
transcript expression for Mmp14 in P84 femoral bone preparations. Data are presented with individual 
samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample 




Figure 3-13: YAP/TAZ deletion did not alter osteogenic or osteocyte-marker gene expression. 
A-E) Femoral bone preparations from P84 mice were harvested to quantify mRNA expression. Expression 
levels, normalized to 18S rRNA, were evaluated for (A) alkaline phosphatase (Alp), (B) osteocalcin (Ocn), 
(C) bone sialoprotein (Bsp), (D) dentin matrix protein 1 (Dmp1), and (E) phosphate-regulating neutral 
endopeptidase (Phex). Data are presented as bars and individual samples with lines corresponding to the 
mean and standard error of the mean (SEM). Sample sizes, N = 6 per group. 
 
In addition to local matrix deposition, osteocytes also locally degrade their 
extracellular matrix. Many of the matrix metalloproteinases and other enzymes employed 
by osteoclasts to resorb bone are also expressed by osteocytes and are critical to 
perilacunar/canalicular remodeling 32–34. Therefore, to test whether YAP/TAZ regulate 
direct matrix remodeling by osteocytes, we measured mRNA and protein expression of the 
matrix proteases, cathepsin K (CTSK), matrix metalloproteinase-13 (MMP13), and matrix 
metalloproteinase-14 (MMP14). Conditional YAP/TAZ deletion reduced the percentage 
of osteocytes that stained positive for CTSK (Figure 3-12D,E), MMP13 (Figure 3-12G,H), 
and MMP14 (Figure 3-12J,K) and decreased mRNA expression of Ctsk (Figure 3-12F), 
Mmp13 (Figure 3-12I), and Mmp14 (Figure 3-12L) in vivo. 
3.4.6 YAP/TAZ inhibition abrogated TGF-b-induced gene expression in vitro 
Though unexplored in osteocytes, YAP and TAZ are known to mediate TGF-b 
signaling in a variety of other cell types117,118,248,249. Further, either pharmacologic 
inhibition or genetic ablation of TGF-b receptors from osteocytes caused defective 
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perilacunar/canalicular remodeling and associated gene expression106.  Therefore, we next 
tested whether YAP/TAZ mediate TGF-b signaling, Cyr61/Ctgf expression, and 
perilacunar/canalicular remodeling-associated gene expression in osteocytes by treating 
two osteocyte-like cell lines with combinatorial TGF-b and/or verteporfin (VP) treatment. 
VP is a small molecule inhibitor that physically blocks the interaction of YAP and TAZ 
with their transcriptional co-effectors, particularly the TEAD transcription factors, 
preventing YAP/TAZ-TEAD transcriptional activity170,218.  
We first used mouse osteocyte-derived IDG-SW3 cells, which carry a DMP1 cis-
regulatory system driving GFP expression, as a marker of living osteocytes263,264. As shown 
previously, IDG-SW3 cells exhibited robust DMP1-GFP transgene expression after 21 
days of in vitro osteocytic differentiation (Figure 3-14A). Beginning at day 20, cells were 
treated with vehicle (DMSO) or 3 µM verteporfin (Figure 3-14A). At day 21, cells were 
treated with 5 ng/ml TGF-b or PBS vehicle for 6 hours and gene expression was evaluated 
by qPCR. Similar experiments were conducted in mouse osteocyte-derived OCY454 
cells265 (Figure 3-15A). 
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Figure 3-14:Inhibition of YAP/TAZ-TEAD with verteporfin (VP) reduced TGF-b-induced PLR gene 
expression in vitro. 
A) Osteocyte-like IDG-SW3 cells were differentiated for 21 days, with osteocyte differentiation reported by 
DMP1-GFP transgene expression. Cells were combinatorially treated with inhibitor verteporfin (VP) and/or 
5 ng/ml TGFb1 at day 21. B-G) mRNA expression, normalized to 18S rRNA, was evaluated for (B) serpin 
family E member 1 (SerpinE1), (C) cysteine-rich angiogenic inducer 61 (Cyr61), (D) connective tissue 
growth factor (Ctgf), (E) cathepsin K (Ctsk), (F) matrix metalloproteinase-13 (Mmp13), and (G) matrix 
metalloproteinase-14 (Mmp14). Relative expression was expressed as fold vs. vehicle (PBS + DMSO)-treated 
cells.  Data are presented with individual samples in scatterplots and bars corresponding to the mean and 
standard error of the mean (SEM). Sample sizes, N = 3. Scale bars equal 75 mm. 
 
First, to test whether verteporfin blocked TGF-b-induced YAP/TAZ signaling, we 
evaluated expression of serpin family E member 1 (SerpinE1) and expression of known 
osteoblast/osteoclast paracrine signaling factors, Cyr61 and Ctgf. Each of these genes are 
established TGF-b-inducible, YAP/TAZ-TEAD target genes126,246,266,267. As expected, 
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TGF-b robustly induced SerpinE1, Cyr61, and Ctgf mRNA expression, which was 
abrogated by verteporfin treatment (Figure 3-14B-D). Next, to test whether YAP/TAZ 
mediate TGF-b induction of genes associated with perilacunar/canalicular remodeling, we 
quantified mRNA expression of Ctsk, Mmp13, and Mmp14. TGF-b significantly induced 
expression of Mmp13 and Mmp14, but not Ctsk, in IDG-SW3 cells, and verteporfin 
treatment abrogated expression of all three genes (Figure 3-14E-G). In OCY454 cells, 
verteporfin similarly abrogated TGF-b induced expression of Ctgf, Cyr61 and SerpinE1 
mRNA (Figure 3-15B-D) as well as Mmp14 and Ctsk, but not Mmp13 (Figure 3-15E-G). 
 
 Figure 3-15:Inhibition of YAP/TAZ-TEAD with verteporfin (VP) reduced TGF-b-induced remodeling 
gene expression in OCY454 cells. 
A) Osteocyte-like cells, OCY454, were differentiated for 12 days. Cells were combinatorially treated with 
inhibitor verteporfin (VP) and 5 ng/ml TGF-b1 at day 12. B-G) mRNA expression, normalized to 18S rRNA, 
was evaluated for (B) serpin family E member 1 (SerpinE1), (C) cysteine-rich angiogenic inducer 61 (Cyr61), 
(D) connective tissue growth factor (Ctgf), (E) cathepsin K (Ctsk), (F) matrix metalloproteinase-13 (Mmp13), 
and (G) matrix metalloproteinase-14 (Mmp14). Relative expression was expressed as fold vs. vehicle (PBS 
+ DMSO)-treated cells. Data are presented as bars and individual samples with lines corresponding to the 
mean and standard error of the mean (SEM). Sample sizes, N = 3. 
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Finally, we evaluated Sost, Opg, and Rankl expression in both IDG-SW3 and 
OCY454 cells as potential YAP/TAZ-regulated mediators of osteocyte-
osteoblast/osteoclast signaling. In IDG-SW3 cells, both verteporfin and TGF-b 
significantly reduced Sost transcript expression, while verteporfin abrogated TGF-b-
induced Rankl and Opg expression (Figure 3-16A-C). In OCY454 cells, verteporfin 
abrogated TGF-b-induced Opg and reduced Sost expression, but did not significantly alter 
Rankl expression (Figure 3-16D-F). In contrast to IDG-SW3 cells, treatment of OCY454 
cells with TGF-b alone significantly reduced Rankl transcript expression (Figure 3-16E).  
 
Figure 3-16: Combinatorial verteporfin (VP) and TGF-b treatment altered bone turnover-related gene 
expression in vitro. 
Osteocyte-like IDG-SW3 cells were differentiated for 21 days and combinatorially treated with inhibitor 
verteporfin (VP) and/or 5 ng/ml TGFb1 at day 21. A-C) mRNA expression, normalized to 18S rRNA, was 
evaluated for (A) sclerostin (Sost), (B) receptor activator of nuclear factor kappa-B ligand (Rankl), and (C) 
osteoprotegerin (Opg). Osteocyte-like cells, OCY454, were differentiated for 12 days. Cells were 
combinatorially treated with inhibitor verteporfin (VP) and 5 ng/ml TGF-b1 at day 12. D-F) mRNA 
expression, normalized to 18S rRNA, was evaluated for (D) sclerostin (Sost), (E) receptor activator of nuclear 
factor kappa-B ligand (Rankl), and (F) osteoprotegerin (Opg). Relative expression was expressed as fold vs. 
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vehicle (PBS + DMSO)-treated cells. Data are presented as bars and individual samples with lines 
corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 3. 
3.5 Discussion 
This study identifies new roles of the transcriptional regulators, YAP and TAZ, to 
enhance our understanding of how osteocyte-mediated bone remodeling contributes to 
skeletal fragility. Here, we show that YAP and TAZ control bone matrix accrual, 
organization, and mechanical properties by regulating both perilacunar/canalicular 
remodeling and osteoblast/osteoclast activity, potentially through TGF-b signaling in 
osteocytes. Osteocyte-conditional YAP/TAZ deletion reduced bone mass by decreasing 
osteoblast number and activity and increasing osteoclast activity, but also impaired 
osteocyte-intrinsic pericellular matrix deposition and degradation, impairing canalicular 
network connectivity without altering lacunar morphology. In vitro, we found that 
YAP/TAZ activity was required for TGF-b1 induction of matricellular growth factors 
involved in paracrine signaling from osteocytes to osteoblasts/osteoclasts and matrix 
proteases necessary for perilacunar/canalicular remodeling. Together, these data identify 
the transcriptional co-activators YAP and TAZ as key mediators of bone remodeling. 
The roles of YAP and TAZ in skeletal-lineage cells are beginning to be clarified. 
Previously, we reported that dual YAP/TAZ deletion from osteoprogenitor cells and their 
progeny using Osterix-Cre mimicked severe cases of osteogenesis imperfecta170. We 
identified a combinatorial role for YAP and TAZ in promoting osteoblast number and 
activity and suppressing osteoclast activity170. Similarly, YAP deletion later in the 
osteoblast lineage, from committed osteoblasts using Osteocalcin-Cre, significantly 
reduced bone formation, further supporting a role for YAP in promoting osteogenesis in 
vivo177. That study did not observe changes in osteoclast activity, potentially due to 
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compensatory effects of TAZ or the Cre line used177. We show here that 8kb-DMP1-Cre-
conditional YAP/TAZ deletion from osteocytes also reduced osteoblast number and 
activity and increased osteoclast activity. Consistent with our data268, Xiong et al. found 
that YAP/TAZ deletion using 10kb-DMP1-Cre reduced bone formation and increased 
osteoclast numbers171. The YAP/TAZ-TEAD target, CTGF was previously reported to 
directly bind to RANKL and OPG to induce osteoclast differentiation in vitro269, but 
neither the present study nor Xiong et al.171 observed significant changes in transcript 
expression of Sost or Opg/Rankl in vivo. Our in vitro experiments in osteocyte-like IDG-
SW3 and OCY454 cells did not reveal consistent regulation of Sost, Opg, or Rankl by 
YAP/TAZ-TEAD, warranting further mechanistic studies. 
Here, we found that YAP/TAZ deletion in vivo and inhibition in vitro reduced 
osteocyte expression of the matricellular growth factors, Cyr61 and Ctgf. Both CYR61 and 
CTGF are induced by TGF-b266,267 and are transcriptionally regulated directly by the 
YAP/TAZ-TEAD complex126,246. CYR61 and CTGF are expressed by osteocytes239 and 
have been implicated in both osteoblastogenesis243,244 and osteoclastogenesis245,270. During 
osteoblastogenesis in vitro, CYR61 enhances mesenchymal stem cell migration and 
regulates WNT3A-induced osteogenic differentiation243. CTGF also enhances 
osteoblastogenesis in vitro, in part by inhibiting Notch signaling and inducing HES-1 
transcription and NFAT transactivation244. In vivo deletion of CTGF in Osteocalcin-
expressing cells led to a mild low bone mass phenotype in male mice without alterations 
in osteoblast or osteoclast numbers271. Similarly, deletion of CYR61 at various stages of 
the osteoblast lineage (Osterix-Cre, Collagen1(2.3kb)-Cre, and Osteocalcin-Cre) resulted 
in low bone mass phenotypes of similar severity, suggesting mature osteoblasts/osteocytes 
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are the primary source of CYR61 in bone240. Deletion of CYR61 from Osteocalcin-
expressing mature osteoblasts also increased osteoclast numbers in vivo240, consistent with 
the effects of osteocyte-conditional YAP/TAZ deletion here. CYR61 inhibits 
osteoclastogenesis in vitro through a RANKL-independent mechanism245, while CTGF has 
been observed to promote osteoclast-precursor fusion through interaction with dendritic 
cell-specific transmembrane protein (DC-STAMP)270. Future studies will be required to 
dissect the varied mechanisms by which osteocytes direct osteoblast/osteoclast-mediated 
remodeling, but these data identify a role for YAP/TAZ in osteocyte-mediated promotion 
of osteoblast activity and suppression of osteoclast activity and implicate a TGF-b–
YAP/TAZ-TEAD signaling axis in CYR61 and CTGF expression by osteocytes. 
In addition to regulating osteocyte-mediated coordination of osteoblasts and 
osteoclasts, we found that YAP/TAZ deletion also impaired perilacunar/canalicular 
remodeling of the bone matrix directly by osteocytes. TGF-b signaling is an osteocyte-
intrinsic regulator of perilacunar/canalicular remodeling106. Here, we found that DMP1-
conditional YAP/TAZ deletion phenocopied the effects of both DMP1-conditional TGF-b 
receptor deletion and pharmacologic inhibition, which impaired canalicular network length 
and reduced expression of matrix-degrading enzymes required for perilacunar/canalicular 
remodeling (i.e. MMP13, MMP14, and CTSK) without altering lacunar morphology106, as 
observed here. Confirming the function of these regulated genes, DMP1-conditional 
YAP/TAZ deletion also partially phenocopied knockout mouse models of these important 
matrix proteases. First, global knockout of MMP13 in mice osteocyte inhibited 
perilacunar/canalicular remodeling by reducing collagen organization, flourochrome-
labeled mineral deposition around osteocytes, and canalicular network connectivity with 
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similar effect sizes to DMP1-conditional YAP/TAZ deletion33. Second, global knockout of 
MMP14 in mice significantly reduced canalicular network development and maintenance, 
reducing osteocyte processes density and length34. Notably, targeted deletion of MMP14 
in skeletal lineage cells using Dermo1-Cre reduced YAP/TAZ activity in osteocytes220, 
suggesting a potential feedback loop between matrix protease activity and matrix 
mechanotransduction. Lastly, global knockout of CTSK in mice impaired bone matrix 
collagen organization that increased bone fragility in spite of high bone mass and increased 
osteoclast activity272. We therefore pose the working hypothesis that YAP and TAZ act 
downstream of TGF-b to mediate perilacunar/canalicular remodeling in osteocytes; further 
investigation will be required to test this in vivo. 
Perilacunar/canalicular remodeling and osteoblast/osteoclast-mediated remodeling 
coordinately determine skeletal strength6,236. Compromised bone strength caused by 
defects in bone mass and/or quality results in fragility fracture6,235,236. Bone quantity is 
primarily regulated by the balance of bone turnover rate while quality includes matrix 
composition and microarchitectural geometry6,235. Both of these factors contribute to the 
pathogenesis of skeletal fragility diseases such as osteoporosis, Paget’s disease, and  
osteogenesis imperfecta6. Here, we found that osteocyte-conditional YAP/TAZ deletion 
decreased bone mass and altered collagen matrix content and organization, producing 
moderate defects in bone mechanical behavior. Osteocyte-specific YAP/TAZ knockouts 
did not exhibit the spontaneous bone fractures prevalent in mice lacking YAP/TAZ in the 
full osteoblast lineage170, but their defects correspond with the increased bone fragility 
described in other models of defective perilacunar/canalicular remodeling33,106. Age-
related decreases in canalicular network connectivity are associated with microdamage 
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accumulation that contributes to age-associated skeletal fragility199, further suggesting a 
contribution of the canalicular network to bone strength.  
This study has several limitations. First, small sample sizes (N = 4-8) produced 
under-powered analyses for some outcome measures. Post-hoc power analyses for 
indicated perilacunar/canalicular phenotypic results are shown in Table 3-3.  
Table 3-3: Post-hoc power analyses. 
Power analyses for perilacunar/canalicular phenotypic results.  
Figure Panel Parameter Power 
Figure 4C Stiffness 0.99 
Figure 5G Canalicular length  0.99 


























Power ranged from 0.74 to 0.99. Thus, not all the studies performed had enough 
power to compare sex as a variable, though our initial assessment of skeletal phenotype did 
not show a significant effect of sex. Second, two different age of mice were used (P28 and 
P84). Both timepoints represent young mice with robust osteocyte canalicular networks 
avoiding the potentially confounding effects of age-related canalicular network 
deterioration199. However, significant changes in development and bone growth occur in 
mice between P28 and P84; future studies will characterize the extent of canalicular 
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development during post-natal growth. Third, recent reports suggest that both the 8-kb and 
10-kb DMP1 promoter fragments used to drive Cre recombinase expression for conditional 
ablation in osteocytes can also induce recombination in mature osteoblasts, and other cell 
types, depending on the sensitivity of the floxed alleles69,70,273,274. Although we observed 
minimal recombination in osteoblasts and growth plate chondrocytes, the 8-kb DMP1-Cre 
model used here is not an inducible model, and potential targeting of earlier stage 
osteogenic cells could still contribute to the developmental changes observed. Fourth, our 
data suggest that YAP/TAZ act downstream of TGF-b in osteocytes, but continued study 
will be required to determine whether YAP and TAZ act downstream of TGF-b in vivo and 
to define the transcriptional mechanisms by which YAP and TAZ regulate 
perilacunar/canalicular remodeling genes. Finally, osteocytes are the key mechanosensing 
cells in bone275, and YAP and TAZ are important mediators of mechanotransduction in 
many cell types150; however, the putative roles of YAP and TAZ in osteocyte 
mechanotransduction are unknown. As mechanical loading also induces 
perilacunar/canalicular remodeling276, continued investigation is warranted.  
In conclusion, this study identifies the transcriptional co-activators, YAP and TAZ, 
as regulators of bone quantity and quality that mediate osteocyte regulation of 
osteoblast/osteoclast activity and perilacunar/canalicular remodeling. Specifically, 
osteocyte YAP and TAZ are required for the expression of paracrine growth factors that 
regulate osteoblast/osteoclast coupled remodeling (i.e., Cyr61, Ctgf) and the effector 
enzymes that enable perilacunar/canalicular remodeling. Further elucidation of the 
mechanisms by which the TGF-b and YAP/TAZ signaling pathways interact to regulate 
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osteocyte function may help guide the development of targeted therapies for the treatment 



















CHAPTER 4: YAP AND TAZ PROMOTE PERIOSTEAL OSTEOBLAST 
PRECURSOR EXPANSION AND DIFFERENTIATION FOR FRACTURE 
REPAIR 
4.1 Abstract 
In response to bone fracture, periosteal progenitor cells proliferate, expand, and 
differentiate to form cartilage and bone in the fracture callus. These cellular functions 
require the coordinated activation of multiple transcriptional programs, and the 
transcriptional regulators Yes-associated protein (YAP) and transcriptional co-activator 
with PDZ-binding motif (TAZ) regulate osteochondroprogenitor activation during 
endochondral bone development. However, recent observations raise important 
distinctions between the signaling mechanisms used to control bone morphogenesis and 
repair. Here, we tested the hypothesis that YAP and TAZ regulate osteochondroprogenitor 
activation during endochondral bone fracture healing in mice. Constitutive YAP and/or 
TAZ deletion from Osterix-expressing cells impaired both cartilage callus formation and 
subsequent mineralization. However, this could be explained either by direct defects in 
osteochondroprogenitor differentiation after fracture, or by developmental deficiencies in 
the progenitor cell pool prior to fracture. Consistent with the second possibility, we found 
that developmental YAP/TAZ deletion produced long bones with impaired periosteal 
thickness and cellularity. Therefore, to remove the contributions of developmental history, 
we next generated adult onset-inducible knockout mice (using Osx1-CretetOff) in which 
YAP and TAZ were deleted prior to fracture, but after normal development. Adult onset-
induced YAP/TAZ deletion had no effect on cartilaginous callus formation, but impaired 
bone formation at 14 days post-fracture (dpf). Earlier, at 4 dpf, adult onset-induced 
 112 
YAP/TAZ deletion impaired the proliferation and expansion of osteoblast precursor cells 
located in the shoulder of the callus. Further, activated periosteal cells isolated from this 
region at 4 dpf exhibited impaired osteogenic differentiation in vitro upon YAP/TAZ 
deletion. Finally, confirming the effects on osteoblast function in vivo, adult onset-induced 
YAP/TAZ deletion impaired intramembranous bone formation in the callus shoulder at 7 
dpf. Together, these data show that YAP and TAZ promote the expansion and 
differentiation of periosteal osteoblast precursors to accelerate bone fracture healing. 
  
4.2 Introduction 
Bone is a remarkable tissue in its capacity to heal without forming a scar, and most 
bone injuries heal readily, with bone fractures healing at success rates of 90-95%277. This 
is due, in part, to the maintenance of a skeletal stem cell population capable of 
recapitulating many aspects of embryological programs for adult tissue regeneration37. As 
in development, bone formation during fracture repair can occur through both direct 
intramembranous ossification and endochondral ossification via a cartilage 
intermediate39,40,43. However, the source, niche, and molecular regulation of the progenitor 
cells responsible for bone fracture repair are distinct from those that produce the skeleton 
during development37,278. In the embryo, mesodermal mesenchymal progenitors in the limb 
bud form a template of the skeletal elements, while bone fracture healing initiates by 
expansion and differentiation of osteochondroprogenitor cells resident in the bone-lining 
periosteum39,40,50. Understanding the mechanisms that regulate the proliferation and 
differentiation of these cells will be critical to develop new therapeutic strategies for 
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accelerating fracture repair and regenerating challenging bone injuries that cannot heal on 
their own.  
To define the roles of the molecular mediators that regulate adult periosteal 
progenitor cell function, we must decouple the developmental history of the 
osteochondroprogenitor cells that come to reside in the periosteum from the regenerative 
function of these cells after fracture to accurately evaluate their contribution to responding 
to injury in the adult. For example, a recent study in which PDGFRb was deleted from 
Osterix-expressing cells found no notable defects in skeletal development, but severe 
impairment of fracture healing279, demonstrating contextual distinctions between 
development and fracture repair. Further, skeletal cell- and bone-specific gene deletion 
during development may alter the number, location, or niche of progenitor cells that, during 
injury, are activated for skeletal regeneration58. In this study, we assessed the effects of 
conditional gene deletion from osteochondroprogenitors on endochondral bone fracture 
repair, with deletion performed either constitutively during development or inducibly after 
normal development to skeletal maturity prior to fracture. Several types of inducible Cre-
loxP systems exist to temporally regulate Cre-mediated gene recombination, including the 
interferon-responsive Mx1 promoter280, tamoxifen-inducible mutated estrogen- and 
progesterone-receptors281, and tetracycline-controlled systems282.  Here, we used the 
Osterix-CretetOff (Osx-Cre) mouse in which Cre-recombinase is driven by the Osterix 
promoter and temporally controlled by tetracycline (or its more stable derivative, 
doxycycline)63. Osx-Cre is expressed in hypertrophic chondrocytes and osteoprogenitors, 
including those of the primary ossification center in the embryo as well as the periosteum 
in the adult63,283.  
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Periosteal cell expansion and differentiation require the coordinated activation of 
multiple transcriptional programs, and the transcriptional regulators, Yes-associated 
protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) have 
recently emerged as critical mediators of osteoblast progenitor proliferation and 
differentiation during bone development170,171,177. Previously, we found that constitutive 
homozygous deletion of both YAP and TAZ from Osterix-expressing cells caused severe 
skeletal fragility and neonatal lethality170. Mice with a single allele of either YAP or TAZ 
survived, but sustained spontaneous long bone fractures due to both reduced bone mass 
and defects in bone matrix collagen that caused weaker bone mechanical properties170. 
Despite fracture, the neonatal limbs exhibited natural reduction284 and eventually healed 
through callus formation 170. However, the roles of YAP and TAZ in periosteal progenitor 
cell function and their contributions to bone fracture healing are unknown. 
Here, we conditionally deleted YAP and/or TAZ from Osterix-expressing cells 
using either constitutive or tetOFF-inducible deletion and evaluated adult endochondral 
bone fracture healing. We found that constitutive YAP and/or TAZ deletion impaired both 
callus formation and subsequent mineralization, due to developmental deficiencies in the 
progenitor cell pool prior to fracture. In contrast, adult onset-induced YAP/TAZ deletion 
had no effect on cartilaginous callus formation, but impaired both the proliferation of 
osteoblast precursor cells located in the shoulder of the callus and their osteogenic 
differentiation, both, in vitro and in vivo. Together, these data show that YAP and TAZ 
promote the expansion and differentiation of periosteal osteoblast precursors to accelerate 
bone fracture healing. 
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4.3 Methods 
4.3.1 Animals  
Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed 
C57BL/6J genetic background were kindly provided by Dr. Eric Olson (University of 
Texas Southwestern Medical Center). Tetracycline responsive (tetOFF) B6.Cg-Tg(Sp/7-
tTA,tetO-EGFP/Cre)1AMc/J (Osx-CretetOff) mice from The Jackson Laboratory (Bar 
Harbor, MA, USA) were used to generate two mouse models in which we conditionally 
deleted YAP and/or TAZ from Osterix-expressing cells (Table 4-1). In both mouse models, 
tetracycline (or its more stable derivative, doxycycline) administration prevents 
tetracycline-controlled transactivator protein (tTA) binding to the tetracycline-responsive 
promoter element (TRE) in the promoter of the Cre transgene, allowing Cre expression 
only in the absence of doxycycline63 for temporal control of Osx-Cre-mediated gene 
deletion. 
Table 4-1: Experimental fracture healing models, genotypes, and abbreviations (Aim 3) 
 














In our first study, we evaluated constitutive allele dose-dependent deletion of YAP 
and/or TAZ in skeletally mature mice 16-21 weeks of age (Table 4-1). Mice with 
homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl) were mated with 
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double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;Osx-Cre) to produce 
eight possible genotypes in each litter, but only Cre-positive and YAPfl/fl;TAZfl/fl  animals 
were compared (Table 4-1). Here, the littermate YAPfl/fl;TAZfl/fl mice were considered the 
control genotype. All of these mice were bred, raised, and evaluated without tetracycline 
administration to induce gene recombination in Osterix-Cre-expressing cells from 
embryonic development onward, for the duration of the analyses in the constitutive deletion 
model. 
In our second study, we allowed mice to develop to skeletal maturity and induced 
homozygous YAP/TAZ deletion two weeks prior to fracture at 16-18 weeks of age (Table 
4-1). In the inducible deletion model, both littermate YAPfl/fl;TAZfl/fl (YAPWT;TAZWT ) 
mice and separately bred Osx-CretetOff mice were evaluated as control genotypes (Table 4-
1). All mice were bred and raised until skeletal maturity with doxycycline in their drinking 
water to prevent Cre-mediated gene recombination.  For all in vivo fracture healing 
assessments, doxycycline was removed two weeks prior to fracture surgery and normal 
drinking water was provided for the remainder of the study. For periosteal progenitor cell 
isolations from fractured limbs, doxycycline was provided for both YAPWT;TAZWT and 
YAPcKOi;TAZcKOi mice throughout skeletal development and the duration of the fracture 
healing experiment.  
In both studies, mice were tail or ear clipped after weaning or prior to euthanasia 
and genotyped by an external service (Transnetyx, Inc.). All mice were fed regular chow 
(PicoLab Rodent Diet, Cat#: 0007688, LabDiet) ad libitum and housed in cages containing 
2-5 animals each. Mice were maintained at constant 25°C on a 12-hour light/dark cycle. 
Both male and female mice were evaluated with the same fracture healing procedure for 
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both the constitutive and inducible deletion models of fracture healing (Table 4-1). All 
protocols were approved by the Institutional Animal Care and Use Committees at the 
University of Notre Dame and the University of Pennsylvania. All animal procedures were 
performed in adherence to federal guidelines for animal care and conform to the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. 
 
4.3.2 Open femoral fracture model and timepoints 
An open, unilateral, and intramedullary pin-stabilized femoral fracture model was 
used to study bone repair in both the inducible and constitutive deletion studies. Femora 
were surgically exposed and manually fractured by applying a bending moment, but 
stabilized with an intramedullary pin285. For the surgical procedure, animals were 
anesthetized using isoflurane (1-5%), all hair was removed from the surgical site, and the 
area was cleansed with sterile water followed by betadine. A 25-gauge needle was inserted 
in a retrograde manner into the intramedullary canal of the right femur286. Subsequently, 
the muscle surrounding the same femur was blunt dissected to expose the femoral midshaft 
and a reproducible fracture was created by applying a three-point bending moment in the 
femur containing the intramedullary pin. The contralateral leg was left intact. Any animals 
that displayed intramedullary pin displacement or fractures that were comminuted or too 
oblique were removed. The mice were allowed to recover under a heating lamp and after 
awakening returned to their cages and allowed to ambulate freely. In the constitutive 
deletion model, mice were euthanized at 14 days post-fracture (dpf) and 42 dpf. In the 
inducible deletion model, mice were euthanized at 4 dpf, 7 dpf, and 14 dpf. At 4 dpf, mice 
were injected intraperitoneally with 5-ethynyl-2’-deoxyuridine (EdU; E10187; Invitrogen) 
at 10 mg/kg 3 hours prior to euthanasia to assay cellular proliferation. 
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4.3.3 Microcomputed tomography  
Micro-computed tomography (microCT) was performed according to published 
guidelines208 on two separate systems. In the constitutive deletion study, 14 and 42 dpf 
fractured limbs were dissected free from surrounding musculature and the intramedullary 
pins were removed. Samples from 14 and 42 dpf limbs were wrapped in PBS-soaked gauze 
and frozen at -20°C. When removed from the freezer, bones were allowed to thaw while 
being imaged using a µCT 35 system (Scanco Medical). Samples from 14 and 42 dpf bone 
were imaged with an X-ray intensity of 114 µA, energy of 70 kVp, integration time of 200 
ms, and resolution of 15µm. Based on the precedent set in a similar fracture healing 
study286,287, we defined the fracture callus mineralization threshold as 50% of the mineral 
density that we used to segment intact cortical bone under these conditions on this system. 
2D tomograms of the fracture calluses both excluding and including the intact cortical bone 
were manually contoured, stacked and binarized by applying a Gaussian filter (sigma =0.8, 
support =1) at a threshold of 345 mg HA/cm3. 3D quantification of the mineralized callus 
excluding the intact bone were reported as total callus volume, percent callus 
mineralization, and volumetric bone mineral density. Five to eight mice were analyzed per 
group. Investigators were blinded to animal genotype during scan quantification. 
In the inducible deletion study, 7 and 14 dpf limbs were dissected free from 
surrounding musculature and the intramedullary pins were removed. Bones from 7 and 14 
dpf were then snap-frozen in liquid nitrogen-cooled isopentane for 1-minute, wrapped in 
gauze and imaged on a vivaCT 80 system (Scanco Medical). Samples from 7 and 14 dpf 
were imaged with an X-ray intensity of 114 µA, energy of 70 kVp, integration time of 200 
ms, and resolution of 15µm. We again defined the fracture callus mineralization threshold 
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as 50% of the mineral density that we used to segment intact cortical bone under these 
conditions on this system. 2D tomograms of the fracture calluses both excluding and 
including the intact cortical bone were manually contoured, stacked and binarized by 
applying a Gaussian filter (sigma =0.8, support =1) at a threshold of 254 mg HA/cm3. 3D 
quantification of the mineralized callus excluding the intact bone were reported as total 
callus volume, percent callus mineralization, and volumetric bone mineral density. Six to 
eight mice were analyzed per group. Investigators were blinded to animal genotype during 
scan quantification. 
To assess the cross-sectional bone distributions on the scans from both systems, the 
“Bone Midshaft” evaluation script (Scanco Medical) was used to quantify polar moment 
of inertia (pMOI)288. Limbs from 14 dpf in the constitutive deletion model and 14 dpf from 
the inducible deletion model were evaluated on each system using a negative, non-
physiological threshold so as to include all parts of the callus in the “Bone Midshaft” 
evaluation. Limbs from 42 dpf were scanned on the µCT 35 system were evaluated using 
the same threshold for mineralized tissue above (345 mg HA/cm3). In both cases, pMOI 
values for all groups were binned into 25 equal distance bins from the center of the fracture 
using a custom MATLAB script and presented as the mean with error bars corresponding 
to the standard deviation (SD).  
 
4.3.4 Mechanical testing 
Following microCT scanning, 14 and 42 dpf limbs from the constitutive deletion 
model were tested in torsion to failure. For torsional testing, we used fixtures and a custom 
potting apparatus that allowed us to reproducibly align and pot the fractured limbs in 
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polymethylmethacrylate bone cement. After the fractured limbs were potted, they were 
loaded in torsion at a rate of 1°/s until failure using a custom-designed micro-torsional 
testing system. Recorded torque-rotation data were normalized by gauge length on a per-
sample basis289.  Torsional rigidity, maximum torque to failure, work to maximum torque 
and work to failure were quantified from the normalized torque-rotation data using a 
custom MATLAB script170. Five to eight mice were analyzed per group per timepoint. 
Investigators were blinded to animal genotype during data quantification. 
4.3.5 Histology, immunohistochemistry, and immunofluorescence  
Limbs from 7 and 14 dpf were fixed with 10% neutral buffered formalin for 48 
hours and decalcified for 4 weeks with 0.25M EDTA (pH 7.4) at 4°C. Paraffin sections (5 
µm thickness) were processed for either immunohistochemistry or histology. Primary 
antibodies were compared to normal rabbit sera IgG control sections. For immunostaining, 
anti-OSX (1:500, ab22552; abcam), anti-YAP (1:500, 14074; Cell Signaling), and anti-
TAZ (1:250 NB110-58359; Novus Biologicals) primary antibodies were applied overnight. 
Next, sections were incubated with corresponding biotinylated secondary antibody, avidin-
conjugated peroxidase, and diaminobenzidine substrate chromogen system (329ANK-60; 
Innovex Biosciences), which allowed for immunohistochemical detection of positively 
stained cells. Hematoxylin and eosin stains (H&E), Safranin-O, and Picrosirius Red stains 
were used to stain for bone, cartilage, and collagen. 
 Limbs from 4 dpf and intact femora were fixed with 10% neutral buffered formalin 
for 48 hours at 4°C, transferred to 30% sucrose in PBS overnight at 4°C, and then 
embedded in O.C.T. compound (Tissue-Tek). Thin sections (7 µm thickness) were made 
from undecalcified fractured femurs using cryofilm IIC tape (Section Lab Co. Ltd.) as 
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previously described258 and processed for immunofluorescence and/or aqueous H&E 
staining. Taped sections were glued to microscope slides using a UV-adhesive glue, 
rehydrated and then decalcified with 0.25M EDTA (pH 7.4) for 3 minutes prior to staining. 
5-ethynyl-2’-deoxyuridine (EdU)) staining were performed using the Click-iT Plus EdU 
Assay kit (C10339; Invitrogen) according to the manufacturer’s instructions. 
4.3.6 Imaging and histomorphometric analysis 
Histological and immunohistochemical sections were imaged on either on an Axio 
Observer Z1 (Zeiss) at the 10x and 25x objectives or using an Axioscan microscope (Zeiss) 
at the 10x and 20x objective.  Quantification of paraffin immunohistochemistry and 
histology was performed using ImageJ (NIH). To determine the number of positively 
immunostained cells, 4 regions of interest per sample per antibody were manually scored 
as either positive or negative and reported as percentage positively stained osteoblasts, 
osteocytes, and chondrocytes per total number of each cell type using ImageJ (NIH). Bone 
and cartilage area per callus area were calculated using ImageJ (NIH) on histological 
sections with 3-4 mice per group per timepoint.  
Samples from 7 and 14 dpf were stained with Picrosirius Red and imaged under 
polarized light using an Axioscan microscope (Zeiss) at the 20x objective and using second 
harmonic generated (SHG) microscopy. SHG images were taken on a TCS SP8 
Multiphoton Confocal microscope (Leica) at a fundamental wavelength of 880 nm with 
the 10x and 40x objective on sections oriented in the same direction for all groups. All 
SHG images were quantified using ImageJ (NIH) and reported as mean pixel intensity 
within the cortical and callus region relative to WT bone. Mean pixel intensities across four 
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separate regions of interests were averaged as technical replicates for a given sample within 
either the callus or cortex area with 3-4 mice per group.  
Immunofluorescence sections of 4 dpf limbs were imaged on an Axio Observer Z1 
(Zeiss) at the 5x, 10x, and 25x objectives. To determine the number of positively EdU-
stained periosteal cells, 4 regions of interest were outlined per mouse 1-3 mm from the 
fracture on the periosteal cortical bone290. Images were manually scored as either positive 
or negative, averaged together from each of the 4 regions and reported as percent positively 
stained per total number of periosteal cells in ImageJ (NIH). Periosteal area and average 
thickness from these same 4 regions of interested were outlined in ImageJ (NIH) using 
both immunofluorescence and aqueous H&E sections and averaged together with 6-9 mice 
per group. 
 
4.3.7 Periosteal cell isolation and osteogenic differentiation 
Mouse periosteal cells were isolated from either WT or Osterix-conditional 
YAP/TAZ deficient (YAPcKOi;TAZcKOi) femurs on 4 dpf and cultured at 37°C and 5% O2, 
as described previously291. Briefly, mice were anesthetized by carbon dioxide inhalation 
and euthanized via cervical dislocation. Fractured limbs were carefully dissected of all non-
osseous tissue, the epiphyses were then removed, and marrow cavities were flushed. The 
periosteum was scraped and enzymatically digested for 1 hour at 37°C on an orbital shaker 
(0.5 mg/ml collagenase P, 2mg/ml hyaluronidase in PBS). Following washing, 2 x 104 
cells/cm2 were seeded in growth medium (a-MEM, 10% FBS, 1% penicillin-streptomycin, 
and 1ug/ml doxycycline) and cultured in 5% oxygen for the first 4 days. Half of the media 
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was changed on day 4 and cultures were then incubated in 21% O2. Primary cells reached 
confluence by day 7 and were passaged once into osteogenic differentiation experiments.  
Passage 1 periosteal cells were then seeded at 21% O2 into 24-well plates (15 x 103 
cells/cm2) and cultured in growth medium. After reaching confluence, primary periosteal 
cell cultures were induced towards osteogenic differentiation (50 µg/mL ascorbic acid and 
4mM b-glycerophosphate) for 21 days. Osteogenic media was changed every other day 
prior to RNA isolation and alizarin red staining for mineral deposition at 21 days.  
 
4.3.8 RNA isolation and qPCR 
Limbs from 7 and 14 dpf were carefully dissected and removed of all non-osseous 
tissue. The intramedullary pin was removed, and marrow flushed before being snap-frozen 
in liquid nitrogen-cooled isopentane for 1 minute prior to microCT imaging and storage at 
-80°C until processing. Tissues were then homogenized via mortar and pestle and RNA 
from the sample was collected using Trizol Reagent (15596026; Life Technologies) 
followed by centrifugation in chloroform. RNA from fractured limb tissue and cell culture 
experiments were purified using the RNA Easy Kit (74106; Qiagen) and quantified by 
spectrophotometry using a NanoDrop 2000 (Thermo-Fisher Scientific). Reverse 
transcriptase polymerase chain reaction (RT-PCR) was performed on 0.1-0.5 μg/μl 
concentration of RNA using the High-Capacity cDNA Reverse Transcription Kit 
(4368814; Thermo-Fisher Scientific). Quantitative polymerase chain reaction (qPCR) 
assessed RNA amount using a StepOnePlusTM Real-Time PCR System (Thermo-Fisher 
Scientific) relative to the internal control of 18S ribosomal RNA (18S rRNA). Data are 
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presented using the DDCt method. Six mice per group were used. Specific mouse primer 
sequences are listed (Table 4-2).   
Table 4-2: qPCR primers (Aim 3) 
Mouse primers used for qPCR 
Gene Primer Sequence (5’ to 3’) 
18S rRNA F R 
  CGAACGTCTGCCCTATCAAC 
  GGCCTCGAAAGAGTCCTGTA 
Yap F R 
  GATGTCTCAGGAATTGAGAAC 
  CTGTATCCATTTCATCCACAC 
Taz F R 
  GGATACAGGTGAAAATTCCG 
  GATTACAGCCAGGTTAGAAAG 
Sox9 F R 
  AGTACCCGCATCTGCACAAC 
  ACGAAGGGTCTCTTCTCGCT 
Acan F R 
  CCTGCTACTTCATCGACCCC 
  AGATGCTGTTGACTCGAACCT 
Col2a1 F R 
  GACTGAAGGGACACCGAG 
  CCAGGGATTCCATTAGAG 
Col10 F R 
  ATGCTGCCTCAAATACCCT 
  TGCCTTGTTCTCCTCTTACT 
Vegfa F R 
  TAGAGTACATCTTCAAGCCG 
  TCTTTCTTTGGTCTGCATTC 
Runx2 F R 
  AGCCTCTTCAGCGCAGTGAC 
  CTGGTGCTCGGATCCCAA 
Col1a1 F R 
  GCTCCTCTTAGGGGCCACT 
  CCACGTCTCACCATTGGGG 
Col1a2 F R 
  GCTCCTCTTAGGGGCCACT 
  CCACGTCTCACCATTGGGG 
SerpinH1 F R 
  AGCCGAGGTGAAGAAACCC 
  CATCGCCTGATATAGGCTGAAG 
Osx F R 
 CTGGGGAAAGGAGGCACAAAGAAG 
  GGGTTAAGGGAGCAAAGTCAGAT 
Alp F R 
  GGACAGGACACACACACACA 
  CAAACAGGAGAGCCACTTCA 
Bsp F R 
  ACAATCCGTGCCACTCACT 
  TTTCATCGAGAAAGCACAGG 
Cyr61 F R 
  CTGCGCTAAACAACTCAACGA 
  GCAGATCCCTTTCAGAGCGG 
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Ctgf F R 
  GGGCCTCTTCTGCGATTTC 
  ATCCAGGCAAGTGCATTGGTA 
 
4.3.9 Statistics and regression 
Sample sizes were selected a priori by power analyses based on effect sizes and 
population standard deviations taken from published data on YAPfl/fl;TAZfl/fl mice in other 
tissues188, assuming a power of 80% and α=0.05. All statistics and power analyses were 
performed in GraphPad Prism. Comparisons between two groups were made using the 
independent t-test while comparisons between 3 or more groups were made using a one-
way ANOVA with post-hoc Tukey’s multiple comparisons test, if the data were normally 
distributed according to D’Agostino-Pearson omnibus normality test and homoscedastic 
according to Bartlett’s test. When parametric test assumptions were not met, data were log-
transformed, and residuals were evaluated. If necessary, either the non-parametric Kruskal-
Wallis test with post-hoc Dunn’s multiple comparisons or the non-parametric Mann-
Whitney test were used. A p-value < 0.05 (adjusted for multiple comparisons) was 
considered significant. On the graphs, repeated significance indicator letters (e.g., “a” vs 
“a”) signify P > 0.05. while groups with distinct indicators (e.g., “a” vs “b”) signify P < 
0.05. Summary data are presented as bars, with independent samples indicated in scatter 
plots and error bars representing standard error of the mean (SEM). Distributions of pMOI 
were binned and presented as individual samples with lines corresponding to the mean and 




4.4.1 Constitutive Osterix-conditional YAP and/or TAZ deletion impaired 
endochondral fracture repair 
 To determine the roles of YAP and TAZ in endochondral fracture repair, we used 
Cre-lox to delete YAP and/or TAZ from Osterix-Cre expressing cells from embryonic 
development onward63. We selected a breeding strategy that generated YAP/TAZ allele 
dosage-dependent Osterix-conditional knockouts and compared four genotypes (Table 4-
1)170. Homozygous YAP/TAZ knockout mice were not evaluated due to perinatal lethality 
170. We then evaluated adult bone fracture repair at 14- and 42-days post fracture (dpf).
 All genotypes exhibited callus formation by 14 dpf (Figure 4-1A). However, 
constitutive YAP and/or TAZ deletion reduced total callus volume and mineralized callus 
percentage (i.e. BV/TV) at 14 dpf in an allele dosage-dependent manner (Figure 4-1B,C). 
Similarly, constitutive YAP and/or TAZ deletion also reduced mineralized tissue volume 
and volumetric mineral density at 14 dpf (Figure 4-2A,B). We then tested 14 dpf limbs in 
torsion to failure and observed a similar reduction in maximum torque to failure and 
torsional rigidity (Figure 4-1D,E). However, work to max torque and work to failure did 




Figure 4-1: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired 
endochondral fracture repair. 
A) MicroCT reconstructions at 14 days post-fracture (dpf). Quantification of 14 dpf callus architecture: (B) 
total callus volume and (C) mineralized callus percentage. Quantification of 14 dpf callus mechanical testing 
in torsion to failure: (D) maximum torque and (E) torsional rigidity. F) MicroCT reconstructions at 42 dpf. 
Quantification of 42 dpf callus architecture: (G) total callus volume and (H) mineralized callus percentage. 
Quantification of 42 dpf callus mechanical testing in torsion to failure: (I) maximum torque and (J) torsional 
rigidity. Data are presented as individual samples in scatterplots and bars corresponding to the mean and 




At 42 dpf, all genotypes similarly underwent hard callus remodeling (Figure 4-1F). 
However, constitutive YAP and/or TAZ deletion again reduced mineralized callus 
percentage, maximum torque to failure, and torsional rigidity, but at this timepoint 
differences in total callus volume did not reach statistical significance (Figure 4-1G-J). At 
42 dpf, constitutive YAP and/or TAZ deletion reduced volumetric mineral density, but did 
not significantly reduce mineralized tissue volume, work to maximum torque, or work to 
failure (Figure 4-2E-H). 
 
Figure 4-2: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired 
endochondral fracture repair, but not callus toughness. 
14 and 42 dpf calluses were analyzed using microCT and torsion testing to failure. Quantification of 14 dpf 
callus architecture: (A) total mineralized tissue volume and (B) volumetric mineral density. Quantification 
of 14 dpf callus mechanical testing in torsion to failure: (C) work to maximum torque and (D) work to failure. 
Quantification of 42 dpf callus architecture: (E) total mineralized tissue volume and (F) volumetric mineral 
density. Quantification of 42 dpf callus mechanical testing in torsion to failure: (G) work to maximum torque 
and (H) work to failure. Data are presented as individual samples in scatterplots and bars corresponding to 
the mean and standard error of the mean (SEM). Sample sizes, N = 5-8.  
4.4.2 Constitutive Osterix-conditional YAP and/or TAZ deletion reduced callus 
formation 
To determine the distribution of the callus, including cartilage and bone, at 14 dpf, 
we quantified total callus polar moment of inertia (Figure 4-3A). Independent of bone 
formation, constitutive YAP/TAZ deletion reduced callus formation, particularly in the 
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YAPcHET;TAZcKO mice, which are homozygous for TAZ deletion and heterozygous for 
YAP deletion (Fig. 4-3B). At 42 dpf, similar results were observed where the polar moment 
of inertia distribution of mineralized tissue within the callus were reduced in the 
YAPcHET;TAZcKO mice (Figure 4-4A,B). At 42 dpf, we performed an analysis of covariance 
(ANCOVA) using linear regression to decouple the contributions of callus mineralization 
and geometric distribution from the mechanical behavior170,216, since constitutive 
YAP/TAZ deletion reduced both callus mineralization and geometry. We found that 
individual regression lines for each genotype best predicted maximum torque to failure and 
torsional rigidity, suggesting that differences in connectivity or composition also contribute 
to mechanical behavior (Figure 4-4C,D).  
 
Figure 4-3: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells reduced overall 
callus size. 
A) MicroCT reconstructions at 14 dpf showing longitudinal cut-planes within the callus. Dotted lines indicate 
the callus boundary. B) Polar moment of inertia distributions of the entire callus for each of the YAP/TAZ 
allele dose-dependent knockout genotypes. Data were binned into 25 equal distance bins from the center of 
the callus and presented as dots representing the mean and error bars corresponding to the standard deviation 





Figure 4-4:Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells reduced hard 
callus size and mechanical properties. 
A) 42 dpf post fracture microCT reconstruction of longitudinal cut planes within the callus. Mineralized 
tissue within the callus were included in polar moment of inertia analysis B) Polar moment of inertia 
distributions of the mineralized limb for each of the YAP/TAZ allele dose dependent knockout genotypes. 
Data were binned into 25 equal distance bins from the center of the callus and presented as dots representing 
the mean and bars corresponding to the standard deviation (SD). ANCOVA analysis accounting for fractured 
limb geometry revealed significant differences between genotypes in (C) failure properties and (D) elastic 
properties. Sample sizes, N = 5-8. Scale bars indicate 1 mm for microCT reconstructions. 
4.4.3 Constitutive Osterix-conditional YAP and/or TAZ deletion impaired periosteal 
development 
To determine whether developmental defects in the periosteum contributed to the 
reduced callus formation, we evaluated the periosteal thickness and cellularity of intact 
femurs from constitutive knockout mice. Constitutive YAP and/or TAZ deletion 
significantly reduced periosteal thickness (Figure 4-5A-C). Similar to younger mice170, 
constitutive YAP and/or TAZ deletion reduced periosteal cell number per bone surface in 




Figure 4-5: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired 
periosteal development in intact bone. 
A) Representative micrographs of 18-21 weeks-old distal cortical bone stained by aqueous H+E. 
Quantification of (B) periosteal thickness, (C) periosteal area and (D) periosteal cell number per bone surface 
(N.Pc /PS). Data are presented as bars and individual samples with bars corresponding to the mean and 
standard error of the mean (SEM). Sample sizes N = 6-7. Scale bar indicates 50 µm for all images. 
 
4.4.4 Inducible Osterix-conditional YAP/TAZ deletion impaired callus 
mineralization, but not formation 
The impairment of endochondral bone fracture healing observed in the constitutive 
YAP/TAZ deletion knockout model could be a consequence of defective periosteal stem 
cell supply, expansion, and/or differentiation. To address this question, we generated adult-
inducible, dual homozygous YAP/TAZ knockout mice (YAPcKOi;TAZcKOi) in which the 
periosteal progenitor population was allowed to develop normally prior to fracture. Here, 
we induced homozygous Osterix-conditional YAP/TAZ deletion two weeks prior to 
fracture.  During those two weeks prior to fracture, Osterix-conditional YAP/TAZ deletion 
did not significantly affect periosteal cell thickness, area, or cell number (Figure 4-6A-D). 
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Figure 4-6: Periosteal thickness and cellularity developed normally in adult onset-induced, Osterix-
conditional, homozygous YAP/TAZ knockout mice. 
A) Representative micrographs of 16-18 weeks-old cortical bone stained by aqueous H&E. Dotted lines 
indicate the periosteum. Quantification of (B) periosteal thickness, (C) periosteal area and (D) periosteal cell 
number per bone surface (N.Pc/PS). Data are presented as individual samples in scatterplots and bars 
corresponding to the mean and standard error of the mean (SEM). Sample sizes N = 8-9. Scale bars indicate 
30 µm for all images. 
 
To analyze the recombination efficiency of inducible Osterix-Cre-mediated 
YAP/TAZ deletion following fracture, we evaluated YAP/TAZ expression in 
chondrocytes, osteoblasts, and osteocytes within the callus at 14 dpf by 
immunohistochemistry and qPCR (Figure 4-7A-C). YAP cellular expression was 
significantly reduced in chondrocytes (23% reduction), osteoblasts (23% reduction), and 
osteocytes (26% reduction) (Figure 4-7D-F). YAP mRNA expression was reduced by 59% 
in YAPcKOi;TAZcKOi  callus lysate preparations (Figure 4-7G). TAZ cellular expression was 
moderately reduced in chondrocytes (11% reduction; p = 0.1) and significantly reduced in 
osteoblasts (18% reduction), and osteocytes (12% reduction) (Figure 4-7H-J). TAZ mRNA 




Figure 4-7:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells moderately reduced 
callus YAP/TAZ expression on 14 dpf. 
A-C) Representative micrographs of chondrocyte, osteoblast, and osteocyte immunostaining for YAP, TAZ, 
and IgG control sections at 14 dpf. Quantification of YAP and TAZ protein expression in (D) chondrocytes, 
(E) osteoblasts, and (F) osteocytes from callus sections at D14. G) Yap and Taz mRNA expression, relative 
to 18S rRNA, from callus bone preparations at 14 dpf. Data are presented as individual samples in scatterplots 
and bars corresponding to the mean and standard error of the mean (SEM). N = 6 per group for qPCR and N 
= 3 per group for IHC. Scale bars equal 50 µm for all images. 
 
All genotypes underwent initial callus formation by 14 dpf (Figure 4-8A). Inducible 
Osterix-Cre-mediated YAP/TAZ deletion reduced mineralized callus percentage and 
volumetric bone mineral density, but differences in total callus volume between groups 
were not observed (Figure 4-8B-D). Further, inducible Osterix-Cre-mediated YAP/TAZ 
deletion significantly increased variability in total callus volume size and the polar moment 
of inertia distribution within the callus in comparison to YAPWT;TAZWT and Osx:Cre mice 
(Figure 4-8B; Figure 4-9A,B). 
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Figure 4-8:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired callus 
mineralization, but not formation. 
A) MicroCT reconstructions at 14 dpf. Quantification of 14 dpf callus architecture: (B) total callus volume, 
(C) mineralized callus percentage, and (D) volumetric mineral density. Data are presented as individual 
samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample 
sizes, N = 6-8. Scale bars indicate 1 mm for microCT reconstructions. 
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Figure 4-9: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells increased variability 
in overall callus size. 
A) 14 dpf microCT reconstruction of longitudinal cut planes within the callus. Dotted lines represent how all 
tissue within the callus were included in polar moment of inertia analysis B) Polar moment of inertia 
distributions of the entire callus for Osx:Cre, YAPWT;TAZWT, and YAPcKOi;TAZcKOi genotypes. Data were 
binned into 25 equal distance bins from the center of the callus and presented as dots representing the mean 
and bars corresponding to the standard deviation (SD). Sample sizes, N = 5-8. Scale bars indicate 1 mm for 
microCT reconstructions. 
4.4.5 Inducible Osterix-conditional YAP/TAZ deletion did not significantly alter 
cartilaginous callus formation, but reduced bone formation 
 As the formation of a cartilaginous callus template is a critical step during 
endochondral fracture healing39,40,43, we histologically evaluated cartilage formation at 14 
dpf (Figure 4-10A,B). Consistent with microCT, inducible Osterix-Cre-mediated 
YAP/TAZ deletion did not affect total callus area at 14 dpf, but increased variability was 
observed YAPcKOi;TAZcKOi mice (Figure 4-10C). Differences in total cartilage area and 
percent cartilage area were not detected between groups (Figure 4-10D,E). However, 
inducible Osterix-Cre-mediated YAP/TAZ deletion resulted in a non-significant trend 
towards increase percent cartilage area at 14 dpf (p = 0.12; Figure 4-10E). At 14 dpf, 
inducible Osterix-Cre-mediated YAP/TAZ deletion did not significantly alter mRNA 
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expression of markers for chondrogenesis, including SRY-Box Transcription Factor 9 
(Sox9) and Aggrecan (Acan), but resulted in a non-significant trend towards reduced 
collagen, type II, alpha 1 (Col2a1) mRNA expression (p = 0.06; Figure 4-10F).  
 
Figure 4-10: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not significantly 
alter cartilaginous callus formation at 14 dpf. 
A) Micrographs of Safranin-O stained calluses at 14 dpf. Black dotted boxes outline three zoomed-in regions 
of interest found for each genotype in (B). Quantification of cartilaginous callus histomorphometry at 14 dpf 
of (C) total callus area, (D) cartilage area, and (E) percent cartilage area of total callus. F) Sox9, Acan, and 
Col2a1 mRNA expression, relative to 18S rRNA, from callus lysate preparations at 14 dpf. Data are presented 
as individual samples in scatterplots and bars corresponding to the mean and standard error of the mean 
(SEM). N = 6 per group for qPCR and N = 3-4 per group for histomorphometry. Scale bars equal 50 µm for 
all zoomed images and 500 µm for callus images. 
 
Following formation of the cartilaginous callus, extensive bone formation occurs 
within the callus through both intramembranous and endochondral ossification40. Thus, we 
next histologically evaluated endochondral ossification and bone formation at 14 dpf 
(Figure 4-11A,B).  At 14 dpf, differences in Osterix (OSX)-positive hypertrophic 
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chondrocytes were not detected between groups (Figure 4-11C). At 14 dpf, the number of 
OSX-positive osteoblasts per bone surface, bone area, and percent bone area were reduced 
following inducible Osterix-Cre-mediated YAP/TAZ deletion (Figure 4-11D-F). Further, 
inducible Osterix-Cre-mediated YAP/TAZ deletion reduced mRNA expression of markers 
for hypertrophic chondrocytes, including collagen, type X, alpha 1 (Col10) and vascular 
endothelial growth factor (Vegfa) (Figure 4-11J). Similarly, inducible Osterix-Cre-
mediated YAP/TAZ deletion reduced mRNA expression of markers of collagen, including 
collagen type I, alpha 1 (Col1a1) and collagen type I, alpha II (Col1a2), but not serpin 
family H member 1 (SerpinH1) (Figure 4-11K). Lastly, inducible Osterix-Cre-mediated 
YAP/TAZ deletion reduced mRNA expression markers of osteogenesis, including 
osteoblast-specific transcription factor Osterix (Osx) and alkaline phosphatase (Alp), while 
reductions in runt-related transcription factor 2 (Runx2) or bone sialoprotein (Bsp) did not 
reach statistical significance (Figure 4-11L).  
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Figure 4-11:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells reduced callus bone 
formation. 
A) Micrographs of Picrosirius Red-stained calluses at 14 dpf. White boxes outline three regions of interest 
(B) in which second harmonic generated imaging (SHG) and anti-Osterix (aOSX) immunostaining are 
highlighted. Quantification of callus histomorphometry at 14 dpf of (C) the number Osterix-positive 
hypertrophic chondrocytes per cartilage area (OSX+ N.HC/CA), (D) Osterix-positive osteoblasts per bone 
surface (OSX+ N.Ob/BS), (E) bone area, and  (F) percent bone area. Quantification of relative SHG intensity 
per bone area at 14 dpf of (G) the intact cortical bone, (H) the newly formed callus bone, and (I) normalized 
callus-to-intact SHG intensity. Messenger RNA was extracted from callus lysate preparations at 14 dpf and 
target gene expression was normalized to 18S rRNA and quantified as fold-change relative to wild type (J-
L). J) Col10 and Vegfa mRNA expression. K) Col1a1, Col1a2, and SerpinH1 mRNA expression. L) Runx2, 
Osx, Bsp, and Alp mRNA expression. Data are presented as individual samples in scatterplots and bars 
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corresponding to the mean and standard error of the mean (SEM). N = 6 per group for qPCR and N = 3-4 per 
group for histomorphometry. Scale bars indicate 50 µm for all high-power images and 500 µm for callus 
images. 
 
4.4.6 Inducible Osterix-conditional YAP/TAZ deletion reduced periosteal osteoblast 
precursor expansion in vivo and osteogenic differentiation in vitro  
Given the defect in osteogenesis resulting from inducible Osterix-Cre-mediated 
YAP/TAZ deletion, we evaluated activated periosteal progenitors at 4 dpf in four regions 
distal and proximal to the fracture line, in which periosteal osteoblast precursors are 
primarily fated to form bone through direction intramembranous ossification292 (Figure 4-
12A). At 4 dpf, inducible YAP/TAZ deletion reduced periosteal osteoprogenitor cell 
expansion in terms of total area and average thickness (Figure 4-12B-D). However, 
inducible YAP/TAZ deletion did not reduce the number of periosteal osteoprogenitor cells 
per expanded periosteal area, but significantly reduced the percentage of proliferating, 
EdU-positive periosteal osteoprogenitor cells (Figure 4-12E,F).  
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Figure 4-12: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired periosteal 
osteoblast precursor cell expansion and osteogenic differentiation. 
A) Representation of the regions of interest in the callus “shoulder,” in which we evaluated periosteal 
osteoblast precursor expansion and proliferation. B)  Representative micrographs of EdU+ periosteal cells 
(red) at 4 dpf, with all nuclei counterstained by DAPI (blue). White dotted lines indicate periosteal cell 
expansion zone; “m” indicates muscle, “c” indicates cortical bone. Quantification of the expanded (C) 
periosteal area, (D) average thickness, (E) number of periosteal cells per bone area (N.Pc/BA), and (F) 
percentage of EdU-positive periosteal cells. G) Activated periosteal cells isolated from 4 dpf limbs were 
cultured in osteogenic media for 21 days. H) Representative Alizarin Red staining of mineral deposition 
following osteogenic induction. I) Yap, Taz, Ctgf, and Cyr61 and J) Runx2, Osx, Alp, and Bsp mRNA 
expression, relative to 18S rRNA, from periosteal progenitor cell cultures following 21 days of osteogenic 
induction. Data are presented as individual samples in scatterplots and bars corresponding to the mean and 
standard error of the mean (SEM). N = 6-9 per group. Scale bars indicate 100 µm for all high-power EdU 
images and 1 mm for high-power Alizarin Red images. 
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Though unexplored in periosteal osteoprogenitor cells, YAP and TAZ are known 
to mediate osteogenic differentiation in MSCs113,147,148,150,160, which originate from a 
common mesenchymal embryonic lineage48. To elucidate if inducible YAP/TAZ deletion 
regulated periosteal osteoprogenitor differentiation, we isolated activated periosteal 
progenitor cells at 4 dpf (Figure 4-12G)290,291. Following culture for 21 days in osteogenic 
media, inducible, Osterix-conditional YAP/TAZ deletion reduced mineral deposition 
stained with Alizarin Red (Figure 4-12G-H). As expected, Osterix-conditional inducible 
YAP/TAZ deletion in vitro reduced mRNA expression of Yap and Taz as well as their 
canonical downstream target, Ctgf and Cyr61 in periosteal progenitor cells from 
YAPcKOi;TAZcKOi mice (Figure 4-12I). Lastly, Osterix-conditional inducible YAP/TAZ 
deletion in vitro reduced mRNA expression of osteogenic differentiation genes including, 
Runx2, Col1a1, Alp, and Bsp while reductions in Osx (p = 0.05) did not reach statistical 
significance (Figure 4-12H).  
Given the defective periosteal osteoblast precursor expansion and osteogenic 
differentiation, we evaluated bone formation in the callus at 7 dpf. Although all genotypes 
underwent periosteal expansion and mineralization (Figure 4-13A), inducible Osterix-Cre-
mediated YAP/TAZ deletion reduced mineralized callus percentage and volumetric 
mineral density at 7 dpf (Figure 4-13B,C). Within regions of the callus undergoing 
intramembranous bone formation (Figure 4-13D), inducible Osterix-Cre-mediated 
YAP/TAZ deletion reduced OSX-positive osteoblasts per bone surface concomitant with 
reduced bone percent area while resulting in a non-significant trend toward reduced bone 
area (Figure 4-13E-H), consistent with our observations at 4 dpf in vivo and in vitro.  At 7 
dpf, significant changes in cartilaginous callus formation were not detected (Figure 4-14A-
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F). Similarly, inducible Osterix-Cre-mediated YAP/TAZ deletion did not significantly 
alter endochondral ossification or matrix collagen content and organization within the 
callus (Figure 4-15A-I).  
 
Figure 4-13: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired periosteal 
osteoblast precursor bone formation. 
A) MicroCT reconstructions at 7 days post-fracture (dpf). Quantification of 7 dpf callus architecture: (B) 
mineralized callus percentage and (C) volumetric bone mineral density. D) Representation of the regions of 
interest in the callus “shoulder,” in which we evaluated (E) anti-Osterix (aOSX) immunostaining at 7 dpf. 
Quantification of callus histomorphometry at 7 dpf of (F) Osterix-positive osteoblasts per bone surface 
(OSX+ N.Ob/BS). (G) bone area, and (H) percent bone area. Data are presented as individual samples in 
scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 6-




Figure 4-14: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not 
significantly alter cartilaginous callus formation at 7 dpf.  
A) Micrographs of Safranin-O stained calluses at 7 dpf. Black dotted boxes outline three zoomed-in regions 
of interest found for each genotype in (B). Quantification of cartilaginous callus histomorphometry at 7 dpf 
of (C) total callus area, (D) cartilage area, and (E) percent cartilage area of total callus. F) Sox9, Acan, and 
Col2a1 mRNA expression, relative to 18S rRNA, from callus lysate preparations at 7 dpf. Data are presented 
with individual samples in scatterplots and bars corresponding to the mean and standard error of the mean 
(SEM). N = 6 per group for qPCR and N = 3 per group for histomorphometry. Scale bars equal 50 µm for all 




Figure 4-15: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not significantly 
alter endochondral ossification or collagen matrix composition at 7 dpf. 
A) Micrographs of Picrosirius Red stained calluses at 7 dpf. White boxes outline three zoomed-in regions of 
interest found for each genotype for both second harmonic generated imaging (SHG) and anti-Osterix 
(aOSX) immunostaining in (B). Quantification of callus histomorphometry at 7 dpf of (C) the number 
Osterix-positive hypertrophic chondrocytes per cartilage area (OSX+ N.HC/CA). Quantification of relative 
SHG intensity per bone area at 7 dpf of (D) the intact cortical bone, (E) the newly formed callus bone, and 
(F) normalized callus-to-intact SHG intensity. G) Col10 and Vegfa mRNA expression, relative to 18S rRNA, 
from callus lysate preparations at 7 dpf.  H) Col1a1, Col1a2, and SerpinH1 mRNA expression, relative to 
18S rRNA, from callus lysate preparations at 7 dpf. I) Runx2, Osx, Bsp, and Alp mRNA expression, relative 
to 18S rRNA, from callus lysate preparations at 7 dpf. Data are presented with individual samples in 
scatterplots and bars corresponding to the mean and standard error of the mean (SEM). N = 6 per group for 
qPCR and N = 3 per group for histomorphometry. Scale bars equal 50 µm for all zoomed images and 500 




This study identifies new roles for the transcriptional regulators, YAP and TAZ, in 
bone fracture healing, adding to our understanding of periosteal osteoblast precursor cell 
regulation. Here, we show that YAP and TAZ promote expansion and osteoblastic 
differentiation of periosteal osteoblast precursors to promote bone fracture healing. 
Constitutive YAP and/or TAZ deletion from Osterix-expressing cells impaired bone 
fracture healing by reducing both callus formation and subsequent mineralization, due in 
part to developmental defects in the periosteal progenitor supply. When we allowed for the 
development of a normal periosteal progenitor population prior to fracture, adult onset-
induced YAP/TAZ deletion did not impair cartilaginous callus formation, but delayed 
mineralization due to impaired osteoblast precursor cells and their osteogenic 
differentiation. Together, these data demonstrate that the transcriptional co-activators, 
YAP and TAZ, promote the expansion and differentiation of periosteal osteoblast 
precursors to accelerate bone fracture healing. 
 Fracture healing recapitulates many aspects of embryonic skeletal development, but 
features a unique post-natal environment, resulting in contextual differences39,293. We 
previously found that Osterix-conditional YAP/TAZ deletion in the embryo caused a 
severe skeletal fragility phenotype170, while Xiong et al. induced Osterix-conditional 
YAP/TAZ deletion at post-natal day 21 (P21) and performed skeletal phenotyping at P84, 
observing increased osteoblast numbers but no measurable effect on whole bone 
microarchitecture171. Our present data resolve the differences between these two studies, 
establishing a critical role for YAP and TAZ in the development of the postnatal 
osteoprogenitor niche and demonstrating critical roles for YAP and TAZ in osteoblast 
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precursor proliferation and differentiation in a context of rapid bone formation, similar to 
that which occurs during bone development, in contrast to postnatal growth and 
homeostasis. The present data are further consistent with other reports. For example, 
deletion of the YAP/TAZ-regulated transcription factors, Snail and Slug, from Osterix-
expressing cells reduced both the proliferative potential of bone surface-associated 
osteoprogenitors and osteogenic differentiation capacity of adult skeletal stem cells294. 
Similarly, conditional deletion of YAP from Osteocalcin-expressing cells reduced 
osteoblast progenitor cell proliferation and differentiation, further supporting a role for 
YAP and TAZ in promoting osteoblast progenitor cell function 177.   
Endochondral bone fracture repair includes both the formation of a cartilage 
template as well as subsequent osteoblast-mediated mineralization39,295. Here, we found 
that while constitutive deletion impaired callus formation, adult onset-inducible YAP/TAZ 
deletion did not significantly affect cartilage formation during fracture healing. A previous 
study found that YAP overexpression in developing chondrocytes, using the Col2a1 
promoter, as well as deletion of MST1/2 using Dermo-Cre impaired endochondral fracture 
healing181, which appears to contradict the results described here. However, both models 
exhibit a developmental skeletal phenotype prior to fracture181, and in particular, observed 
that YAP/TAZ negatively regulate chondrogenesis. Thus, inducible targeting models are 
needed to decouple the developmental history from the process of fracture repair 296,297. 
Here, we selected the tetOFF Osterix-Cre inducible system instead of the tamoxifen-
inducible Osterix-CreERT2 298, as tamoxifen is rapidly cleared299, resulting in transient Cre-
activity300 in newly-generated Osterix-positive cells during fracture repair. Furthermore, 
targeting conditional gene inactivation in chondrocytes versus osteoblast-lineage cells can 
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result in drastically different phenotypes. For example, conditional deletion of Runx2 in 
chondrocytes using Col2a1-Cre phenocopied global Runx2 gene inactivation with 
perinatal lethality and a lack of mineralization while conditional deletion of Runx2 in 
osteoblasts using 2.3kb-Col1a1-Cre resulted in a moderate low bone mass phenotype80,82. 
Nonetheless,  hypertrophic chondrocytes are known to express Osterix during 
endochondral ossification73,301,302 and we observed moderate Osterix-Cre-mediated 
YAP/TAZ recombination in hypertrophic chondrocytes, suggesting that the relative 
contributions of YAP and TAZ during endochondral ossification are potentially stage-
dependent170,171,177,181.  Future studies will identify the temporal and cell-specific 
contributions of YAP and TAZ to bone development and repair. 
Recent and ongoing studies have revealed remarkable diversity in both the cellular 
identity and regulatory signals that contribute to periosteal function. Gli1303, Prx148, 
aSMA304, cathepsin K305, and Osterix306 mark both overlapping and distinct periosteal 
progenitor cell populations, while markers previously thought to define bone marrow 
stromal cells, including CD73, CD90, CD105, PDGFRa, Gremlin 1, Cxcl12, and 
Nestin48,307–310, also show high expression in the periosteal progenitors. Ongoing efforts 
continue to uncover new skeletal progenitor cell populations that contribute to fracture 
repair309,311–315, and the intersection of this cellular diversity with YAP/TAZ signaling 
remains unclear. Here, we observed significant reductions in mRNA expression of 
endochondral-, collagen-, and osteogenesis-related gene expression signatures at 14 dpf, 
which can be explained either by indirect shifts in the cell populations that express these 
targets or by direct YAP/TAZ-mediated transcriptional regulation of those genes. Further 
research will be required to not only systematically identify the transcriptional co-effectors 
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of YAP and TAZ in each cell type of interest, but also delineate the periosteal progenitor 
subpopulations affected by YAP/TAZ signaling.  
 YAP and TAZ may regulate osteoblast precursor cell proliferation and osteogenic 
differentiation through a variety of mechanisms. Conditional deletion of YAP in 
osteoblasts using Osteocalcin-Cre reduced osteoblast progenitor proliferation as well as 
osteogenic differentiation and proposed YAP stabilized β-catenin to promote β-catenin-
mediated osteogenesis177. However, evidence exists for YAP and TAZ playing both a 
positive and negative role in WNT/β-catenin signaling115,148, suggesting that further 
investigation into YAP/TAZ-dependent regulation of this pathway in periosteal 
progenitors is needed. A similar study demonstrated that Snail and Slug form stable 
protein-protein complexes with both YAP and TAZ in tandem to promote osteoprogenitor 
proliferation and differentiation294. In osteoprogenitors, the Snail/Slug-YAP/TAZ axis 
promotes proliferation by interacting with TEAD to enhance TEAD-dependent 
transcriptional activity and downstream expression of YAP/TAZ-TEAD target genes, such 
as Ctgf and Ankrd1294. In contrast, the Snail/Slug-YAP/TAZ axis promotes osteogenic 
differentiation via Snail/Slug-TAZ interactions with Runx2 to promote Runx2-dependent 
transcriptional activity and downstream expression of osteogenic target genes, such as 
Osterix and Alp294. Accordingly, evidence for TAZ interacting with Runx2 to promote 
downstream osteogenic gene expression in vitro is strong 113,157, but YAP has been 
observed to both inhibit and promote downstream osteogenic gene expression in 
vitro112,316–319. Thus, future studies to identify the molecular mechanisms by which YAP 
and TAZ control periosteal progenitor expansion and differentiation are needed.  
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 This study has several limitations. First, small sample sizes (N =3-9) produced 
under-powered analyses for some outcome measures. Thus, not all the studies performed 
had sufficient power to compare sex as a variable, though we did not observe sexually 
dimorphic behavior for any outcome measure, and our prior assessment of YAP/TAZ 
regulation of bone development did not show an effect of sex170. Second, we used an open 
fracture model, which may affect the kinetics and immunology of the fracture repair 
process320,321. We initially began these experiments using a closed fracture model, 
following the Einhorn method322, but this produced a high percentage of comminuted 
fractures in the YAP/TAZ cKO groups. We therefore moved to an open fracture model in 
which the bending moment could be applied with lower kinetic energy. This observation 
suggests that YAP/TAZ deletion during development impaired the bone matrix fracture 
toughness, consistent with our prior report on the bone fragility phenotype170. Third, adult 
onset-inducible Osterix-conditional knockout increased variability in response to fracture, 
adding an additional layer of complexity to the already challenging study of endochondral 
bone fracture healing biology43. The drug used to prevent Cre-mediated recombination, 
doxycycline, is a tetracycline derivative. Tetracycline exhibits high affinity for exposed 
mineral and is therefore commonly used as a label for dynamic bone histomorphometry323. 
Potential embedding of doxycycline into the bone matrix during skeletal development and 
subsequent release following fracture could impair robust Cre-recombination and reduce 
the observed effect size for adult onset-inducible YAP/TAZ knockout mice. We 
recommend additional study to quantify the kinetics of tetOFF inducible systems and 
efficiency of Cre-mediated inducible recombination in bone. Lastly, the Osterix-Cre 
transgene is known to cause defects in craniofacial development72 and in fracture callus 
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formation73, depending on genetic background. However, on this background, we did not 
observe differences between Osx-Cre and YAPWT;TAZWT wild type mice, demonstrating 
phenotypic specificity for YAP/TAZ deletion. 
 In conclusion, this study identifies the transcriptional co-activators, YAP and TAZ, 
as regulators of bone fracture healing that promote periosteal osteoblast precursor 
proliferation and osteogenic differentiation to accelerate bone healing. Further elucidation 
of the mechanisms by which YAP and TAZ control the periosteal progenitor cell response 












CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Chapter Conclusions 
5.1.1 Chapter 2 Conclusions 
Given the conflicting evidence for the contributions of YAP and TAZ to osteogenic 
differentiation in vitro, we used an in vivo combinatorial YAP and/or TAZ deletion 
approach in Chapter 2. Dual-deletion of YAP and TAZ using Osterix-Cre resulted in 
perinatal lethality, while mice harboring a single copy of either YAP or TAZ survived to 
adult hood. However, mice with a single copy of either YAP or TAZ both sustained 
neonatal spontaneous femoral fractures, highlighting the compensatory functions of YAP 
vs TAZ in promoting bone development and post-natal growth. To this end, Osterix-
conditional YAP and/or TAZ deletion in skeletally mature mice resulted in decreased bone 
formation and matrix composition combined with increased osteoclast activity, leading to 
reduced bone mechanical strength. Overall, Chapter 2 demonstrated that YAP and TAZ 
combinatorially promote skeletal development and post-natal growth via regulation of 
osteoblast activity, osteoclast-mediated remodeling and matrix composition.  
5.1.2 Chapter 3 Conclusions 
Given the severe skeletal fragility phenotype discussed in Chapter 2, we next asked 
how YAP and TAZ later in the skeletal lineage (i.e. in osteocytes) regulated bone function. 
In Chapter 3, we combinatorially deleted YAP and/or TAZ from osteocytes using 8kb-
DMP1-Cre. In contrast to combinatorial YAP/TAZ deletion in Osterix-expressing cells, 
only dual, homozygous YAP/TAZ deletion in osteocytes resulted in an obvious skeletal 
phenotype. Therefore, we subsequently examined how dual deletion of YAP and TAZ 
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affected osteocyte functionality. Dual YAP/TAZ deletion from osteocytes resulted in a 
moderate skeletal fragility phenotype, characterized by defective osteocyte-mediated 
remodeling. Chapter 3 identifies YAP and TAZ as regulators of bone quantity and quality 
that mediate osteocyte regulation of osteoblast/osteoclast activity and 
perilacunar/canalicular remodeling. More specifically, we observed that osteocyte YAP 
and TAZ are required for the expression of paracrine growth factors that regulate 
osteoblast/osteoclast coupled remodeling and the effector enzymes that enable 
perilacunar/canalicular remodeling. Overall, Chapter 3 demonstrated that osteocyte YAP 
and TAZ regulate bone function via control of osteocyte-mediated remodeling.  
5.1.3 Chapter 4 Conclusions 
Given their important contributions to bone growth and remodeling, we next 
characterized how skeletal cell YAP and TAZ contributed to endochondral bone fracture 
repair. In Chapter 4, we again conditionally deleted YAP and/or TAZ using Osterix-Cre, 
but here, we initiated deletion either constitutively (during embryonic development) or 
inducibly (following skeletal maturity). Constitutive, Osterix-conditional YAP/TAZ 
deletion impaired endochondral fracture repair with defective callus formation and 
mineralization, especially in the mice lacking both alleles of TAZ. We attributed this defect 
in callus formation to defective periosteal development as a result of YAP/TAZ deletion 
during embryonic development. Thus, we allowed the development of a normal periosteal 
progenitor population, then induced Osterix-Cre-mediated YAP/TAZ deletion prior to 
fracture. Following inducible YAP/TAZ deletion, cartilaginous callus formation remained 
intact, but we again observed defective callus mineralization and bone formation. Here, we 
attributed the defect in the healing callus to reduced expansion and osteogenic 
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differentiation of periosteal osteoblast precursor cells in response to fracture. Overall, 
Chapter 4 demonstrated that osteoprogenitor YAP and TAZ promote bone fracture healing 
via regulation of periosteal osteoblast precursor expansion and osteogenic differentiation. 
5.2 Final Conclusions 
This dissertation characterized the contributions of the paralogous transcription co-
effectors, YAP and TAZ, in skeletal lineage cells in the context of bone growth, 
remodeling, and fracture repair. During skeletal development and early post-natal growth 
and, YAP and TAZ in osteoprogenitor cells and their progeny combinatorially promoted 
bone formation with their dual-deletion resulting in a severe osteogenesis imperfecta-like 
phenotype. Later in the skeletal lineage, YAP/TAZ in osteocytes mediated not only 
perilacunar/canalicular remodeling, but also osteocyte-mediated coordination of 
osteoblast/osteoclast bone remodeling. Finally, skeletal lineage cell YAP and TAZ 
promoted bone fracture repair by regulating both the development and expansion as well 
as the osteogenic differentiation capacity of periosteal osteoblast precursors. Overall, this 
work helps define the multifaceted roles of skeletal cell lineage YAP and TAZ throughout 
bone function and provides a foundation for the development of new targeted therapeutic 
strategies for the treatment of skeletal fragility disease and enhancement of fracture repair.  
We started in Chapter 2 by elucidating the combinatorial in vivo contributions of 
skeletal cell YAP and TAZ in promoting bone development and post-natal growth, given 
the existing conflicting evidence for YAP/TAZ in promoting or inhibiting osteogenesis in 
vitro. Next, in Chapter 3, we evaluated the role for YAP and TAZ later in the osteogenic 
lineage, characterizing their regulation of osteocyte-mediated bone remodeling and 
building upon the skeletal fragility phenotype discovered in Chapter 2. In Chapter 4, we 
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investigated how skeletal cell YAP and TAZ contribute to bone fracture healing, observing 
that both YAP and TAZ combinatorially promote periosteum development and together 
YAP/TAZ regulate periosteal osteoblast precursor expansion, osteogenic differentiation, 
and bone formation.  
Taken together, we observed critical roles of skeletal cell YAP and TAZ where both 
promote bone function in the context of growth, remodeling and fracture repair. As this 
work is primarily observational in nature, future work determining the molecular 
mechanisms by which YAP and TAZ exert their control on these various bone functions is 
needed.   
5.3 Future Directions 
5.3.1 Bone mechanotransduction  
Evaluating the putative roles for YAP and TAZ in bone mechanotransduction is an 
obvious next area of investigation. YAP and TAZ are critical to cellular 
mechanotransduction, responding to a variety of physical cues including extracellular 
matrix rigidity, cell geometry, cell density and actin cytoskeletal tension129,150. Bone 
growth, remodeling, and fracture repair require input from various mechanical signals to 
coordinate an appropriate tissue-level adaptive response324,325. Given the initial 
characterization of skeletal lineage cell YAP and TAZ in bone function, understanding 
their cell-specific contributions to bone mechanotransduction is of potential interest.  
During skeletal development and early post-natal growth, Osterix-conditional 
YAP/TAZ knockout mice sustained spontaneous neonatal fractures. These long-bone 
fractures eventually heal, but the underlying involvement of YAP/TAZ activity in response 
to the mechanical environment during this healing time course is unknown. Experiments 
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performed on neonatal long-bone fractures define a mechanical jack-like mechanism 
driving spontaneous healing in neonatal mice, characterized by an important contribution 
of muscle forces during angulated long-bone fracture realignment284. Similar experiments 
using YAP/TAZ genetic manipulation models could elucidate the relative contributions of 
YAP/TAZ in response to the mechanical environment during neonatal spontaneous 
fracture reduction, identifying critical signaling pathways to modulate and improve adult 
bone fracture healing. 
Osteocytes are not only the most abundant skeletal cell but thought of as the 
primary mechanosensory cell in bone23. Many signaling pathways are important to 
osteocyte-mediated mechanotransduction and the subsequent adaptative response of bone, 
including WNT/β-catenin5,326, which is known to intersect with YAP/TAZ signaling114–116. 
In addition, mechanical stimuli affects osteocyte perilacunar/canalicular remodeling276, 
suggesting a multidimensional role for osteocyte YAP/TAZ in bone adaptation to 
mechanical loading. Standardized experimental conditions for in vivo tibial loading in mice 
are becoming established327, providing an excellent model to study the role of YAP and 
TAZ in bone mechanotransduction. Recent studies have demonstrated the ion channel 
Piezo1 is upstream of YAP/TAZ activation with this signaling axis being required in vitro 
and in vivo for osteoblast lineage cell mechanosensitivity328,329. Nonetheless, the putative 
roles of skeletal cell YAP and TAZ in bone mechanotransduction are unknown. 
Similar to growth and remodeling, the stages of bone fracture repair are highly 
sensitive to the mechanical environment330–333. Moderate levels of interfragmentary motion 
within the fracture result in healing primarily through endochondral ossification while rigid 
fixation heals primarily through intramembranous bone formation333. During fracture 
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healing, periosteal osteoblast precursor cell YAP and TAZ primarily promoted 
intramembranous bone formation to accelerate fracture callus ossification. Thus, 
manipulating both fracture fixation334 and YAP/TAZ activity could further elucidate the 
mechanotransductive contributions of YAP/TAZ signaling during bone healing. Similar 
experiments using the osteocyte-specific YAP/TAZ deletion model could clarify how the 
osteocyte lacunar/canalicular network senses and responds to not only initial fracture, but 
also later-stage bone remodeling.  
5.3.2 Biological factors and spatial localization 
The influence of the genetic background of mice is an important biological 
consideration given the widespread use of skeletal lineage transgenic mouse models  as 
genetic background is known to affect bone structural and mechanical properties335,336. In 
the context of skeletal fragility, genetic strain differences caused different expression of 
phenotypic severity in a mouse model of osteogenesis imperfecta337. Throughout the 
studies presented here, YAP/TAZ-floxed mice were acquired on a mixed C57BL/6J  
background and then subsequently crossed with Osterix-Cre and 8kb-DMP1-Cre mice 
generated on C57BL/6J backgrounds. However, the extent to which genetic background 
variability is contributing to the observed skeletal phenotypes remains unknown. 
Both age and sex are also critical biologic factors to consider when evaluating 
skeletal phenotypes. Throughout the studies presented here, mice at multiple 
developmental ages were evaluated. YAP/TAZ deletion from skeletal lineage cells 
recapitulate aspects of age-related bone phenotypes, including age-related bone loss, 
skeletal fragility, and impaired fracture healing. However, the exact contributions of 
YAP/TAZ during the longitudinal time course of skeletal function (i.e. neonatal growth, 
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skeletal maturity, aged-related decline) are only partially understood. Further, the studies 
presented here were performed in both male and female mice, given that the initial skeletal 
phenotyping did not demonstrate significant differences based on sex in either model. 
Nonetheless, sex hormones and their receptors are critical to bone metabolism338, 
suggesting a more detailed investigation of sex differences following YAP/TAZ 
conditional deletion is warranted.  
 During bone function, spatial localization within the bone is critical for 
coordinating local cellular function. For example, spatiotemporal cues are known to 
regulate both osteogenic-angiogenic coupling during repair339, osteoblast-osteoclast 
mediated bone remodeling340, and bone adaptation during axial tibial compression341. 
Thus, YAP/TAZ-dependent regulation of skeletal cell function could vary between spatial 
locations within the bone and surrounding muscles to coordinate the total tissue-level 
response. Overall, future studies building on the work presented here should exercise 
caution and carefully evaluate both biological factors, such as genetic background, age, 
and sex, and also spatial localization within each bone compartment when evaluating the 
in vivo contributions of YAP/TAZ in skeletal lineage cells.  
5.3.3 Translational approaches 
While the work presented here provides a better basic understanding of how YAP 
and TAZ contribute to bone function, future efforts aimed at developing translational 
strategies for treating skeletal fragility and enhancing fracture repair using this information 
are needed. Given the vast network of YAP/TAZ-dependent signaling, systemic YAP/TAZ 
modulation would cause irreversible off-target effects, suggesting local delivery systems 
are needed to safely target the skeleton. While small molecule drugs that modulate 
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YAP/TAZ-dependent activity exist, the exact specificity to which these drugs alter 
YAP/TAZ activity remains unclear. For example, the most commonly used YAP/TAZ 
inhibitor, verteporfin, was developed initially as a clinical photosensitizer in photodynamic 
therapy for neovascular macular degeneration, but was shown as a potential inhibitor of 
YAP/TAZ-TEAD downstream transcriptional activity218. However, recent work 
demonstrated verteporfin elicited a similar therapeutic response independent of YAP 
activity231, suggesting potential off-target effects. Additional inhibitors of YAP/TAZ 
activity include the small molecule CA3342  and agonism of dopamine receptor D1343, yet 
use of these YAP/TAZ inhibitors in the musculoskeletal field is limited. Regardless, small 
molecule inhibition of YAP/TAZ activity in the skeleton would theoretically impair bone 
function, given the skeletal phenotypes of genetic YAP/TAZ deletion.  
However, pharmacological or genetic activation of YAP/TAZ presents a difficult 
translational challenge, especially in the context of skeletal fragility and fracture repair. 
First, small molecule drugs for specific YAP/TAZ activation remain elusive. Second, YAP 
and TAZ are well known as potent proto-oncogenes, with their overexpression correlated 
with tumorigenesis and poor cancer prognoses120,185. Thus, systemic pharmacological or 
genetic YAP/TAZ activation is not a viable translational solution. Although targeting the 
putative DNA binding co-factors interacting with YAP/TAZ is promising, important 
consideration of the targeted cell type and context is needed. The cell type and context-
dependent contributions of YAP/TAZ to osteogenic differentiation in vitro could provide 
an interesting initial model system. If YAP/TAZ-dependent co-activation and YAP/TAZ-
dependent co-repression of osteogenic genes could be observed in the same model system 
with the addition of a single variable, co-immunoprecipitation combined with mass 
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spectrometry344 could help identify the differences in putative YAP/TAZ DNA-binding co-
factors giving rise to the context dependent regulation of osteogenesis. Instead of direct 
YAP/TAZ activation, targeting context-specific YAP/TAZ co-factors could alternatively 
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MicroCT: AlignZ workflow 
1) In 2D evaluation/contour mode, contour around the sample as close as possible. 
a. Note 1: More empty/unused space around bone in each 2D slice makes 
reorientation the slower 
b. Note 2: Make sure to account for slice to slice movement of the sample 
as needed i.e. go every 5 slices near the ends of the samples, then by 50 
slices in the middle 
i. These are suggestions, change as needed, but keep in mind Note 
1. 
2) In 3D evaluation/display mode, orient the 3D model in the preferred orientation 
a. Note 1: Fracture and contralateral femur samples are most efficiently 
scanned horizontally, but re-oriented vertically in this step 
i. This will be different depending on person scanning, lab, etc. 
3) In 3D evaluation/display mode, use the cut plane function to virtually cut through 
the 3D model 
a. Note 1: The cut plane default is at 100 (all the way to the right) but set it 
around 0 to start and then manipulate the 3D model orientation (i.e. step 
2), and the software will keep the same cut plane, allowing for vertical 
orientation alignment 
b. Note 2: Image does not need to be perfect match to example image 




4) Once the 3D model is aligned and the cut plane looks similar to above image, 
hover over the three areas of interest (p1, p2, p3) and use shift-click, or 
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command click or right click on the 3D model to get the coordinates at each 
point. 
a. Note 1: Write down the coordinates in order as they are needed for next 
steps  
b. Coordinate information: 
i. P1:  the coordinates of the new origin  
ii. P2:  the coordinates of a point on the new Z-axis  
iii. P3:  the coordinates of a point in the new XZ-plane 
iv. Example: P1: (492,363,0); P2: (178,304,0); P3: (293,575,0) 
c. Image 1: 
 
5) Once you have contoured and recorded all the coordinates for each sample, 
switch over to the terminal and get into the MEASUREMENT number directory 
on the server 
a. Using command “cd” with no quotation marks, enters into each directory 
on the software 
b. Using command “cd ..” moves up to the parent directory 
c. Use “dir” to see what files are in the current directory 
d. Screenshot: 
 
6) Once in the correct MEASUREMENT directory, enter image processing language 
(IPL) used by SCANCO, by typing “ipl” 
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7) Once in IPL, use the following commands to re-align any sample 
a. General IPL workflow is as follows: 
i. Get into correct directory 
ii. Start IPL 
iii. Use “read” to read in the corresponding .AIM file corresponding to 
the 3D model of the same measurement you use to get the 
coordinates 
iv. Use “align_z” to input the coordinates found with 3D model 
v. Use “header” to adjust the new origin to [0 0 0] 
1. This step keeps the new origin from going negative after 
reorientation  
vi. Write the .AIM file to an .ISQ file using “toisq” command 
1. I think there is a way to do this in batch, but I have not 
used it yet. 
b. Note 1: This AlignZ method takes up a lot of memory on the microCT 
network. Please be aware of people using the scanners and workstations, 
as you will drastically slow down their reconstructions and evaluations. 
i. Rule from microCT core is to always submit these jobs after 
5pm, unless no one is using either scanner or any workstation, 
which never happens 
c. Note 2: Once inside the correct MEASUREMENT directory, you should 
NOT read the actual file name in the “[in] >” prompt. Just press enter and 
then you won’t use your own computers memory, but rather the microCT 
workstations 
d. Note 3: The “[in] >” from one command becomes the “[out] >” of the next 
command, except for when transitioning from “read” to “align_z”  
i. “[in] >” is still the “[in] >” file from “read”, so just press enter and 
then enter again when prompted for “[out] >” during “align_z” 
ii. Using the “header” and “toisq” commands, the “[in] >” is now “out” 





Fracture healing surgery 
Materials: 
• Needles (25 gauge/blue needles, at least 1 inch long, 1.25 inch preferred)  
• Surgical tools (Robuz tools preferred) 
o Scalpel holder (RS-9843) 
o Hemostats (RS-7111) 
o Dissection scissors (RS-5882, RS-5840) 
o Micro-dissection scissors (RS-5620) 
o Small curved forceps (RS-5136) 
o Large straight forceps (RS-8242) 
o Needle holder with scissors (RS-7892) 
• Metal wire cutters  
• Mouse hair clippers/trimmers  
• Sterile eye lubricant (Paralube) 
• Small surgical drapes, 10 x 20 cm (3M: 1035) 
• Absorbable sutures, 5-0, 13mm, reverse cutting, polyglactin braided (Ethicon: 
J463G) 
• Surgical gloves, multiple sizes from 6.5 to 8.0, powder-free (McKesson: 20-
1080N) 
• Betadine (Emerson healthcare LLC: 6761815117)  
• Nair or equivalent generic brand hair remover  
• Triple antibiotic ointment  
• Sterile saline (Order through ULAR) 
• Soft food or Diet gel (Order through ULAR) 
• 70% ethanol  
• Sterile water 
• Sterile gauze pads  
• Surgical pads 
• Scalpels (#15) 
• Dissection gowns 
• Heat lamp 
• Surgical masks 
 
Drugs and dosing: 
Dilute drugs in sterile vial with rubber top 
• Isoflurane OR Ketamine, Xylazine (Rompun), and Acepromazine 
(PromAce) but NOT BOTH 
o Isoflurane preferred/easier to work with, but depends on 
surgical set up 
§ 1-5%, continuous for 1 hour, inhalation 
o Ketamine – 70-100 mg/kg, once for 20-30 minutes, (i.p.) 
o Xylazine – 5-12 mg/kg, once for 20-30 minutes, (i.p.) 
o Acepromazine – 1-3 mg/kg, once for 20-30 minutes, (i.p.) 
• Buprenorphine  
o Buprenorphine-SR  – 1 mg/kg, once, subcutaneous 
o Buprenorphine-regular – 0.05 - 0.1 mg/kg, every 4-6 hours for 
3 days post-surgery, subcutaneous 
§ Dilute in 0.9% sterile saline 
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• Bupivacaine 
o 0.25%, once, intra-incisional, dilute in sterile saline 
• Meloxicam 
o 5 mg/kg, every 12-24 hours, 3 days post-op 
 
Fracture surgery (performed in 326A or 328A Stemmler): 
 
 Pre-operation: 
1) Weigh mouse 
2) Anesthetize animals by either isoflurane inhalation or intraperitoneal 
injection of rodent anesthetic cocktail 
a. Isoflurane –induce on 3%, maintain on 1-2% 
3) Place sterile eye lubricant in the eyes of the mice 
4) Trim all hair with mouse hair clippers 
5) Spread Nair or equivalent generic hair removal lotion to the surgical 
site, do not leave on skin for more than ~1 minute 
6) Cleanse surgical area with sterile water, repeat hair removal 
application if needed 
7) Cleanse area with betadine in counterclockwise motion away from 
surgical incision site to maintain aseptic surgical area 
8) Transfer mouse to surgical area with heating pad and/or thermal 
waterbed under surgical/dissection pads 
 
Surgical operation:  
1) Apply surgical drape to mouse, exposing only the right limb 
2) Make a unilateral incision on the lateral side of the right knee (3-5mm 
incision) 
3) Straighten leg and displace patella to uncover the femoral condyles 
4) Insert intramedullary rod (25-gauge needle) by twisting and applying 
slight pressure through the intrachondylar notch of the distal femur 
a. Keep inserting until needle tip is within proximal trabecular 
bone (you will feel increased resistance, if you keep pushing 
past this point, you will push needle out the other side) 
5) Use wire cutters to clip needle at the insertion point of the distal 
femoral head 
6) Close first incision site with absorbable sutures 
7) Perform mid-diaphyseal fracture either with open or closed model 
a. Open fracture model 
i.  Make a 1 cm cutaneous incision on the anterolateral 
aspect of the limb near the mid-diaphysis of the femur 
ii. Blunt dissected away the muscle with hemostats to 
expose the mid-diaphysis of the femur 
iii. Insert #15 scapel blade positioned transversely to the 
femur axis 
iv. Apply a three-point bend force to cause a transverse 
fracture of the femur 
v. Verify fracture success visually (transverse, oblique, 
comminuted) 
vi. Close surrounding muscles with single absorbable 
suture  
vii. Close skin with absorbable sutures 
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8) Suture wounds close with 5-0 sutures 
a. Close blunt dissecting muscle first 
b. Close skin 
9) Apply bupivacaine for local anesthesia at incision site during suturing 





1) Administer dose of Buprenorphine as mouse begins to recover from 
Isoflurane to ensure pre-emptive analgesia immediately following surgery 
a. Can be given before, but combination of Buprenorphine and 
Isoflurane can cause mice to stop breathing/die during surgery 
2) Allow mice to recover under heat lamp, on a heated pad, or heated 
chamber to ensure maintenance of body temperature 
3) After awakening, return mouse to their cage to allow free ambulation 
4) Provide Nutrigel in cages with recovering mice as the surgery might 
prevent them from reaching food immediately following surgery 
5) Administer meloxicam subcutaneously every 12-24 hours for three days 
post-surgery 
6) Administer Buprenorphine every 4-8 hours for three days post-surgery 
and as needed beyond three days post-surgery in animals showing signs 
of lameness or distress 
a. Weigh mouse every other day for first week  
7) Observe mice in recovery for signs of posture, activity level, breathing, 
hydration, body/coat condition throughout duration of experiment 
a. Especially monitor intramedullary pin, as needle can become 
displaced if not properly placed during surgery 
b. Keep humane endpoint criteria in mind and euthanize mice 
meeting these requirements: 
i. Animals have body condition scoring (BCS) of 1 
ii. Animals have a body condition scoring (BCS) of 2 in 
addition to other signs such as hunched posture, inactivity, 
ruffled hair coat, or dehydration 
iii. Overt signs of surgical site infection (redness, swelling, 
purulent discharge) 
iv. Weight loss of 20% 
v. Inability to ambulate 
vi. Non-weight bearing lameness on fracture limb despite 
analgesic treatment (e.g. limb dragging) 
 
 
 
 
 
 
 
